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ABSTRACT
Kidney transplantation is the optimal treatment for patients with end-
stage renal disease. The imbalance between supply and demand of kidneys for 
transplantation has led to a progressive expansion of the deceased donor pool. 
However, there is still a general reluctance to use donors after cardiac death for kidney 
donation and transplantation, because of a relatively high incidence of delayed graft 
function and primary non-function compared to conventional donors after brain 
death. However, transplanted kidneys that do not experience these complications 
survive as long as conventional kidneys from donors after brain death. Optimal organ 
preservation and careful selection of kidneys form donors after cardiac death may 
reduce the risk of delayed graft function and primary non-function.
The purpose of this chapter is to describe the definition of donation after 
cardiac death, the current kidney preservation techniques for donors after cardiac 
death and to give insight in new developments that may reduce the warm ischemia 
times and therefore improve graft function after transplantation.
Derived from
E.R. Pieter Hoogland, Maarten G.J. Snoeijs and L.W. Ernest van Heurn. DCD kidney transplantation: results and 
measures to improve outcome. Curr Opin Organ Transplant 2010; 15(2):177-182
Jentina Wind, E.R. Pieter Hoogland and L.W. Ernest van Heurn. Preservation techniques for donors after cardiac death 
kidneys. Curr Opin Organ Transplant 2011; 16(2): 157-161
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INTRODUCTION
Kidney transplantation is the treatment of choice for patients with end-stage 
renal disease. Transplantation of kidneys from deceased donors results in longer 
life expectancy and superior quality of life compared with dialysis treatment (1-3). 
However, its use is limited due to the shortage of organ donors (1). The imbalance 
between supply and demand of kidneys for transplantation has led to a progressive 
expansion of the deceased donor pool. Liberal use of kidneys from donors after 
cardiac death (DCD) holds the potential to increase the number of organ donors 
by 2.5 - 4 times, which is sufficient to stabilize or reduce the waiting lists for kidney 
transplantation (4, 5). In contrast to donation after brain death (DBD), however, organs 
from DCD donors inevitably sustain a period of warm ischemia from circulatory arrest 
until initiation of organ preservation. This causes ischemic acute kidney injury, which 
results in an increased incidence of delayed graft function (DGF) and primary non-
function (PNF) as compared to kidney transplantation from conventional brain-dead 
donors (6). These early complications associated with DCD kidney transplantation 
have led to a reluctance to use these kidneys for transplantation and have restricted 
the expansion of DCD kidney donation to its full potential.
In this chapter we describe firstly the results of kidney transplantation from 
DCD donors, secondly kidney preservation techniques and their results and thirdly to 
give insight in new developments and optimal donor management to reduce warm 
ischemia times in order to reduce the incidence of DGF and PNF.
DEFINITIONS OF DCD DONATION
DCD donation can be defined as donation of organs from patients who have 
died with circulatory arrest. Therefore, DCD kidneys always sustain a period of 
warm ischemia. At the first international workshop on DCD-donation in Maastricht, 
1995, four types of DCD donors were discussed and accepted to categorize DCD 
kidneys according to their period of warm ischemia (Table 1.1) (7). Maastricht 
category 1 donors have the longest warm ischemia time, Maastricht category 3 and 
4 have potentially the shortest. Maastricht category 1 donors are patients who are 
declared dead outside the hospital and are subsequently transferred to the hospital 
with the purpose of organ donation. There are only a few donation programs in 
which category 1 DCD donors are implemented, mainly in Spain and France (8, 9). 
Maastricht category 2 donors are patients who die in the hospital, mostly on the 
emergency department, after unsuccessful resuscitation. Both category 1 and 2 occur 
unexpectedly and therefore are referred to as ‘uncontrolled’ donors. Maastricht 
category 3 donors are patients on the intensive care unit (ICU) who do not meet brain 
death criteria, but for whom further medical treatment is considered to be futile and 
therefore is withdrawn. This gives the donation staff the opportunity to schedule 
the procedure and to meet legal and logistic requirements before organ recovery. 
CHAPTER 1     
10
Because of this planned fashion, category 3 donors are referred to as ‘controlled’ DCD 
donors. Maastricht category 4 donors are brain-dead donors who die of unexpected 
cardiac arrest before organ procurement. 
Table 1.1 Maastricht categories of donation after cardiac death
Category Definition Type
1 Dead on arrival Uncontrolled
2 Unsuccessful resuscitation Uncontrolled
3 Awaiting cardiac arrest Controlled
4 Cardiac arrest while brain dead Controlled / Uncontrolled
RESULTS OF KIDNEY TRANSPLANTATION FROM DONORS 
AFTER CARDIAC DEATH
Previous comparisons of the results of DCD and DBD kidney transplantation 
have shown a relatively high incidence of PNF in DCD kidneys, which has been 
attributed to the ischemic injury suffered before organ recovery. Depending on the 
threshold to discard or to accept DCD kidneys for transplantation, the incidence of 
PNF may be as high as 15 - 25%. More restrictive selection criteria will improve the 
results of DCD kidney transplantation, but will inevitably be associated with the 
discard of viable kidneys.
Kootstra et al. compared several international studies on DCD kidney 
transplantation, and concluded that the incidence of DGF of 20 - 80% in DCD 
kidneys is significantly higher in DCD kidneys compared to DBD kidneys, with an 
incidence between 20 - 30%. However, the short- and medium term graft function 
of functioning grafts is similar in both groups (10). Interestingly, also the long-term 
graft survival of DCD kidneys that overcome the early postoperative period seems 
to be similar to that of DBD kidneys, more than 10 years after transplantation. In 
contrary to DBD kidneys, the relatively high incidence of DGF in DCD kidneys does 
not seem to affect the eventual outcome (11-17). However, less is known about graft 
survival rates after 10 years. 
The Leicester group recently (2009) showed that the results of functioning 
DCD kidneys are similar to DBD kidneys after a follow-up period ranging from 5 to 
15 years for mainly uncontrolled (Maastricht category II) kidneys, despite higher rates 
of DGF (18). This confirms our own results, which show that the long-term outcome 
(follow-up up to 25 years) of viable DCD kidneys is equivalent to grafts recovered 
from brain-dead donors (19).
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STANDARD PRESERVATION TECHNIQUES FOR DONORS AFTER 
CARDIAC DEATH 
Kidneys from DCD donors are inevitably associated with circulatory arrest prior 
to cold preservation and, therefore, with warm ischemic damage to the organs. To 
reduce this damage, rapid cooling of the organs is indicated. In many centers in situ 
preservation (ISP) is the method of choice for uncontrolled (Maastricht category I and 
II) DCD donors. It is an indispensable technique that may provide the opportunity to 
meet legal and logistical requirements for organ recovery without excessive warm 
ischemia times and, depending on the legal opportunities, can be initiated prior to 
consent for organ donation. It is usually performed in the emergency room after failed 
resuscitation (10, 20, 21). Preservation measures are started after a five minutes ‘no 
touch’ period, the interval between cessation of cardiopulmonary resuscitation and 
the moment that preservation measures are started. This minimally invasive surgical 
technique consists of the insertion of a double-balloon triple-lumen (DBTL) catheter 
through the femoral artery into the aorta. After partial inflation of the abdominal 
balloon, the catheter is pulled back until it hooks onto the aortic bifurcation (22). 
The thoracic balloon, which is positioned above the renal arteries, is then inflated so 
that it occludes the aorta proximally to the kidneys and the fully inflated abdominal 
balloon occludes at the aorta’s bifurcation. The third lumen of the catheter is used to 
flush the organs with hypothermic organ preservation solution, flushing and cooling 
the kidneys in situ until organ recovery. A large Foley catheter is placed in the femoral 
vein for decompression (Figure 1.1A). For adolescents, a 16 Ch DBTL catheter with a 
balloon distance of 25cm, and a fully inflated balloon diameter of 40mm (AJ6516, 
Porgès, Le Plessis-Robinson, France) is available. For children between approximately 
5 and 12 years of age, a smaller 12 Ch DBTL catheter with a balloon distance of 
15cm and a balloon diameter of 30mm (61.630.12.080, Meddev, Holm, Germany) can 
be used (23). An infusion system is connected to the catheter and cold perfusate is 
infused until donor nephrectomy. To reduce the chance of capillary occlusion and 
warm ischemic damage to the organs heparin and streptokinase are administered 
at the initial flush after the cannula has been inserted (24). Within two hours after 
starting ISP, the deceased is taken to the operating room for organ recovery.
In Maastricht category III donors, withdrawal of life support usually takes 
place in the ICU. After cardiac arrest and the obligatory no-touch period, the patient 
is transported to the operating room where prepared surgical staff is waiting. After 
arrival in the operating room, rapid laparotomy is done with direct cannulation of 
the aorta (Figure 1.1B). In general, the warm ischemia time with this technique can 
be limited to 20 minutes. One of the conditions to use this preservation method is a 
short distance between the ICU and the operating room, so that the transportation 
time can be kept to a minimum. Others prefer to withdraw medical treatment in the 
operating room so that no time is lost to transport the deceased to the operating 
room and the warm ischemia time is reduced. However, withdrawal of treatment in 
the operating room may influence good end of life care and, if the patient’s heart 
does not stop beating after the cessation of medical treatment, the patient has to 
be transported back to the ICU, with potentially negative feelings for relatives and 
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involved medical staff. Irrespective of where treatment is withdrawn, after a no-touch 
period of at least 5 minutes during which no invasive or medical donor treatment is 
given, the organs are rapidly flushed and cooled, immediately procured and stored 
on melting ice or preserved on a machine (23).
Figuur 1.1 Surgical techniques for organ preservation in donors after cardiac death. (A) In situ 
preservation technique. Reproduced with permission from “Nederlands Tijdschrift voor Geneeskunde”. 
(B) After rapid laparotomy, the abdominal organs are perfused through an aortic cannula. The figure 
was adapted from Casavilla et al. (25)
RESULTS OF ISP AND DIRECT CANNULATION OF THE AORTA
Only a minority of initiated ISP procedures leads to transplantation. Often 
it is done in patients with a contra-indication to donation, or consent to procure 
the organs is not obtained. Furthermore, there are technical complications of the 
procedure itself, such as an inaccessible femoral artery for catheter insertion, wrong 
position of the DBTL catheter or rupture of the abdominal balloon that are responsible 
for unsuccessful donation. A prolonged catheter insertion time is associated with 
poor transplant outcome, which not only depends on the longer warm ischemia 
time, but also on the quality of the arterial tract. For controlled DCD donors, rapid 
laparotomy and direct cannulation of the aorta lead to a significantly superior graft 
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survival compared to DCD donor kidneys that are preserved in situ. These donors 
have shorter warm ischemia times and lower rates of discard. Concluding, rapid 
laparotomy and direct aortic cannulation is considered preferable above in situ 
perfusion using double-balloon triple-lumen catheters as the method for initiation of 
organ preservation in controlled DCD donors (21).
KIDNEY PRESERVATION AFTER RECOVERY
After organ procurement, kidneys can be preserved by static cold storage (CS), 
which is currently the standard technique for organ preservation, or by hypothermic 
machine perfusion (HMP) (26). The latter method has many advantages over 
CS for the donor kidney. In theory, continuous pulsatile flow through the kidney 
can provide nutrients and oxygen and it can eliminate metabolic by-products and 
toxins. It decreases vasospasm and protects the endothelium, possibly due to flow-
dependant genes. Furthermore, HMP offers the opportunity to apply therapeutic 
interventions, like the addition of pharmacological agents or even gene therapy 
(27, 28). A meta-analysis showed that a 20% reduction in the relative risk of DGF of 
both DBD and DCD donor kidneys can be achieved by using HMP instead of CS (29). 
More recent studies in human kidney transplantation show high level evidence that 
HMP is associated with a decreased risk of DGF and improved one-year and 3-year 
graft survival, although the latter was only proven for DBD kidneys and not for DCD 
kidneys (30-33). 
 In addition to improving graft function, HMP offers a good opportunity to 
test the viability of deceased donor kidneys in order to prevent transplantation of 
non-viable grafts. In the past, machine viability testing has been used to decide if 
kidneys should be discarded or accepted for transplantation. Many studies evaluated 
the perfusate biomarker concentration and machine perfusion parameters as a tool 
to estimate graft viability. However, its use was often justified by the argument that 
results of transplantation had improved after the introduction of machine perfusion 
viability testing. High quality evidence was usually not available (34-37). Recently, we 
described that viability testing has not offered clinicians the expected tools to decide 
whether to discard or accept a kidney for transplantation. There is little evidence 
that current viability tests during HMP are reliable enough to make a decision prior 
to transplantation. Expanding viability testing with new biomarkers and novel 
techniques may provide tests with better predictive value, but their values have to be 
proven. Viability testing during normothermic perfusion offers a novel opportunity 
to assess the quality of a donor kidney, as the function of metabolically active organs 
is tested, instead of surrogate indicators, which measure cell death, inflammation or 
other kidney injury.
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DONOR MANAGEMENT BEFORE AND DURING ORGAN 
PRESERVATION; NEW DEVELOPMENTS
Donor kidneys are sustained to a period of warm ischemia from cardiac arrest 
until preservation. To reduce ischemic damage to the kidney of a potential donor, 
maintaining an adequate circulation after the cessation of treatment or cardiac arrest 
and a no-touch period of 5 minutes, CPR can be used while preservation measures are 
taken. CPR primarily aims to increase cardiac and cerebral perfusion, whereas blood 
flow to visceral organs is relatively low. Indeed, renal blood flow in dogs was reduced 
by 85% during resuscitation as measured by radioactively labeled micro spheres 
(38). When adrenalin was administered during resuscitation, renal blood flow was 
further reduced down to 2% of the blood flow before cardiac arrest (39). These 
data indicate that despite CPR, donor kidneys suffer extensive warm ischemic injury. 
This can potentially be reduced by automated chest compression devices. Manual 
CPR is a simple and quick technique for maintaining a circulation during cardiac 
arrest. However, limitations of manual CPR are inconsistency of rate and depths of 
chest compression, regardless of the experience of the person performing the chest 
compressions, resulting in less blood flow through vital organs (40).  In order to improve 
CPR by performing consistent rates and depths of chest compressions, a variety of 
automated chest compression devices have been studied. Improved hemodynamic 
effects and better coronary perfusion with increased peak aortic pressure over manual 
CPR have been described. This suggests a better perfusion of visceral organs using an 
automated chest compression device after cardiac death (40, 41). Chest compression 
devices, such as the Autopulse (ZOLL Circulation, Sunnyvale, California) (Figure 1.2), 
are also used to preserve DCD donor organs from cardiac arrest until in situ cooling 
using a DBTL-catheter (42). In a group of uncontrolled category 1 donors, supported 
by the Autopulse, the 6 month graft survival after transplantation was 89% (9). The 
use of automated chest compression devices may contribute to a better perfusion 
of visceral organs, resulting in less ischemic injury and better graft function after 
transplantation. However, proper positioning of the device is essential for adequate 
chest compressions and to limit intra-abdominal damage. Bilateral rib fractures, a 
fractured manubrium of the sternum, lateral cutaneous lacerations, a ruptured spleen 
and liver were found at autopsy of a 49-year-old patient, admitted because of an out-
of-hospital resuscitation, which may have been related to inappropriate placement 
of the Autopulse (43). Therefore, it is recommended that proper positioning of the 
device is regularly checked when the Autopulse is used.
Extracorporeal membrane oxygenation (ECMO) has the potential to improve 
organ quality by providing normal tissue perfusion after cardiac death (45). Since 
its introduction in the early 1970, it has become a standard therapy to provide 
temporary circulatory support and systemic oxygenation for patients with reversible 
cardiac or respiratory failure that cannot be supported with conventional mechanical 
ventilation. The use of ECMO after cardiac death in order to maintain sufficient 
oxygenation of potential donor organs has been evaluated in several studies (46-
49). In Spain, the ECMO is used for uncontrolled category I donors. Once death is 
declared, an automated chest compression device is used while perfusion catheters 
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are being inserted in the femoral artery and vein. When the catheters are in place, 
the compression device is turned off and an occlusive balloon is placed in the thoracic 
aorta. Extracorporeal circulation is then begun using a heat exchanger in the circuit 
to maintain normal body temperature (Figure 1.3). 
Figure 1.2 The AutoPulse (ZOLL Circulation, Sunnyvale, California) for delivery of chest compressions 
during cardiopulmonary resuscitation. The figure was adapted from Risom  
et al. (44)
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Figure 1.3 Extracorpereal membrane oxygenation configuration. The figure was adapted from 
Magliocca et al. (47)
A group from Madrid demonstrated a substantial expansion of the DCD donor 
pool after ECMO use. Donor criteria were a witnessed arrest, age between 7 and 55 
years and initiation of CPR within 10 minutes after cardiac arrest. Time limit from 
cardiac arrest until organ preservation is fixed at 120 minutes, time limit until organ 
procurement is fixed at 240 minutes from cardiac arrest. Kidney function is stated to 
be as good or better than kidneys obtained from DBD donors, with a superior long-
term graft survival (50).  
For controlled donors, once consent has been obtained for ECMO use after 
cardiac death when treatment has been withdrawn, the University of Michigan 
places the femoral artery and venous catheters and a thoracic occlusion balloon 
before cardiac arrest occurs, without activating the system. When death is declared 
by the treating physician, the thoracic balloon is inflated and the ECMO support 
starts. Without any rush, organ recovery can take place by first cooling the organs 
by adding cold perfusate solution to the arterial catheter of the ECMO, which is 
then turned off. With this latter method, measures to preserve donor organs are 
taken before death has occurred, which limits its use because of legal or ethical 
objections. The organs are removed using conventional organ recovery techniques 
(46). Graft survival of controlled, ECMO assisted donors appears to be similar or even 
better than kidneys obtained from conventional brain-dead donors (46, 47, 51, 52). 
Normothermic ECMO with the donor’s own blood reduces the incidence of DGF and 
PNF compared to the ISP perfusion with the DBTL catheter and to total body cooling 
with a cardiopulmonary bypass. Normothermic ECMO also enables the use of other 
organs than kidneys for transplantation, such as the liver and lungs (53). 
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Preservation and assessment of kidneys after recovery
After successful organ recovery from donors after cardiac death, kidneys 
are stored either on melting ice or on a hypothermic pulsatile perfusion machine. 
Machine perfusion may provide a useful platform to assess kidney function by several 
viability tests (54-59), however, these tests have insufficient diagnostic accuracy to 
be clinical useful in deciding whether to transplant or discard DCD kidneys that have 
suffered prolonged warm ischemia time (60). 
Next to assessment of acute ischemic injury, kidneys from older donors 
may have chronic degenerative changes. Among several selection criteria, the 
only proven predictor for graft function and survival is histological assessment of 
degenerative changes in pre-transplant kidney biopsies in donors aged 60 or older. 
In contrast to donor age, kidney function, kidney weight and perfusion parameters, 
pre-implantation histological kidney damage is associated with premature graft 
loss in older donors (61). Histological assessment of pre-transplant kidney biopsies 
is reproducible among pathologists and evaluation of small needle biopsies give a 
reasonable estimate of degenerative changes in the entire kidney (62). Therefore, 
histological assessment of renal biopsies is a clinically useful tool to select kidneys 
from donors with satisfactory outcome and this approach may be more appropriate 
than setting arbitrary age limits for kidney donation.
CONCLUSION
In this chapter, we show that the liberal use of organs from donors after 
cardiac death greatly increases the number of available donor kidneys. However, 
kidney transplantations from DCD donors are characterized by a higher incidence of 
PNF and DGF. Nevertheless, viable grafts that do not experience PNF survive as long as 
conventional kidneys from donors after brain death, and wait-listed dialysis patients 
experience a survival benefit from DCD kidney transplantation. The risk of DGF 
and PNF with DCD kidneys can be reduced firstly by organ preservation using rapid 
laparotomy and direct aortic cannulation for controlled DCD donors and secondly by 
reducing the warm ischemia time using automated chest compression devices and 
extracorporeal membrane oxygenation. Expansion of the donor pool by using more 
uncontrolled donors supported with ECMO is of paramount importance to improve 
the treatment of wait-listed dialysis patients. Major efforts should continue to be 
made to improve the quality of DCD kidneys and thereby expand the utilization of 
this large pool of donor kidneys to its full potential.
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AIMS OF THE THESIS
Based on this chapter, there is a discrepancy between the number of patients 
on the waiting list for a kidney transplantation and the number of kidney donors. One 
method to increase the donor pool is by using uncontrolled DCD donors, however, 
there is still a general reluctance to accept kidneys from these donors because of 
the potential higher risk of complications after transplantation. Therefore, this thesis 
focuses on methods to increase the number and quality of DCD kidney donation and 
transplantation.
Firstly, Chapter 2 provides results of uncontrolled DCD kidneys compared 
with controlled DCD kidneys. Insight into the short-term and long-term results 
of uncontrolled DCD kidneys is indispensible to decide whether or not to start or 
continue expensive kidney donation programs. Next, we investigated which variables 
in uncontrolled DCD donors are of importance in order to assess organ viability 
(Chapter 3), and how the results of DCD kidney donation and transplantation can be 
improved (Chapter 4).
Secondly, this thesis aims to identify strategies to predict PNF of DCD kidneys, 
which is extremely important as PNF is a serious complication of kidney transplantation 
(Chapters 5-8). A better selection of DCD kidneys before transplantation may reduce 
the incidence of PNF, which results in a better quality of care.
Thirdly, we investigated new potential therapies in experimental models to 
protect the kidney from ischemia-reperfusion injury in order to prevent or treat 
ischemic acute renal injury after DCD kidney transplantation (Chapters 9-11).
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ABSTRACT
Background: Kidney donation after cardiac death has been popularized over 
the last decade. The majority of these kidneys are from controlled donors. The number 
of organs for transplantation can be further increased by uncontrolled donors after 
cardiac death. The outcome of uncontrolled compared to controlled donor kidney 
transplantation is relatively unknown. 
Methods: We compared the long-term outcome of kidney transplantation 
from uncontrolled (N = 128) and controlled (N = 208) donor kidneys procured in 
the Maastricht region from 01/01/1981 until 01/01/2008, and transplanted in the 
Eurotransplant region. 
Results: The incidence of primary non-function and delayed graft function 
in both uncontrolled and controlled donor kidneys is relatively high (22% vs. 21%, 
and 61% vs. 56%, p=0.43, respectively). Ten-year graft and recipient survival are 
similar in both groups (50% vs. 46%, p=0.74 and 61% vs. 60%, p=0.76, respectively). 
Estimated glomerular filtration rates one year after transplantation are 40±16 vs. 
42±19 mL/min/1.73m2, p=0.55, with a yearly decline thereafter of 0.67±3 vs. 0.70±7 
mL/min/1.73m2/year, p=0.97. 
Conclusion: The outcome of kidney transplantation from uncontrolled and 
controlled donors after cardiac death is equivalent. This justifies the expansion of 
the donor pool with uncontrolled donors to reduce the still growing waiting list 
for renal transplantation, and may stimulate the implementation of uncontrolled 
kidney-donation programs.
Published as
E.R.P. Hoogland, M.G.J. Snoeijs, B. Winkens, M.H.L. Christiaans, L.W.E. van Heurn. Kidney Transplantation from Donors 
after Cardiac Death: Uncontrolled versus Controlled Donation. Am J Transplant 2011; 11(7): 1427-1434
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INTRODUCTION
Kidney transplantation is the treatment of choice for patients with end-stage renal 
disease, but its use is limited due to the shortage of organ donors (1). The number of 
patients on the waiting list for renal transplantation is still increasing while the number 
of donors after brain death remains stable. One method to expand the donor pool is by 
the use of organs from donors after cardiac death (2). These kidneys are increasingly used 
and recipients of these kidneys have comparable long-term survival rates as recipients 
of kidneys from brain-dead donors (3). Recently, it has been shown that for patients on 
dialysis, transplantation with a kidney from a donor after cardiac death results in a survival 
benefit compared to staying on dialysis and wait for a kidney from a brain-dead donor (4). 
 Kidneys from donors after cardiac death sustain an inevitable period of warm 
ischemia between cardiac arrest and flushing of the organs. This period of warm 
ischemic damage may result in higher incidences of primary non-function and delayed 
graft function. In controlled donation after cardiac death, organs are recovered after 
withdrawal of futile treatment. The donor characteristics are usually known and the warm 
ischemic injury to the organs can be estimated by the duration of the hypotensive period 
after the cessation of treatment and the period between cardiac arrest and the time that 
preservation of the organs has been started. In uncontrolled donation, donors die after 
failed resuscitation. There is a period without circulation, after which cardiopulmonary 
resuscitation is initiated. The period of circulatory arrest is usually not exactly known and 
the efficacy of cardiopulmonary resuscitation is difficult to assess. The relatively unknown 
extent of ischemic injury to uncontrolled donor kidneys and the unplanned fashion of its 
preservation and procurement has led to a general reluctance to use these kidneys for 
transplantation.
 The pool of controlled donors after cardiac death is limited. Only a small 
proportion of intensive care patients, in whom further treatment is considered to be futile 
and who are not brain dead, meet donation criteria. The number of patients who die after 
failed resuscitation is much higher. Therefore, we assessed if this large donor potential 
could be safely used for renal transplantation to reduce the period on the waiting list for 
patients with end-stage renal disease.
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MATERIALS AND METHODS
Study design
Kidneys from donors after cardiac death, procured in the Maastricht region 
from 01/01/1981 until 01/01/2008 were included in the current observational study. 
Patients were followed until the earliest of death or 01/01/2009. The initial function 
and the long-term graft and recipient survival of the included uncontrolled and 
controlled donor kidneys transplanted within the Eurotransplant region were 
assessed. 
Data sources and definitions
Data on all kidney transplantations from donors after cardiac death were 
extracted from our periodically updated database. Patient follow-up information 
was submitted by the transplant centers on a regular basis. Missing data were 
supplemented by chart review at the transplant center at the request of the study 
coordinator. In the controlled group, five patients (2.5%) were lost to follow-up after 
a minimum follow-up period of 0.4 years, of whom all had experienced graft loss. 
One patient (0.8%) was lost to follow-up in the uncontrolled group after a follow-
up period of 5.8 years with a functioning graft. Patient data were collected, stored 
and used in agreement with the code of conduct ‘Use of data in health research’ put 
forward by the federation of Dutch medical scientific societies (http://www.federa.
org/).
Warm ischemia time in uncontrolled donors is defined as the time between 
cessation of cardiopulmonary resuscitation and the start of organ perfusion. For 
controlled donors, warm ischemia time is defined as the time from cardiac arrest 
(no arterial pulse) to the start of organ perfusion. Both include the obligatory no-
touch period of five minutes. Graft function in the early postoperative period was 
defined as 1) immediate function, without the need for dialysis treatment after 
transplantation, 2) delayed graft function, temporary dialysis treatment initiated in 
the first week after transplantation and 3) primary non-function, inadequate renal 
function, necessitating continuation of dialysis treatment or re-transplantation.  
 Renal function after transplantation was assessed using the estimated 
glomerular filtration rate which was calculated with the abbreviated Modification of 
Diet in Renal Disease equation (5-7). Estimated glomerular filtration rate at one year 
after transplantation and the rate of decline in estimated glomerular filtration rate 
thereafter were studied as measures of kidney function. Graft failure, censored for 
death, was defined as permanent return to dialysis treatment or retransplantation. 
 Expanded criteria donors (ECD) were defined as any donor aged 60 years or 
older or over 50 years old with at least two of the following risk factors: hypertension 
history, serum creatinine > 130 mmol/mL, or death caused by cerebrovascular accident (8).
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Management of donors after cardiac death
Kidneys from uncontrolled donors included Maastricht category II kidneys 
only (Table 2.1). The donor criteria for uncontrolled donation during the study 
period are listed in Table 2.2. Organs were preserved with the in situ preservation 
technique, described previously (9). In short, after unsuccessful resuscitation and an 
obligatory no-touch period of five minutes, during which no interventions to the 
donor were taken, a double-balloon triple-lumen catheter was inserted into the 
aorta via one of the femoral arteries, followed by in situ preservation of the donor 
kidneys with histidine-tryptophan-ketoglutarate solution (Custodiol, Dr. Franz Köhler 
Chemie, Alsbach, Germany) with heparin 300 IE/kg and occasionally streptokinase 
added to the preservation fluid (Chapter 1, Figure 1.1A) (10, 11). This technique is 
minimally invasive, can be performed in the emergency department and allows fast 
and effective organ preservation by surgeons with limited experience in donation 
procedures. After preservation and consent for organ donation, the organs were 
procured in the operating room. 
 Controlled donor kidneys included only Maastricht category III kidneys after 
withdrawal of futile medical treatment (Table 2.1). This gives the donation-staff the 
opportunity to schedule the procedure and to meet legal and logistic requirements 
before organ recovery. Withdrawal of life support took place in the intensive care unit 
(ICU). After cardiac arrest and the no-touch period, organs were either preserved in the 
intensive care unit with a double-balloon triple-lumen catheter, or the deceased was 
immediately transported to the operating room, where prepared surgical staff was 
waiting. A rapid laparotomy and direct cannulation of the aorta was then performed 
and organs were procured afterwards. The maximum time between withdrawal of 
life support (ventilator switch-off) and cardiac arrest was set at two hours.
Table 2.1 Maastricht categories of donation after cardiac death
Category Definition Type
1 Dead on arrival Uncontrolled
2 Unsuccessful resuscitation Uncontrolled
3 Awaiting cardiac arrest Controlled
4 Cardiac arrest while brain dead Controlled / Uncontrolled
Following recovery, most of the kidneys were machine perfused (82% vs. 84% 
for uncontrolled and controlled donors, respectively), initially, on a Gambro PF-3B 
machine and after 2006, on a Lifeport (Organ Recovery Systems, Des Plaines, IL). 
Preservation fluids used included Eurocollins before 1985 (N = 8) and University of 
Wisconsin machine perfusion solution (UW-MPS) since 1985 (12). 
 Kidneys were allocated by Eurotransplant, according to the Kidney Allocation 
System and consequently transplanted in the Eurotransplant region (13).
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Table 2.2 Donor criteria for uncontrolled donation after cardiac death.
1. Age <65 years
2. Witnessed cardiac arrest
3. Effective, professional resuscitation <45 min (<90 min in donors <50 years old)
4. Time between cessation of resuscitation and start of in situ preservation <45 min
5. No systemic signs of infection or evidence of sepsis
Statistical analysis
Continuous variables are presented as means ± standard deviations (SD) if 
normally distributed (histogram), and as median and inter-quartile range otherwise. 
Categorical variables are presented as percentages. Baseline donor, preservation 
and recipient characteristics are compared between donor types (uncontrolled 
vs. controlled) with the independent-samples t-tests for approximately normally 
distributed continuous variables, with the Mann-Whitney U-tests if the distribution 
clearly deviated from normality and with chi-square tests for categorical variables. The 
rate of decline in estimated glomerular filtration rate is calculated for each patient 
by simple linear regression from yearly glomerular filtration rate estimates, starting 
at one year after transplantation. The difference in mean estimated glomerular 
filtration rate was tested using the independent-samples t-test.
 Graft and patient survival are calculated with the Kaplan-Meier method; the 
log-rank test was used to compare the survival curves between donor types. 
 The effects of donor type and other potential risk factors on PNF were 
tested with univariate logistic regression analysis. All clinically relevant potential risk 
factors associated with PNF were selected for further analysis in a multivariate logistic 
regression model, with correction for those characteristics that are considered to be 
potential confounders, defined by the 10% change-in-estimate rule (14). Similarly, 
Cox-regression analyses were performed to assess the effect of donor type on 
recipient survival and to identify potential risk factors associated with graft failure.
 Additionally, a subgroup analysis was done for standard criteria donors (SCD) 
versus expanded criteria donors (ECD) and their relation with PNF.
 All analyses were performed using Statistical Package for the Social Sciences 
(SPSS) software version 15.0 for Windows, and a p-value ≤ 0.05 was considered 
statistically significant.
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RESULTS
From 01/01/1981 until 01/01/2008, 535 kidneys from donors after cardiac death 
(267 uncontrolled and 268 controlled) were procured in the Maastricht region, of 
which 174 (129 uncontrolled and 45 controlled) from 111 donors were discarded. 
Twenty-two kidneys were transplanted outside the Eurotransplant region. From 3 
recipients, no data was available. The remaining 336 kidneys (128 uncontrolled and 
208 controlled) transplanted in the Eurotransplant region entered analyses. Kidneys 
from 5 controlled donors were transplanted en bloc and were analyzed as one single 
kidney. 
Baseline characteristics of uncontrolled and controlled kidney donation and 
transplantations
Hundred twenty-nine (48%) kidneys were discarded in the uncontrolled group 
versus 45 (17%) in the controlled group (p < 0.001). Reasons for discard were often 
multifactorial, including poor flush out, unfavorable donor characteristics, anatomical 
variations, surgical damage of the kidney or if no suitable recipients were available 
(9). Donors of discarded kidneys were not significantly different in the uncontrolled 
and the controlled group for age (51 ± 12 vs. 56 ± 12, p=0.11) and warm ischemia time 
(32 ± 15 vs. 34 ± 13, p=0.56).
 The donor, graft and recipient characteristics of transplanted kidneys are 
presented in Table 2.3. The warm ischemia time was similar in uncontrolled and 
controlled donors (25 ± 14 vs. 25 ± 10 minutes respectively, p=0.96). Uncontrolled 
donors had more often a cardiac cause of death and organs were always preserved 
with the double-balloon triple-lumen catheter (100% vs. 88% in controlled donors, 
p=0.001). Uncontrolled donors had a significantly higher serum creatinine (124 ± 
39 vs. 86 ± 33, p<0.001), however, the relevance of this finding is limited as blood 
samples were usually taken after the initiation of CPR.
 Recipient characteristics were not significantly different for age, sex, 
anastomosis time and HLA-mismatches. Recipients of controlled kidneys more often 
received induction therapy (21% vs. 9%, p=0.003) and mycophenolate mofetil (54% 
vs. 23%, p<0.001). The cold ischemia time was shorter in the controlled donation 
group (26 ± 7 vs. 28 ± 6 hours, p=0.02) and dialysis time was longer (4 ± 3 vs. 3 
± 3 years, p=0.02) (Table 2.3). Controlled DCD kidneys were significantly less often 
transplanted at our unit (41% vs. 64%, p<0.001). All kidneys were allocated to a total 
of 26 centers throughout the Eurotransplant region.
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Table 2.3  Baseline characteristics of uncontrolled and controlled kidney 
transplantationsa
Uncontrolled
(N = 83)b
Controlled
(N = 111)b p
Donor characteristics
 Age (years) 46 ± 15 46 ± 17 0.84
 Sex (male / female) 72 / 28% 60 / 40% 0.08
 Cause of death (cardiovascular / other) 75 / 25% 2 / 98% <0.001
 Serum creatinine (μmol/L)c 124 ± 39 86 ± 33 <0.001
 Hypertension (yes / no) 11 / 89% 15 / 85% 0.47
 Donor BMI (kg/m2) 26 ± 3 (N = 21) 25 ± 3 (N = 39) 0.22
Preservation characteristics
 CPR time (min)d 44 ± 25 - -
 Ventilator switch-off time (min)e - 20  (14-47) -
 Warm ischemia time (min)f 25 ± 14 25 ± 10 0.96
 Preservation technique (ISP / aorta cannulation) 100 / 0% 88 / 12% 0.001
N = 128g N = 203g P
  Preservation type (cold storage / machine  perfusion) 18 / 82% 16 / 84%  0.59
 Cold ischemia time (hours) 28 ± 6 26 ± 7 0.02
 Anastomosis time (min) 39 ± 14 39 ± 16 0.99
 Standard vs. expanded criteria donor kidneys 79 / 21% 77 / 23% 0.92
Recipient characteristics
 Age 51 ± 13 51 ± 13 0.98
 Sex (male / female) 68 / 32% 65.5 / 34.5% 0.68
 BMI (kg/m2) 24 ± 3 (N = 61) 25 ± 4 (N = 59) 0.42
     Transplant center (regional / export) 64 / 36% 41 / 59% <0.001
     Transplantation year
      1981 - 1989 13% 9%
      1990 - 1998 40% 22% <0.001
     1999 - 2007 47% 69%
 Kidney (single / double) 100 / 0% 97.5 / 2.5% 0.07
 Kidney disease (renovascular / other) 16 / 84% 26 / 74% 0.05
 Dialysis time (years) 3 ± 3 4 ± 3 0.02
  Dialysis type (haemodialysis / peritoneal  dialysis) 68 / 32% 62 / 38% 0.30
 Retransplantation (yes / no) 12 / 88% 14 / 86% 0.56
 Total HLA mismatches 2.44 ± 1.0 2.54 ± 1.12 0.43
 Peak panel reactive antibody (PRA) 3.8 ± 12.6 2.1 ± 10.7 0.37
 Calcineurin inhibitor (cyclosporine / tacrolimus) 43.5 / 56.5% 34 / 66% 0.11
  Anti-metabolite (azathioprine / mycophenolate  
mofetil / none) 18 / 23 / 59% 10 / 54 / 36% <0.001
 Sirolimus (yes / no) 22 / 78% 15 / 85% 0.10
 Induction therapy (yes / no) 9 / 91% 21 / 79% 0.003
 Follow-up time (years) 7.9 ± 5.8 6.1 ± 4.9 0.004
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Table 2.3 continued
a Data are presented as mean (standard deviation) or as percentages. 
b Number of donors. 
c  Blood samples from uncontrolled DCD kidney donors were usually taken after the initiation of CPR.
d Not for controlled kidney transplantations. 
e  Not for uncontrolled kidney transplantation. Ventilator switch-off time was defined as the time from 
withdrawal of supportive treatment until circulatory arrest. Presented as median and inter-quartile 
ranges.
f  Warm ischemia time was defined as the time from circulatory arrest until initiation of hypothermic 
organ perfusion and therefore does not include ventilator switch-off time and cardiopulmonary 
resuscitation time.
g Number of single donor kidneys / recipients.
Clinical outcome 
The short-term graft function was similar in the uncontrolled and controlled 
group (primary non-function: 22% vs. 21%, delayed graft function: 61% vs. 56%, 
immediate function; 17% vs. 23%, respectively, p=0.43).
 The estimated glomerular filtration rates of functioning kidneys were 
comparable in the uncontrolled and controlled group; 37 ± 16 mL/min/1.73m2 in both 
groups at 3 months after transplantation (p=0.96), 40 ± 16 mL/min/1.73m2 vs. 42 ± 19 
mL/min/1.73m2 at 1 year (p=0.55) with a yearly decline thereafter of 0.67 ± 3.1 mL/
min//1.73m2/year vs. 0.70 ± 6.9 mL/min/1.73m2/year (p=0.97), respectively.
 The incidence of PNF in both uncontrolled and controlled DCD kidneys was 
relatively high due to a liberal acceptance policy. We analyzed the effect of donor 
type and other potential risk factors for PNF in a multivariate logistic regression 
model (Table 2.4). Donor type had no significant influence on PNF (OR 0.900, 95% CI 
0.493 – 1.644, p=0.73). Increasing warm ischemia time (OR 1.038, 95% CI 1.012 – 1.065, 
p=0.004), cold ischemia time (OR 1.046, 95% CI 1.002 – 1.092, p=0.04), increasing 
donor age (OR 1.024, 95% CI 1.002 – 1.046, p=0.03) and immunosuppressive therapy 
(OR 1.919, 95% CI 1.059 – 3.476, p=0.03) were independent predictors of PNF. 
 Graft survival did not significantly differ between both groups with a death-
censored 5 and 10 year graft survival of 63% vs. 64% and 50% vs. 46% (log-rank 
p=0.74), for uncontrolled and controlled donor kidneys, respectively (Figure 2.1A). 
The 5 and 10 year recipient survival of the respective groups was 78% vs. 80% and 
61% vs. 60% (log-rank p=0.76, Figure 2.1B). In the Cox-regression analysis, only donor 
age was a risk factor for graft failure (HR 1.016, 95% CI 1.004 – 1.027, p=0.007). Donor 
type had no influence on graft survival (HR 0.670, 95% CI 0.670 – 1.336, p=0.75) and 
recipient survival (HR 1.008, 95% CI 0.697 – 1.460, p=0.96) (data not shown).
 The number of SCD kidneys and ECD kidneys was similar in both groups 
(Table 2.3). A subgroup analysis between SCD and ECD kidneys showed no difference 
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in the percentage of PNF for controlled donor kidneys (19% vs. 26%, respectively, 
p=0.32). For the uncontrolled donor kidneys, ECD kidneys had a significantly higher 
risk on PNF compared to SCD kidneys (37% vs. 17%, respectively, p=0.03).
Table 2.4 Logistic regression analysis of risk factors for primary non-function
Univariate analysis Multivariate analysis
OR (95% CI) p OR (95% CI) p
Donor characteristics
 Donor type 1.071 (0.624 – 1.837) 0.80 0.900 (0.493 – 1.644) 0.73
 Age 1.024 (1.005 – 1.043) 0.01 1.024 (1.002 – 1.046) 0.03
 Sex (male / female) 0.876 (0.506 – 1.515) 0.64
 Serum creatinine (mmol/mL) 1.001 (0.994 – 1.007) 0.85
 Hypertension (yes / no) 2.059 (0.974 – 4.332) 0.06
Preservation characteristics
 Warm ischemia time (min) 1.013 (1.007 – 1.056) 0.01 1.038 (1.012 – 1.065) 0.004
  Preservation technique (ISP / aorta 
cannulation) 2.366 (0.693 – 8.077) 0.17
  Preservation type (cold storage /  
machine perfusion) 0.510 (0.219 – 1.188) 0.12
 Cold ischemia time (hours) 1.030 (0.989 – 1.072) 0.15 1.046 (1.002 – 1.092) 0.04
 Anastomosis time (min) 1.016 (1.000 – 1.033) 0.05 1.017 (1.000 – 1.034) 0.06
Recipient characteristics
 Age 1.027 (1.005 – 1.049) 0.02
 Sex (male / female) 1.236 (0.698 – 2.190) 0.47
 Transplant center (regional / export) 0.909 (0.536 – 1.541) 0.72
 Transplantation yeara 1.011 (0.970 – 1.053) 0.61
     1981 - 1989 35 (11%)
     1990 - 1998 96 (29%)
     1999 - 2007 200 (60%
  Kidney disease (renovascular / other) 0.867 (0.427 – 1.761) 0.69
 Dialysis time (years) 1.016 (0.928 – 1.113) 0.73
  Dialysis type (haemodialysis / peritoneal 
dialysis) 0.944 (0.540 – 1.649) 0.84
 Retransplantation (yes / no) 1.207 (0.561 – 2.598) 0.63
 Total HLA mismatches 1.077 (0.839 – 1.382) 0.56
 Peak panel reactive antibody (PRA) 0.992 (0.953 – 1.033) 0.71
  Calcineurin inhibitor (cyclosporine / 
tacrolimus) 0.799 (0.447 – 1.428) 0.45
 Anti-metabolite (yes) 0.471 (0.275 – 0.806) 0.006 1.919 (1.059 – 3.476) 0.03
 Sirolimus (yes / no) 1.383 (0.716 – 2.670) 0.33
 Induction therapy (yes / no) 1.942 (1.016 – 3.711) 0.045
a As continuous variable.
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When thirteen controlled DCD donors which were preserved with rapid 
laparotomy and direct cannulation of the aorta (26 kidneys) were excluded from 
analysis, the short and long-term graft function of controlled DCD kidneys remained 
equivalent as previously and there were still no significant differences with 
uncontrolled DCD kidney transplantation. However, the p-value of cold ischemia as 
an independent risk factor for kidney failure increased to 0.07, which may be due to 
the smaller number of kidneys in this analysis (data not shown).
Figure 2.1 Kaplan-Meier curves of uncontrolled and controlled kidney transplantation for (A) death-
censored graft survival and (B) recipient survival of all kidneys.  
* One recipient died with an unknown graft function and was excluded from the Kaplan-Meier analysis.
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DISCUSSION
According to the National Organ Procurement and Transplantation Network 
(OPTN) in the United States, the total number of candidates waitlisted for a kidney-
alone transplantation at the beginning of 2010 rose to 83 321. The United States Renal 
Data System reported that Medicare spent $18.5 billion on the treatment of dialysis 
patients in 2007. In addition, Medicare pays billions each year for the hospitalization 
of dialysis patients. Despite the costs, a substantial proportion of dialysis patients 
die every year. In 2006, 20.1% of U.S. dialysis patients died, most often of heart 
disease or infections. In the U.S. and the largest part of Europe, where brain death 
is legally and culturally acceptable, most donor kidneys are recovered from brain-
dead donors (15). Efforts to increase the number of organ donors have resulted in 
increases both in living donation and use of deceased donors at the extremes of age 
(16). Although the use of donors after cardiac death has been popularized in the past 
decade, the number of organ donors is not sufficient to shorten the waiting list. In 
the Netherlands, almost 50% of the deceased donors are donors after cardiac death, 
which has led to a stable number of deceased organ donors, despite the reduction of 
brain-dead donors.
 In our series, the threshold to discard kidneys is relatively high and therefore 
the percentage of kidneys from donors after cardiac death with delayed graft function 
and primary non-function is higher than that of brain-dead donor kidneys. However, 
the long-term graft survival of functioning kidneys is similar to kidneys from brain-
dead donors and also the recipient survival does not differ (3). Moreover, delayed 
graft function in kidneys from donors after cardiac death does not adversely affect 
graft survival as in brain-dead donor grafts (17). Recently it has been shown that, 
despite the relatively high incidence of never functioning grafts, waitlisted patients 
who receive a kidney from a donor after cardiac death live longer than patients who 
continue dialysis treatment with the option of later receiving a brain-dead donor 
kidney transplantation (4). This justifies a more widespread use of donation after 
cardiac death. 
 The pool of controlled donors is relatively small, compared to the potential 
pool of uncontrolled donors. In the United States, the United Kingdom, and in the 
Netherlands, most donors after cardiac death are controlled donors. In southern 
Europe, uncontrolled donation has been increasingly used since 1989 (18). The results 
of centers in Spain are very promising, but information about the comparison with 
controlled donation is very limited (19-21). In our center we have used both controlled 
and uncontrolled donors after cardiac death since 1981. However, as the long-term 
outcome of uncontrolled compared to controlled donation remained unknown, the 
use of uncontrolled donor kidneys was relatively limited and nephrologists were 
reluctant to accept these kidneys for transplantation. 
 Further obstacles to initiate uncontrolled donor programs include legislation 
which differs per country, and the relatively complicated infrastructure required to 
recognize uncontrolled donors and to preserve and procure the organs. Potential 
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donors have to be recognized on the streets by the ambulance crew and to be taken 
to the hospital where trained surgical staff is available to preserve the organs at every 
moment. In the Netherlands, the law has been changed to allow minimally invasive 
procedures to preserve potential uncontrolled donor kidneys, prior to consent from 
relatives.
 The insertion of a double-balloon triple-lumen catheter is a minor surgical 
procedure, but carries a relatively large incidence of complications such as catheter 
malposition and poor perfusion of the organs, particularly if done by inexperienced 
doctors. This partly explains the high percentage of discarded uncontrolled kidneys 
in this study, as in situ preservation in uncontrolled donors is usually done by junior 
staff. For controlled DCD donors, rapid laparotomy and direct aortic cannulation can 
be arranged and should be preferred to ISP because it is associated with reduced 
warm ischemia times, lower discard rate and superior graft survival. Moreover, organs 
other than kidneys may be procured by this technique (9). In the present series, in 
only 12% of the controlled DCD donors, direct aortic cannulation was used. Direct 
aortic cannulation became the preservation technique of choice since 2006, after 
introduction of DCD multi organ donation. In donors after cardiac death, warm 
ischemic damage is the most crucial factor for transplant outcome. In controlled 
donors, the warm ischemic injury can be estimated from the hypotensive period 
prior to cardiac death and the period between death and organ preservation. For 
uncontrolled donors it is difficult to quantify warm ischemic damage. The moment 
of cardiac arrest is often not exactly known and organ perfusion during resuscitation 
varies widely. Machine perfusion characteristics and organ viability markers have not 
been shown to reliably estimate warm ischemic damage and viability of the kidneys 
(22, 23). Therefore, we have used the criteria set in Table 2.2 to accept uncontrolled 
donor kidneys for transplantation. However, these criteria differ between institutions 
and depend on resuscitation and preservation methods. Selecting expanded criteria 
uncontrolled donors should be done with extreme caution, since these kidneys are 
related with a high risk of PNF. Advances in resuscitation, such as portable automated 
chest compression devices and the use of extracorporeal membrane oxygenation, 
may improve organ perfusion during resuscitation or after cardiac death and widen 
the criteria for donation and increase the number of donors, but are ethically 
controversial (24). 
 This study demonstrates that the initial function and long-term outcome 
of kidneys from uncontrolled donors after cardiac death is comparable with the 
outcome of kidneys from controlled donors. The majority of the controlled DCD 
kidneys were preserved with the DBTL-catheter. Future studies with large populations 
may determine whether direct aortic cannulation improves the results of controlled 
DCD transplantation. For both groups, a careful selection of both donor kidneys 
and recipients remains mandatory to reduce the risk of non-functioning grafts. 
These results justify the expansion of the donor pool with uncontrolled donors to 
reduce the still growing waiting list for renal transplantations and may stimulate the 
implementation of uncontrolled kidney donation programs.
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ABSTRACT
Background: Kidneys from uncontrolled donors after cardiac death (DCD) 
expand the donor pool, but are associated with more primary non-function (PNF) 
and delayed graft function (DGF) compared with more conventional donor kidneys. 
It remains unclear, which factors influence outcome of uncontrolled donation. 
Therefore, we studied which donor, graft, and recipient characteristics are associated 
with PNF in a large cohort study. 
Methods: The association between different characteristics and short-term 
graft-function was analyzed for kidneys procured in the Maastricht region from 1 
January 1981 until 1 July 2009. Patients were followed until 1 July 2010. 
Results: A total of 135 uncontrolled donor kidneys were included in this study. 
The incidence of PNF and DGF was 22% and 61%, respectively. Increasing donor 
age is an independent risk factor for graft failure in a univariate analysis (OR 1.035, 
95%CI 1.004–1.068, p=0.028). Donor age remains strongly associated with PNF in a 
multivariate analysis (OR 1.064, 95%CI 1.013–1.118, p=0.014). However, the predictive 
value of donor age alone is poor (AURC 0.640, 95%CI 0.553–0.721). 
Conclusion: Increasing donor age of uncontrolled DCD donors is a major risk 
factor for PNF. Other clinically relevant variables were not associated with PNF. Donor 
age is strongly associated with PNF and remains an important parameter in donor 
selection.
Published as
E.R. Pieter Hoogland, Tim C. van Smaalen, Maarten H.L. Christiaans, L.W. Ernest van Heurn. Kidneys from uncontrolled 
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INTRODUCTION
In the past decades, kidney transplantation using organs obtained from donors 
after cardiac death (DCD) has gained popularity and a wider acceptance in many 
countries as a valuable tool to decrease the waiting time for kidney transplantation 
(1-3). Most DCD kidney donation programs only include kidneys from controlled DCD 
donors, donors who died after withdrawal of futile medical treatment. Uncontrolled 
DCD donation has not yet obtained the same wide acceptance, but its use is increasing. 
In uncontrolled donors, donors who die after failed resuscitation, the period 
between circulatory arrest and organ preservation is often not exactly known and the 
efficacy of cardiopulmonary resuscitation is difficult to assess. Therefore, these kidneys 
are exposed to unknown ischemic injury during the inevitable period of warm ischemia, 
which may result in higher incidences of primary non-function (PNF) and delayed 
graft function (DGF). The relatively unknown ischemic injury and the unplanned 
situation of the procedure have led to a general reluctance to initiate uncontrolled 
DCD programs and to accept uncontrolled DCD kidneys for transplantation. There 
are a limited number of uncontrolled DCD kidney transplantation programs in Spain 
and France with excellent results (4, 5). Furthermore, a recent study shows that the 
clinical outcome of uncontrolled DCD kidneys is comparable to that of controlled 
DCD kidneys (6). This justifies a more widespread use of uncontrolled DCD donors to 
reduce the still growing waiting list for renal transplantation and may stimulate the 
implementation of uncontrolled DCD kidney programs. 
Most studies which assessed DCD kidney transplantation outcomes analyzed 
either controlled DCD kidneys or uncontrolled and controlled DCD kidneys together. 
Despite the different mechanism of ischemic injury, the risk factors for the outcome 
of uncontrolled DCD kidney transplantation have not been studied before. Because 
of the increased popularity, it is essential to know which uncontrolled DCD kidneys 
can be accepted for transplantation and which kidneys better can be discarded. Our 
center has a long-time experience with the use of uncontrolled donor kidneys for 
transplantation since 1981. To describe the opportunities and limits of uncontrolled 
DCD kidney transplantations, we assessed the results of our uncontrolled DCD 
program and determined which factors are associated with PNF or inferior graft 
function after transplantation of uncontrolled donor kidneys. 
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MATERIALS AND METHODS
Study design
Kidneys from uncontrolled DCD donors, procured in the Maastricht region 
from 1 January 1981 until 1 July 2009 and transplanted within the Eurotransplant 
region, were included in the current observational study. Patients were followed 
until the earliest of death or 1 July 2010. Kidneys were allocated according to the 
Eurotransplant allocation rules and were matched for Human Leukocyte Antigen 
(HLA) and blood group.
Donor and recipient data
Donor and perfusion characteristics of machine-preserved kidneys were 
routinely recorded at our institution. Recipient follow-up data were kindly provided 
by the recipient transplant centers, and was periodically updated in our database. 
The following graft characteristics were recorded: warm ischemia time (WIT), the 
period from circulatory arrest or stop of resuscitation until the initial cold flush of the 
kidneys; cold ischemia time (CIT), the period between the initial flush and the start of 
first anastomosis of the recipient operation; and the anastomosis period, the time to 
complete arterial and venous anastomoses. 
Short-term graft function after transplantation was classified as 1) primary 
non-function (PNF): permanent inadequate renal function necessitating continuation 
of dialysis or retransplantation; 2) delayed graft function (DGF): renal function which 
was ultimately life sustaining but required temporary dialysis in the first week after 
transplantation; and 3) immediate function (IF): immediate renal function without 
the need of postoperative dialysis. Graft survival is defined as functional survival off 
dialysis.
Renal function after transplantation was assessed using the estimated 
glomerular filtration rate (eGFR), which was calculated with the abbreviated 
Modification of Diet in Renal Disease equation (MDRD) (7-9). eGFR at 1 year after 
transplantation and the rate of decline in eGFR thereafter were studied as measures 
of kidney function.
Collection, storage, and use of patient data were performed in agreement 
with the code of conduct ‘use of data in health research’ from the Dutch Federation 
of Biomedical Scientific Societies (http://www.federa.org/); According to Dutch law, 
Institutional Review Board (IRB) approval was not required for scientific analysis of 
anonymous data.
Management of uncontrolled donors after cardiac death
Kidneys were procured from uncontrolled (Maastricht category II) donors 
according to the Maastricht DCD categories (10, 11). Organs were preserved with the 
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in situ preservation (ISP) technique, as described previously (11, 12). In short, after 
unsuccessful resuscitation and an obligatory no-touch period of five minutes, during 
which no interventions to the donor were taken, a double-balloon triple-lumen (DBTL) 
catheter was inserted into the aorta via one of the femoral arteries, followed by ISP 
of the donor kidneys with histidine-tryptophan-ketoglutarate solution (Custodiol; 
Dr. Franz Köhler Chemie, Alsbach, Germany) (13, 14). A large Foley catheter is 
placed in the femoral vein for decompression. This indispensable, minimally invasive 
technique may provide the opportunity to meet legal and logistical requirements for 
organ recovery without excessive WITs and, depending on the legal opportunities, 
can be initiated prior to consent for organ donation. It can be performed in the 
emergency department and allows fast and effective organ preservation. Insertion 
of the cannulas can be performed by surgeons with limited experience in donation 
procedures. After preservation and consent for organ donation, the organs were 
procured in the operating room. Following recovery of the kidneys in the operating 
room within two hours after the start of ISP, most of the kidneys were weighed and 
prepared for machine preservation and were placed in sterile organ chambers on 
Gambro PF-3B perfusion machines (Gambro, Lund, Sweden) using Belzer’s University 
of Wisconsin machine perfusion solution since 1985, at a mean temperature of 4 ºC. 
Eurocollins preservation solution was used before 1985 (15). Since 2006, the Lifeport 
(Organ Recovery Systems, Des Plaines, IL, USA) has been used as pulsatile perfusion 
machine. Added to the solution were 40 IU of insulin, 200.000 U of penicillin and 16 
mg of dexamethason. During machine perfusion, pH was adjusted to values >7.10, 
using sodium bicarbonate.
Statistical analysis
Continuous variables are presented as mean ± standard deviation (SD) if 
normally distributed, and as median and interquartile range (IQR) otherwise. 
Categorical variables are presented as percentages. Baseline donor, preservation, 
and recipient characteristics are compared with the Student’s t-tests for normally 
distributed continuous variables, with the Mann-Whitney U-test if the distribution 
was not normal, and with chi-square tests for categorical variables. The effects 
of all variables on PNF were tested with univariate logistic regression analysis. 
Multivariate logistic regression analysis was performed to identify potential risk 
factors for PNF, with correction for those characteristics that are considered to be 
potential confounders, defined by the 10% change-in-estimate rule (16), or if these 
criteria were not met, significant variables from the univariate analyses and potential 
confounders based on clinical relevance were used. The same criteria were used to 
determine the predictive value for PNF by the area under the ROC-curve (AURC). 
Sensitivity, specificity, positive predictive value (PPV), and negative predictive value 
(NPV) were analyzed using MedCalc statistical software.
Cox proportional hazards model was used to assess the effect of variables 
on death censored graft failure of primarily functioning kidneys, correcting for 
confounders as described for the multivariate analysis. Graft survival censored for 
recipient death with a functioning graft and patient survival was calculated with the 
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Kaplan-Meier method. 
The rate of decline in estimated glomerular filtration rate was calculated 
for each patient by simple linear regression from yearly glomerular filtration rate 
estimates, starting at 1 year after transplantation.
Machine-perfused kidneys were further analyzed to determine machine 
perfusion characteristics that are associated with outcome after transplantation.
All analyses were performed using Statistical Package for the Social Sciences 
(SPSS) software version 16.0 for Windows, and a p-value < 0.05 was considered 
statistically significant.
RESULTS
Patients
From 1 January 1981 to 1 July 2009, 280 kidneys from uncontrolled donors 
after cardiac death were procured in the Maastricht region, of which 133 from 85 
donors were discarded based on vascular anatomy (e.g. multiple renal arteries, 
renal artery stenosis, N = 14), macroscopic appearance (e.g. poor flush-out, cysts, 
renal capsula tears, N = 33), long WIT (N = 17), donor related problems (e.g. positive 
virology, diabetic nephropathy, N = 14), malplacement of the cannulas (N = 7), if there 
were no suitable recipients (N = 14), if the kidneys were considered too marginal to 
transplant (N = 24) or not reported (N = 10). Ten kidneys were transplanted outside 
the Eurotransplant region, data were missing of one transplanted kidney and one 
recipient died with an unknown graft function. Of the remaining 135 kidneys 
transplanted in the Eurotransplant region, 110 kidneys were machine perfused and 
25 kidneys were stored on melting ice until transplantation (cold-storage). 
Donor, graft, and recipient characteristics are summarized in Table 3.1. Mean 
donor age was 45 ± 16 years. The mean WITs and CITs were 26 ± 11 minutes and 27 ± 
6 hours, respectively. Donors and recipients predominantly comprised of men (73% 
and 68%, respectively).
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Table 3.1 Baseline characteristics and their association with primary non-function
Univariate analysis
OR (95% CI) p
Donor related
 Age (years) 45 ± 16 1.035 (1.004 – 1.068) 0.028
 Sex (male) 99 (73%) 0.658 (0.273 – 1.585) 0.351
 Cause of death (cardiovascular/other) 71 / 29% 2.934 (0.843 – 6.798) 0.101
 Hypertension (N = 107) (yes) 11% 1.479 (0.409 – 5.354) 0.551
 Creatinine (μmol/L) 122 ± 37 1.002 (0.991 – 1.013) 0.671
 Total CPR time (min)a 48 ± 25 1.001 (0.984 – 1.018) 0.911
Graft related
 Warm ischemia time (min) 26 ± 13 1.021 (0.988 – 1.054) 0.221
 Machine perfusion / cold storageb 81.5 / 18.5% 1.625 (0.511 – 5.164) 0.410
 Cold ischemia time (h)
 Of which machine perfusion time (h)
27 ± 6
22 ± 6 
0.999 (0.935 – 1.067)
1.026 (0.951 – 1.108)
0.972
0.505
 Anastomosis time (min) 39 ± 14 0.998 (0.968 – 1.028) 0.878
 GST T4 (U/L/100g) 71 (52 – 111)
c 1.005 (0.999 – 1.010) 0.089
 LDH T4 (U/L/100g) 565 (405 – 756)
c 1.001 (1.000 – 1.001) 0.104
 Renovascular resistance T0 1.03 ± 0.63 1.542 (0.768 – 3.093) 0.223
Recipient related
 Age (years) 51 ± 13 1.012 (0.980 – 1.044) 0.472
 Sex (male) 92 (68%) 2.118 (0.794 – 5.651) 0.134
 Re-transplantation (yes) 15 (11%) 1.301 (0.382 – 4.424) 0.674
 Total HLA mismatches 2.5 ± 1.1 1.066 (0.722 – 1.572) 0.746
 Transplant center (regional / export) 64 / 36% 1.182 (0.502 – 2.782) 0.702
 Kidney disease (renovascular / other) 
 (N = 116)
18 / 82% 0.964 (0.317 – 2.931) 0.949
 Dialysis time (years) 3.2 ± 2.6 1.020 (0.874 – 1.190) 0.799
 Dialysis type (hemodialysis) 88 (65%) 0.773 (0.310 – 1.931) 0.582
 Calcineurin inhibitor (yes) 118 (87%) 0.645 (0.208 – 2.003) 0.448
 Anti-metabolite (yes) 55 (41%) 0.449 (0.183 – 1.099) 0.080
 Sirolimus (yes) 29 (21%) 1.148 (0.436 – 3.022) 0.780
 Induction therapy (yes) 12 (9%) 1.185 (0.300 – 4.686) 0.809
a Resuscitation time + CPR after declaration of death.
b Odds ratio relates to machine perfusion.
c Expressed as median (interquartile range).
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Figure 3.1 Receiver operating characteristics (ROC) curve for PNF: Model A: Donor 
age; Model B: multivariate model with donor age, warm ischemia time, cold ischemia time and 
renovascular resistance at T0. The number in brackets indicates the area under the curve for 
each line. 
Short-term graft function
Of the transplanted kidneys, 30 recipients developed PNF (22%), 83 recipients 
DGF (62%) and 22 recipients IF (16%). Donor, graft, and recipient characteristics and 
their association with PNF are shown in Table 3.1. Only donor age was a significant 
risk factor for PNF in the univariate analysis (Table 3.1) and remained an independent 
risk factor for PNF in the multivariate analysis (Table 3.2). Further analysis of donor 
age, using the ROC-curve and its accompanying table (i.e. the point closest to the 
[1-1]-corner), showed the strongest association with PNF from an age of 54 years and 
older with an odds ratio of 2.857 (95% CI 1.242 – 6.571; p=0.013). Kidneys from donors 
of 54 years and older have a higher percentage of PNF compared with younger donor 
kidneys (35% vs. 16%, p=0.012, respectively).
The predictive value of donor age on PNF was poor (AURC 0.640, 95% CI 0.553 
– 0.721). Adding the variables as used in the multivariate analysis to the model, the 
predictive value increased to ‘fair’ (AURC 0.719, 95% CI 0.618 – 0.805) (Figure 3.1, 
Table 3.3). 
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Table 3.2 Multivariate analysis of the risk of primary non-function and graft failurea
Multivariate logistic regression Cox regression
Odds ratio (95% CI) p Hazards ratio (95% CI) p
Donor age (years) 1.064 (1.013 – 1.118) 0.014 1.038 (1.015 – 1.060) <0.001
Warm ischemia time (min) 1.045 (0.997 – 1.096) 0.068 1.015 (0.992 – 1.039) 0.202
Cold ischemia time (hours) 1.047 (0.946 – 1.158) 0.376 1.045 (0.996 – 1.096) 0.074
Renovascular Resistance T0
(mmHg/mL/min/100 g)
1.256 (0.602 – 2.618) 0.544 - -
a A logistic regression model was used to determine the odds ratio for PNF, and a Cox proportional hazards model was 
used to determine the hazards ratio for death censored graft failure of primarily functioning kidneys.
Long-term outcomes
The median period of follow-up after transplantation was 6.5 (IQR 3.5 – 
12.2) years. Graft survival at 1 and 5 years after transplantation was 75% and 63%, 
respectively; kidneys with PNF included. Figure 3.2 shows graft survival, censored for 
recipient death with a functioning graft, of all transplanted kidneys (Figure 3.2A) 
and functioning kidneys alone (Figure 3.2B), with donor age categorized in groups. 
Graft survival of all transplanted kidneys was significantly lower for donor kidneys of 
54 years and older, but graft survival of functioning kidneys was equivalent in both 
groups. Recipient survival was similar in both groups (Figure 3.2C).
 Mean eGFR of functioning grafts was 36.2 mL/min/1.73 m2 at 3 months, 40.7 
mL/min/1.73 m2 at 1 year, and 45.0 mL/min/1.73 m2 at 5 years after transplantation. 
Donor age was significantly correlated with a decrease in eGFR (Pearson’s r=-.418, 
p<0.001) at 1 year after transplantation and at 5 years after transplantation (Pearson’s 
r=-.497, p<0.001).
 In the Cox proportional hazards model, donor age was significantly associated 
with death censored graft failure of primarily functioning kidneys (HR 1.038, 95% CI 
1.015 – 1.060, p<0.001) (Table 3.2).
Table 3.3 Predictive values of donor age for PNF
AURC (95% CI) Sensitivity Specificity PPV NPV
Model A 0.640 (0.553 – 0.721) 0.533 0.714 0.348 0.843
Model B 0.719 (0.618 – 0.805) 0.500 0.933 0.687 0.864
Model A: Donor age alone; Model B: Donor age, warm ischemia time, cold ischemia time, and renovascular resistance 
at T0. PPV: positive predictive value, NPV: negative predictive value.
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DISCUSSION
The use of kidneys from controlled Maastricht category III DCD donors for 
transplantation is generally accepted in most countries where it is legal to withdraw 
futile medical treatment (17, 18). The pool of controlled donors after cardiac death, 
however, is limited. Only a small proportion of intensive care patients, in whom 
further treatment is considered to be futile and who are not brain-dead, meet 
donation criteria. The number of patients who die after failed resuscitation is much 
higher (6). Therefore, these patients can be a valuable addition to the DCD donor 
pool as uncontrolled Maastricht category I and II DCD donors. However, uncontrolled 
DCD donor kidneys are rarely used. There is a general reluctance to use uncontrolled 
DCD kidneys, with only a few uncontrolled DCD programs, mainly in Spain and in 
France (19).
In the present study, Maastricht categories I and II are analyzed together as 
‘uncontrolled donors’. It is difficult to distinguish category I from category II DCD 
donors, estimate resuscitation time, and ischemic damage. In the Netherlands, 
patients are not taken to the hospital after declaration of death on the street as 
category I donors are in Spain. It is forbidden to transport dead people to a hospital, 
but allowed for resuscitation only. So, potential donors are resuscitated and if the 
patient dies, only in the hospital death is declared. This results in longer resuscitation 
periods of our category II donors than the category I donors in Spain.
Figure 3.2 Kaplan-Meier graft survival curves of A) all transplanted uncontrolled DCD kidneys, B) 
functioning kidneys only, all censored for recipient death with a functioning graft, and C) recipient 
survival.
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 The use of uncontrolled kidney donors has led to an increase in the number 
of available donor kidneys for transplantation at our center. A recent study from our 
group showed no difference in transplant outcomes of uncontrolled compared with 
controlled donor kidneys (6).
The incidence of PNF was relatively high in this group of patients, which 
enabled us to adequately assess risk factors for non-function after transplantation. 
Reasons for the high incidence of PNF may be influenced by several factors. First, 
the definition of PNF used in our center is permanent inadequate renal function 
necessitating continuation of dialysis or retransplantation. This includes kidneys which 
failed because of hyperacute rejection, graft thrombosis, and surgical complications. 
Second, the CIT with a mean period of 27 hours is much longer than in other studies. 
All kidneys are allocated according to the Eurotransplant allocation rules. As many 
centers are reluctant to accept marginal DCD kidneys and decline an organ offer, it 
usually takes hours before kidneys are finally offered to our center. Third, because of 
the shortage of donor organs, we had a liberal acceptance strategy for DCD kidneys. 
Despite our finding of a higher incidence of PNF and DGF in kidneys from DCD 
donors, patients who receive a DCD kidney have better survival rates than patients 
who continue dialysis treatment while waiting for a kidney from a conventional 
brain-dead donor (3, 20, 21).
Kidneys from DCD donors that overcome the early post-transplantation period 
function as long as DBD (donation after brain death) kidneys. Contrary to DBD 
kidneys, DGF in DCD kidneys hardly affects graft survival (22, 23). As transplantation 
of non-viable kidneys results in unnecessary risk of surgery and immunosuppression, 
and sensitizes the recipient for future transplants, it is essential, particularly for DCD 
kidneys with a relatively high risk of PNF, to adequately assess the risk of non-function 
after transplantation (21).
Our results show that only donor age is independently associated with PNF. 
The predictive value of donor age only was poor, but adding the clinically important 
variables WIT, CIT and renovascular resistance during machine perfusion to the 
model, the predictive value increased to fair. Kidneys from donors of 54 years and 
older do worse than younger donor kidneys; however, like in controlled DCD kidneys, 
an absolute cut-off value cannot be provided. In a relatively large group of controlled 
and uncontrolled DCD kidneys, the results of pre-transplant biopsy increase the 
predictive value for graft survival in older donor kidneys (24).
Kidneys from DCD donors are inevitably subjected to a period of warm 
ischemia. Our data, however, shows no significant association between WIT and PNF. 
This may be biased as a total WIT longer than 45 minutes was a reason to discard 
kidneys for transplantation. Despite this potential bias, we found a trend towards 
significance in the multivariate analysis. In controlled DCD kidneys, a WIT longer than 
45-60 minutes is also associated with an increased risk of PNF and DGF (25, 26).
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In our present study of uncontrolled DCD kidneys only, renovascular resistance 
was not associated with PNF. In a previous study from our group, we have shown that 
renovascular resistance of all Maastricht category II and III machine perfused DCD 
kidneys at the beginning of machine perfusion is independently associated with PNF, 
however, its predictive value is low (27).
Perfusate biomarkers of machine-perfused kidneys, including glutathione 
S-transferase (GST) and lactate dehydrogenase (LDH), have been used to identify 
risk factors for PNF and DGF in DCD kidneys (28-31). In some studies, GST has a 
strong correlation with graft viability, but others have not been able to confirm this 
association (29-31). For LDH concentration, no correlations were found with short-
term graft function (29, 31, 32). This makes it hard to discard DCD kidneys based 
purely on perfusate biomarker concentrations. In the present study, GST and LDH 
concentrations were not correlated with PNF. 
Direct cannulation of the aorta is the method of choice to preserve kidneys 
of DCD donors (33). In the Netherlands, minor invasive procedures are allowed to 
preserve the organs of potential donors before consent of the relatives and if a 
patient is not registered with objection in the national donor registry. Therefore, 
laparotomy with direct cannulation of the aorta is not feasible in uncontrolled 
donors. In this study, ISP with cold perfusate has been used to preserve donor kidneys. 
This technique is associated with longer WITs, a higher discard rate, and inferior 
graft survival compared to direct aortic cannulation (6). The use of normothermic 
extracorporeal membrane oxygenation (ECMO) after cardiac arrest may be a valuable 
alternative for hypothermic ISP with the DBTL-catheter. Advantages of ECMO include 
recirculation of oxygenated blood until organ procurement, maintaining or restoring 
adenosine levels, and it may offer the opportunity of viability testing of normothermic 
perfused kidneys (34, 35). This technique has the potential to improve organ quality 
of ischemically damaged uncontrolled DCD kidneys with better graft function and 
graft survival (36, 37). In addition, preservation with ECMO after cardiac death may 
provide the opportunity to procure more organs, including the liver, so that they can 
be used for transplantation (34). However, more clinical evidence of the benefits of 
ECMO is necessary (38).
It cannot be excluded that there are more risk factors for poor uncontrolled 
DCD kidney function than old age. Despite the relatively high percentage of PNF, 
which increases the power to identify risk factors and, compared with other studies, 
the large group of DCD transplantations, the number of analyzed donor kidneys 
remains relatively small to identify all possible risk factors for PNF.
The present study shows that donor age is associated with graft function of 
uncontrolled DCD kidneys, so this may influence the decision to accept or discard an 
uncontrolled DCD kidney.
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ABSTRACT
Background: To reduce the growing waiting list for kidney transplantation, 
we explored the limits of kidney transplantation from donors after cardiac death by 
liberally accepting marginal donor kidneys for transplantation. As the percentage 
of primary non-function (PNF) increased, we evaluated our transplantation program 
and implemented changes to reduce the high percentage of PNF in 2005, followed by 
a second evaluation over the period 2006 - 2009. 
Methods: Recipients of a kidney from a donor after cardiac death between 
1998 and 2005 were analyzed, with PNF as outcome measure. 
Results: During the period 2002 - 2005, the percentage of PNF increased and 
crossed the upper control limit of 12% which was considered as unacceptably high. 
After implementation of changes, this percentage was reduced to 5%, without 
changing the number of kidney transplantations from donors after cardiac death. 
Conclusion: Continuous monitoring of the quality of care is essential as the 
boundaries of organ donation and transplantation are sought. Meticulous donor, 
preservation and recipient management make extension of the donor-potential 
possible, with good results for the individual recipient. Liberal use of kidneys from 
donors after cardiac death may contribute to a reduction in the waiting list for kidney 
transplantation and dialysis associated mortality.
Published as
E.R.P. Hoogland, M.G.J. Snoeijs, M.A.W. Habets, D.S. Brandsma, C.J. Peutz- Kootstra, M.H.L. Christiaans, L.W.E. van 
Heurn. Improvements in kidneys transplantation from donors after cardiac death. Clin Transplant 2013;27(3):E295-301
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INTRODUCTION
The Maastricht University Medical Center (MUMC) started a kidney 
transplantation program in 1980. At that moment, only excellent donor kidneys from 
young, brain-dead donors (DBD) were used for transplantation. While the waiting 
list for kidney transplantation was growing, the number of organ donors remained 
stable. Therefore, the need for additional sources of organ donors became more 
important, and the pool of donor organs was expanded by the use of kidneys from 
donors after cardiac death (DCD). In the early years of the transplant program, DCD 
kidneys were only occasionally used. However, the demand for donor organs increased 
and DCD kidney transplantation was stimulated. We started using organs from older 
DCD donors and with longer periods of warm ischemia for transplantation. In the 
early nineties, 25% of the deceased donors were DCD donors. 
The promising results of DCD kidney transplantation, which were equivalent to 
the results of DBD kidney transplantation, made us to further expand the criteria for 
DCD donation (1). Unfortunately, the expanded use of DCD kidneys was accompanied 
with an increase of the percentage primary non-function (PNF) of transplanted 
kidneys. Therefore, we evaluated the quality of care at our center and assessed if 
improvements could be made to reduce the high PNF rate.
MATERIALS AND METHODS
Study design
All patients who received a kidney from a DCD donor at the surgical department 
of the Maastricht University Medical Center were analyzed. Their data were extracted 
from our periodically updated database. The quality of DCD kidney transplantation 
was monitored with the incidence of PNF as quality indicator. An incidence of PNF of 
12% was considered to be the upper limit of good clinical practice. 
Initially, the quality of care was monitored for DCD kidneys transplanted 
between 1998 and 2006. When our results crossed the upper control limit of good 
clinical practice, possible risk factors for unfavorable outcome were identified, and 
a change to our practice was implemented. Four years after the implementation of 
drastic measures to reduce PNF, a second analysis was performed of all DCD kidney 
transplantations from 01/01/2006 until 01/01/2010. 
Data source and definitions
Data of all kidney transplantations from DCD donors were extracted from our 
periodically updated database. 
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Warm ischemia time in uncontrolled donors was defined as the time between 
cessation of cardiopulmonary resuscitation and the start of organ perfusion. For 
controlled donors, warm ischemia time was defined as the time from cardiac arrest 
(no arterial pulse) to the start of organ perfusion. Both included the obligatory no-
touch period of five minutes. The management of DCD donors has been described 
previously (2).
PNF was defined as an inadequate renal function after transplantation, which 
necessitated continuation of dialysis treatment or retransplantation. This definition 
included kidneys that failed because of hyperacute rejection, graft thrombosis, and 
surgical complications.
Graft failure, censored for recipient death with a functioning graft, was 
defined as permanent return to dialysis treatment or retransplantation.
The immunosuppressive regimen evolved over the study period and depended 
on different trials. Immunosuppression was mainly based on a combination of a 
calcineurin inhibitor (cyclosporin or tacrolimus) and prednisolone. Depending on 
the protocol at the time, these were combined with azathioprine, mycophenolate 
mofetil, sirolimus or daclizumab in recipients with an increased immunological risk 
(e.g., HLA immunization and retransplants).
Collection, storage and use of patient data was performed in agreement with 
the code of conduct ‘use of data in health research’ from the Dutch Federation of 
Biomedical Scientific Societies (http://www.federa.org/); According to Dutch law, 
Institutional Review Board (IRB) approval was not required for scientific analysis of 
anonymous data. 
Statistical analyses
Continuous variables are presented as means ± standard deviations (SD) if 
normally distributed (histogram), and as median and inter-quartile range otherwise. 
Categorical variables are presented as percentages. 
Transplantation outcome, with PNF as outcome measure, was monitored 
using a funnel plot; the standard deviation was calculated with the formula 
“σ=√p(1-p)/n”, where p is our pre-selected standard of good clinical care, and n is the 
number of transplantations. Within the funnel plot, upper control limits were set at 
2 (‘alert’) and 3 (‘alarm’) standard deviations above the target standard. The funnel 
plot shows the percentage of PNF on the y-axis against case number on the x-axis. 
Baseline donor, preservation, and recipient characteristics are compared 
between the periods 1998 - 2001, 2002 - 2005 and 2006 - 2009 with the ANOVA 
test for approximately normally distributed continuous variables and with chi-square 
tests for categorical variables. 
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All analyses were performed using Statistical Package for the Social Sciences 
(SPSS) software version 16.0 for Windows, and a p-value ≤ 0.05 was considered 
statistically significant.
RESULTS
From 1/1/1998 until 12/31/2005, 173 DCD kidneys were transplanted at 
the Maastricht University Medical Center. Of these, four kidneys were excluded 
because the recipient died with an unknown graft function within 24 hours after 
transplantation due to cardiac failure (N = 3) or the recipient underwent transplant 
nephrectomy due to a malignancy found after donor autopsy (N = 1). Two kidney 
pairs were transplanted en bloc and analyzed as one. Initially, the PNF rate was 11% 
in the period 1998 – 2001, but it gradually increased in the period 2002 – 2005, during 
which the PNF percentage followed the alert line in 2003 and 2004 and crossed the 
upper control limit (the alarm line) of good clinical practice in 2005 (Figure 4.1 and 
4.2). 
Figure 4.1 Number of primary non-function of all DCD kidneys transplanted in Maastricht University 
Medical Center. Dashed bars represent numbers after implementation of strategies to reduce the high 
rate of primary non-function.
 To assess if the high percentage of PNF could be reduced, room for 
improvement of donor, preservation, and recipient characteristics that potentially 
affect the outcome after transplantation in our previously treated group of transplants 
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were evaluated. Potential risk factors for poor outcome that were analyzed included: 
1) donor age; 2) DCD category; 3) warm ischemia time, including duration and the 
method of in situ preservation (ISP); and 4) duration of cold ischemia time (CIT) (2-5).
1. DCD kidneys from donors aged 60 years or older showed a higher incidence 
of PNF and inferior graft survival compared to kidneys from younger 
donors (3, 6, 7). The worse results in this age-group were correlated with 
the results of pre-implantation histology, defined by Remuzzi et al. (3, 7, 
8).
2. The incidence of PNF in controlled and uncontrolled DCD donors was 
equivalent (2).
3. Prolonged in situ preservation with a duration of preservation longer 
than 17 minutes was associated with a higher percentage of PNF. The 
association was stronger than for warm ischemia time (including the no-
touch period and ISP insertion time) (4). Moreover, direct cannulation of 
the aorta was superior to ISP for controlled donors (5).
4. Duration of cold ischemia was tried to be kept to a minimum.
Consequently, the following changes were implemented: Firstly, in donors 
older than 60 years, the decision to transplant a kidney, to use both kidneys as dual 
transplant or to discard the donor kidney was made with the help of pre-implantation 
histology. If the Remuzzi score was ≥ 4, kidneys were generally discarded or, if 
available, used for dual transplantation. If the score was ≤ 3, kidneys were accepted 
for transplantation (3). Secondly, donor kidneys with ISP insertion time longer than 
30 minutes were generally discarded. Thirdly, for controlled DCD donors, direct aortic 
cannulation rather than ISP became the preservation method of choice. Fourthly, 
extra attention was paid to emphasize the importance of shorter CIT by reducing 
waiting time for operating theatre availability.
 To assess if these changes were effective and resulted in a lower incidence 
of PNF, we performed a second evaluation. In the period 1/1/2006 until 1/1/2010, 
100 DCD kidney transplantations were performed. Three patients with an unknown 
short-term graft function were excluded from analysis. Reasons for exclusion were 
recipient death due to cardiac failure (N = 1), removal of transplanted kidney due to 
a Grawitz-tumor detected after transplantation (N = 1), and a surgical complication 
during transplantation (N = 1). Three kidney pairs were transplanted en bloc and 
were analyzed as one. 
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The implemented changes resulted in the following improvements:
1. Biopsies were routinely taken for donors older than 60 years of age. Four 
kidneys from two donors older than 60 years of age were transplanted en 
bloc in the 2006-2009 period, compared to none in the 2002 - 2005 period.
2. The percentage of transplanted kidneys with an ISP duration ≥ 30 minutes 
was reduced to 19% compared to 28% before; however, due to a small 
number, this difference was not statistically significant (p=0.398).
3. Direct aortic cannulation was used in 66%, compared with 36% in the 
period 2002 - 2005 (Pearson chi square; p<0.001), while the percentage 
of controlled donors was similar in both periods (73% and 81%, p=0.181) 
(Table 4.1).
4. The total CIT was reduced with an average of three hours (21 ± 5 vs. 24 ± 7, 
p<0.001, for the periods 2006 - 2009 vs. 2002 - 2005, respectively) (Table 4.1). 
The incidence of PNF of DCD kidneys transplanted at our center decreased 
to 5% in the period 2006 – 2009 (5 out of 94 transplants), significantly lower than 
in the period 2002 – 2005 (Pearson chi-square; p<0.001), and was well below the 
limits of our standard of good clinical care (Figure 4.1). The number of DCD donors 
(57 vs. 55 during the periods 2002 - 2005 and 2006 - 2009, respectively) and the 
percentage of DCD donors of all deceased donors (60% vs. 56%), have not changed 
since 1/1/2006. The donor age was higher in the period 2006 - 2009 (53 ± 15 vs. 45 
± 18, p=0.003); kidneys were less often preserved on a perfusion machine and a 
different immunosuppressive regimen was followed, which was a result of different 
trials during the study periods (Table 4.1).
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Table 4.1  Donor and recipient characteristics of DCD kidney transplantation in the 
period 1998-2001,  2002-2005 and 2006-2009.a
1998 - 2001 2002 - 2005 2006 - 2009
N = 72 N = 95 N = 94 p
Donor related
 Age (years) 47 ± 14 45 ± 18 53 ± 15 0.004
 Sex (male) 64% 60% 61% 0.866
 Donor type (controlled / uncontrolled) 67 / 33% 73 / 27% 81 / 19% 0.111
 Donor center (MUMC / other)b 79 / 21% 39 / 61 % 37 / 63% <0.001
Graft related
 Warm ischemia time (min)c 26 ± 9 23 ± 9 23 ± 11 0.082
 ISP method (DBTL / aortic cannulation) 98 / 2% 64 / 36% 34 / 66% <0.001
 Preservation type (cold storage / 
 machine perfusion)
7 / 93% 46 / 54% 63 / 37% <0.001
 Cold ischemia time (h) 28 ± 6 24 ± 7 21 ± 5 <0.001
 Anastomosis time (min) 35 ± 9 38 ± 19 42 ± 16 0.023
Recipient related
 Age (years) 54 ± 12 54 ± 13 57 ± 13 0.215
 Sex (male) 58% 64% 67% 0.508
 Re-transplantation (yes) 10% 11% 21% 0.067
 Total HLA mismatches 2.5 ± 0.9 2.6 ± 1.1 2.9 ± 1.3 0.208
 Dialysis time (years) 3.2 ± 2.7 3.8 ± 2.8 4.1 ± 3.0 0.101
 Dialysis type (hemodialysis / 
 peritoneal dialysis)
71 / 29% 57 / 43% 59 / 41% 0.157
 Cyclosporine/tacrolimus/none (%) 0 / 100 / 0% 1 / 87 / 12% 0 / 78 / 22% <0.001
 Anti-metabolite (yes) 46% 37% 23% 0.009
 Sirolimus (yes) 15% 64% 53% <0.001
 Induction therapy (yes) 6% 8% 1% 0.065
a       Data are presented as mean ± standard deviation, or as percentages. 
b       MUMC: Maastricht University Medical Center. 
c         Warm ischemia time was defined as the time from circulatory arrest until initiation of 
hypothermic organ perfusion and therefore does not include ventilator switch-off time and 
cardiopulmonary resuscitation time.
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Figure 4.2  Funnel plot of the percentage of primary non-function during the time period 1998 – 2005 and 
during 2006 – 2009, after implementation of strategies to reduce the high rate of primary non-function. Upper 
control limits can be seen to funnel towards the standard as procedure number increases.
DISCUSSION
Continuous efforts to improve the quality of care have become an important 
point of interest in health care organizations. Collection and repeated analysis of 
clinical data are indispensable steps in quality improvement, ensuring the highest 
quality of care for patients. To guarantee the optimal use of the limited number 
and often marginal donor organs on one side, and, in the meantime, to keep the 
outcomes of our DCD kidney transplantations within the limits of good clinical 
practice, the quality of the DCD kidney transplantations at our center is continuously 
monitored with primary non-function as outcome measure. Delayed graft function 
(DGF) is less appropriate as outcome measure, because DGF does not or hardly affect 
long-term graft survival in DCD kidneys (9-11).
At the moment of the first evaluations, it was unknown at which percentage 
of PNF the individual patient still benefits from transplantation with a DCD kidney. 
Therefore, we had arbitrarily set the PNF percentage at 12% as the standard of good 
clinical care. A PNF percentage of 12% seems unacceptably high in clinical practice 
compared with other studies (United States 1.6% (12), United Kingdom 3% (13)), 
because it results in unnecessary risk of surgery and immunosuppression, and sensitizes 
the recipient for future transplants. However, the yearly mortality of patients on 
the waiting list for kidney transplantation is between 6 and 10%. A more restrictive 
acceptance policy for transplantation of marginal kidneys would lead to discard of 
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many viable organs. To make sure that our policy had not lead to unacceptable risk 
for transplant recipients, we have addressed this dilemma. We showed that patients 
on the waiting list for kidney transplantation benefit from DCD transplantations, 
despite an incidence of PNF of 12%, instead of staying on the waitlist and wait for a 
conventional DBD kidney transplantation; DCD kidney transplantation was associated 
with a mean survival benefit of 2.4 months in the first 4 years after transplantation 
(14). Therefore, we think that 12% is an acceptable standard; however, every effort 
must be taken to get the PNF percentage below 5%. 
To compare the outcome with the standard of good clinical care, it is essential 
to use an adequate number of patients. If the evaluation period is too short, 
deviation from the standard may be due to chance. If the period is too long, results 
may be obscured by previous data in the evaluated period. A period of 4 years with 
approximately 100 transplants seems appropriate to adjust for deviations.
The rate of PNF was compared with the standard rate of 12% in a funnel chart. 
These charts measure performance over time and ‘signal’ if there is a deviation from 
accepted standards (15). If the line of 3 standard deviations is exceeded, one must 
conclude that a change must be implemented to return to the standard level of PNF. 
This would imply either to restrict the number of DCD donor transplants by stricter 
acceptance policy or to improve the complete process of DCD kidney transplantation 
which includes donor selection and management, preservation, and recipient care. In 
our series, we implemented four changes after which a re-evaluation was performed. 
These changes were derived from studies at our institute, from available literature 
and based on assumptions of factors which may affect short-term graft function. 
Kidneys from older donors have a worse outcome than kidneys from younger donors 
(7). The selection of kidneys for transplantation from DBD donors aged 60 years 
and older can be improved with histological assessment of chronic renal injury in 
pre-implantation biopsies (7, 16, 17). We confirmed these findings in our group of 
DCD kidneys and showed that histological assessment of pre-implantation biopsies 
is superior to other selection algorithms such as donor age and donor glomerular 
filtration rate (GFR) to predict short term graft function and graft survival (3). Since 
2006, all DCD donor kidneys from donors aged 60 years or older are histologically 
examined before implantation at our transplant unit (3, 8).
The quality of uncontrolled (Maastricht category II) DCD donor kidneys is 
intuitively considered to be less than the quality of controlled DCD kidneys. The warm 
ischemia time of uncontrolled kidneys is often not exactly known, and the effectiveness 
of cardiopulmonary resuscitation can hardly be assessed. In the analysis of our results, 
the short-term renal function and long-term graft survival were equivalent, so the 
uncontrolled DCD program was continued. Because the number of patients who die 
after failed resuscitation is relatively high compared with the number of controlled 
DCD donors, uncontrolled donors may be an important population to consider for 
kidney donation. An uncontrolled DCD program is a potential way to further expand 
the donor pool.
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Warm ischemia time and organ preservation techniques which limit warm 
ischemic injury to the organs are important variables for the outcome of DCD 
transplantation. Prolonged ISP is associated with poor outcome. This does not only 
reflect prolonged warm ischemia, but is also caused by difficult insertion of the ISP 
catheter in donors with severe atherosclerosis. We lowered the threshold to discard 
DCD kidneys with prolonged and difficult insertion of the cannulas. Furthermore, 
direct cannulation of the aorta with a laparotomy results in superior graft survival and 
has therefore become the preservation method of choice in controlled DCD donors. In 
uncontrolled donors, the use of extra corporeal membrane oxygenation (ECMO) may 
also improve preservation quality (18). In this study, the agonal phase, also known as 
ventilator switch-off time, was not analyzed. Data suggests that transplant outcome 
of DCD kidneys is not compromised by lengthening the minimum waiting time after 
withdrawal of life-supporting treatment (WLST) from one to four hours (19). In the 
Netherlands, the maximum agonal phase after WLST is two hours or an O2 saturation 
<80% and/or a mean arterial pressure <50 mmHg longer than 15 minutes within 
those two hours. If these phases are exceeded, the donation procedure normally is 
abandoned. In agreement with the recipient centers, longer agonal phases can be 
accepted (19, 20).
Several studies have reported that optimized peri-operative hemodynamic 
management of DBD donor kidney recipients is associated with a reduction of DGF 
(21-28). For the best initial graft function, adequate perfusion of the transplanted 
kidney is required. To achieve this, careful selection of the recipients is mandatory. 
Patients with a low blood pressure, including young recipients and recipients with 
cardiac failure, may not be able to generate a high enough blood pressure to 
adequately perfuse a kidney with ischemia reperfusion injury, which also may be 
adapted to the often higher blood pressure of the donor, and may not be suitable 
candidates to receive a DCD kidney. Optimal hemodynamic management is further 
achieved by expansion of the intravascular volume of the recipient. Dialysis with fluid 
extraction prior to transplantation is avoided. Together with the anaesthesiologists, 
we revised the operative and post-operative fluid management protocol with better 
expansion of the intravascular volume and, if necessary, inotropic support. However, 
this implemented change was difficult to quantify.
 One major limitation of this study is that it is difficult to assess the degree of 
contribution of each implementation specifically. Other developments may also have 
affected graft outcome including a significant reduction of the long cold ischemia 
times (29, 30). Although beneficial, the percentage of kidneys which were preserved 
by machine perfusion decreased after 2006. It remains routine to preserve most DCD 
kidneys which are procured in our own region during the Eurotransplant organ 
allocation process. DCD kidneys procured in other regions are not routinely machine 
perfused, unless prolonged cold ischemia times are expected. Additionally, in DCD 
donors younger than 50 years of age, machine perfusion is a risk factor for graft 
failure (Hazards ratio 1.35, p=0.02) (12). Therefore, these kidneys are not routinely 
machine perfused.
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Expansion of the donor pool is necessary to reduce the growing waiting list 
for kidney transplantation. Therefore, we have explored the limits of DCD kidney 
transplantation by liberally accepting marginal DCD kidneys for transplantation. This 
has led to a high percentage of PNF, which necessitated a change of our practice 
either by a restriction of our liberal acceptance strategy for DCD kidneys, which 
would undoubtedly have led to a reduction of the number of organ donors, or 
by improvement of our care. With our ‘aggressive’ DCD program, equivalent graft 
survival of primarily functioning DCD and DBD kidneys was achieved (31). Therefore, 
we continued our program after implementation of changes, without a reduction in 
the number of DCD donors. The latter has resulted in a significant decrease in the PNF 
rate without a reduction in the number of transplanted donor kidneys. 
Continuous monitoring of the quality of care is essential if the boundaries in 
organ transplantation are searched for. Meticulous donor, preservation, and recipient 
management make expansion of the donor potential possible with a favorable 
result for the individual recipient, who is better off with a marginal DCD kidney 
transplantation than staying on the waiting list and wait for a better organ. Another 
effort to be made is a further reduction of cold ischemia times in the Netherlands, 
because this may positively affect graft function (29). Too strict standards of good 
clinical care may contribute to an inadequate use of potential marginal donors 
for transplantation. If the PNF rate in our hospital remains substantially below our 
standard of good clinical practice, the threshold to accept kidneys for transplantation 
will be gradually lowered. In general, a liberal approach to accept marginal DCD 
donors for transplantation may contribute to a more widespread strategy to 
transplant DCD kidneys with a reduction of the number of patients on the waiting 
list with the dialysis associated mortality. However, such strategy requires careful 
monitoring of transplant outcome to guarantee that results remain within the limits 
of acceptable practice.
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ABSTRACT
Background: Donation after cardiac death (DCD) increases the number of 
donor kidneys but is associated with more primary non-function (PNF) and delayed 
graft function (DGF). It has been suggested that biomarkers in the preservation 
solution of machine perfused kidneys may predict PNF, although evidence is lacking. 
Methods: We analyzed the diagnostic accuracy of the perfusate biomarkers 
GST, LDH, H-FABP, redox-active iron, IL-18 and NGAL to predict PNF and DGF in 335 
DCD kidneys preserved by hypothermic machine perfusion at our center between 1 
January 1997 and 1 January 2008. The diagnostic accuracy of these biomarkers to 
predict PNF was evaluated with the area under the receiver operator characteristics 
curves (AURC). Additionally, the risk of DGF and graft failure was assessed. 
Results: LDH and IL-18 concentrations were associated with PNF (OR 1.001, 95% 
CI 1.000 - 1.002, p=0.005 and 1.001, 95% CI 1.000 - 1.002, p=0.003, respectively) in a 
multivariate analysis; the diagnostic accuracy for PNF was ‘poor’ for all biomarkers, 
but increased to ‘fair’ for redox-active iron and IL-18 in a multivariate analysis (AURC 
0.701 and 0.700, respectively). LDH and IL-18 concentrations were associated with 
DGF; biomarker concentration was not associated with 1-year graft survival. 
Conclusions: The diagnostic accuracy of the perfusate biomarkers GST, LDH, 
H-FABP, redox-active iron, IL-18 and NGAL to predict viability of DCD kidneys varies 
from ‘poor’ to ‘fair’. Therefore, DCD kidneys should not be discarded because of high 
biomarker perfusate concentration.
Published as
E.R.P. Hoogland, E.E. de Vries, M.H.L. Christiaans, B. Winkens, M.G.J. Snoeijs, L.W.E. van Heurn. The value of machine 
perfusion biomarker concentration in DCD kidney transplantation. Transplantation 2013;95(4):603-10
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INTRODUCTION
Renal transplantation is the treatment of choice for patients with end-
stage renal disease on dialysis treatment (1, 2). The growing waiting list for kidney 
transplantation has led to the use of kidneys from donors after cardiac death (DCD) as 
alternative organ source. Kidneys from these donors inevitably suffer from a period 
of warm ischemia (WIT), resulting in a higher percentage of delayed graft function 
(DGF) and primary non-function (PNF) compared with kidneys from conventional 
brain-dead donors (DBD) (3-5). 
 In recent years, kidney preservation by hypothermic machine perfusion 
has experienced renewed interest. In addition to the intended benefit of improved 
tissue preservation, machine perfusion also provides the opportunity to assess organ 
viability with the help of perfusion parameters and biomarkers in the perfusate (6, 
7). The assessment of organ viability is especially important in marginal kidneys with 
their increased risk of developing DGF and particularly PNF. Perfusate biomarkers, 
including glutathione S-transferase (GST) and lactate dehydrogenase (LDH), are 
promising or accepted tools to accept or discard kidneys for transplantation (8-
10). However, the value of perfusate biomarkers to predict organ viability is not or 
hardly known. Previous studies only assessed the value of biomarker concentration in 
selected kidneys and described the improvement of the results of DCD transplantation 
after the introduction of perfusate biomarkers to assess organ viability. Other studies 
included limited numbers of kidneys with an a priori good prognosis, and therefore 
without adequate power to determine if perfusate biomarker concentration can be 
safely used to discard valuable kidneys for transplantation (10-14).
 We evaluated the predictive value of the concentration of perfusate 
biomarkers GST, LDH, heart-type fatty acid binding protein (H-FABP) and redox-
active iron of a large unselected group of DCD kidneys with a relative poor prognosis 
and a high incidence of graft failure, in which perfusion parameters and biomarkers 
have not been used to discard the organs. Additionally, new potential biomarkers 
interleukin (IL)-18 and neutrophil gelatinase-associated lipocalin (NGAL) were 
measured.
MATERIALS AND METHODS
All DCD kidneys preserved with hypothermic pulsatile machine perfusion at 
our center between 1 January 1997 and 1 January 2008, which were transplanted 
within the Eurotransplant region, were analyzed. This included kidneys procured at 
our center and kidneys procured elsewhere which were transplanted either at our 
center or elsewhere. 
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Organ procurement and preservation
Kidneys were procured from uncontrolled (category 1 and 2) and controlled 
donors (category 3 and 4) according to the Maastricht DCD categories (15, 16). Kidneys 
were preserved with in situ preservation using a double-balloon triple-lumen (DBTL) 
catheter or with direct aortic cannulation after rapid laparotomy (16, 17). After donor 
nephrectomy, the kidneys were weighed and placed in sterile organ chambers on 
Gambro PF-3B perfusion machines (Gambro, Lund, Sweden). Kidneys were perfused 
with 500 mL of UW-MPS (Belzer MPS, Trans-Med Corporation, MN, USA) at a mean 
temperature of 4 ºC. After connection of the kidney to the machine, perfusion flow 
was set to a systolic pressure of 55 mmHg, which was maintained during the first 60 
minutes by adjusting machine flow. After this, renal flow was kept constant. During 
perfusion, pH was adjusted to values more than 7.10. 
Sample collection and measurement
Perfusate samples for biochemical analysis were taken at 1, 2 and 4 hours 
of perfusion (T1, T2 and T4, respectively). Samples were immediately stored at 
-80 ºC. The assays used for detection of GST and LDH were routine assays from our 
local laboratory. GST activity was determined by measuring the enzyme-catalyzed 
conjugation of GST with 1-chloro-2,4-dinitrobenzene, using a spectrophotometer 
at λ 340 nm. LDH measurement is based on the measurement of NAD+ formed via 
the enzymatic reaction of LDH with pyruvate and NADH, using a spectrophotometer 
at λ 340 nm. For H-FABP, standard enzyme-linked immunosorbent assay (ELISA) 
kits (Human H-FABP ELISA kit, cat. number HK401; Hycult Biotechnology, Uden, 
The Netherlands) were used. For redox-active iron measurements, the bleomycin 
detectable iron assay, used before by our group, was applied (18).
 At T0 to T4, machine perfusion characteristics (temperature, pressure, flow, 
and renovascular resistance) were registered. Perfusate biomarker concentration is 
expressed per 100 g kidney weight. 
 Additionally, IL-18 and NGAL concentrations (of transplanted kidneys only) 
at 4 hours after start of machine perfusion were measured. For NGAL and IL-18, 
standard ELISA kits were used (Human Lipocalin-2 ELISA kit, cat. number orb50149 
and Human IL-18 ELISA kit, cat. number orb50153, respectively; Biorbyt, Cambridge, 
UK). 
Donor and recipient data
Donor and perfusion characteristics were routinely recorded at our institution. 
Recipient follow-up data were kindly provided by the recipient transplant centers 
and was periodically updated in our database. The following graft characteristics 
were recorded: warm ischemia time (WIT), the period from circulatory arrest or 
stop of resuscitation until the initial cold flush; cold ischemia time (CIT), the period 
between the initial flush and the start of first anastomosis; and the anastomosis 
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period, the time to complete both vascular anastomoses. Short-term graft function 
after transplantation was classified as 1) PNF: permanent inadequate renal function 
necessitating continuation of dialysis or retransplantation; 2) DGF: renal function that 
was ultimately life sustaining but required temporary dialysis in the first week after 
transplantation; and 3) immediate function (IF): renal function without the need of 
postoperative dialysis.
 The immunosuppressive regimen evolved over the study period and 
depended on different trials. Immunosuppression was mainly based on a combination 
of a calcineurin inhibitor (cyclosporin or tacrolimus) and prednisolone. Depending on 
the protocol at the time, these were combined with azathioprine, mycophenolate 
mofetil, sirolimus or daclizumab in recipients with an increased immunological risk 
(e.g. HLA immunization and re-transplants).
 Collection, storage and use of patient data were performed in agreement 
with the code of conduct ‘use of data in health research’ from the Dutch Federation 
of Biomedical Scientific Societies (http://www.federa.org/); According to Dutch law, 
Institutional Review Board (IRB) approval was not required for scientific analysis of 
anonymous data. 
Statistical analysis
Continuous variables are presented as means ± standard deviations (SD) if 
approximately normally distributed, and as median and interquartile range (IQR) 
otherwise. Categorical variables are presented as percentages. 
 Biomarker concentrations at four hours after the start of machine perfusion 
(T4) of discarded kidneys were compared with the biomarker concentrations of 
all transplanted kidneys and kidneys with PNF, using a Mann-Whitney-U test, and 
compared with their contralateral kidneys using a paired samples t-test or Wilcoxon 
signed rank test where appropriate.
 The association between biomarker concentration at T4 and transplant 
outcome was first tested with univariate logistic regression analysis. For each 
biomarker, a multivariate logistic regression model was then applied to the data, 
correcting for potential confounders based on clinically relevance. Additionally, Cox 
proportional hazards model was used to assess the effect of these biomarkers on 
graft failure of functioning kidneys within one year after transplantation, correcting 
for the same confounders. 
 The predictive value of individual biomarker concentrations and of biomarker 
concentrations in addition to clinically relevant confounders were assessed by the 
area under the ROC-curve (AURC). 
 Correlations between biomarkers and estimated GFR (eGRF), calculated 
with the abbreviated modification of diet in renal disease equation (MDRD), at one 
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year after transplantation and between biomarkers and perfusate hemoglobin were 
evaluated with the Pearson’s test for normally distributed data and the Spearman’s 
test otherwise.
 Graft survival censored for recipient death with a functioning graft was 
calculated with the Kaplan-Meier method; the log-rank test was used to compare the 
survival curves of the specific biomarker concentration below and above the median. 
 All analyses were performed using Statistical Package for the Social Sciences 
(SPSS) software version 16.0; a p-value ≤ 0.05 was considered statistically significant.
RESULTS
Patients
Between January 1997 and 2007, 517 DCD kidneys were machine perfused. 
From these kidneys, 153 were discarded based on vascular anatomy (e.g., multiple 
renal arteries, renal artery stenosis), macroscopic appearance (e.g., poor flush-out, 
cysts, renal capsula tears), long WIT, or if there were no suitable recipients. Of the 
remaining 364 kidneys, one pair of kidneys was a dual transplant and analyzed as 
one. Excluded from the analysis were 16 kidneys with major leakage at the arterial 
connection to the machine or without complete machine perfusion records, 10 
kidneys transplanted outside the Eurotransplant region, and two recipients who died 
with an unknown graft function. The remaining 335 machine perfused DCD kidneys 
entered the analysis.
 The donor, graft, and recipient characteristics are summarized in Table 5.1. 
Mean donor age was 45 ± 16 years. Most kidneys were from controlled donors (73%). 
The mean WIT and CIT were 26 ± 11 minutes and 27 ± 6 hours, respectively. Donors 
and recipients predominantly comprised men (61% and 63%, respectively).
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Table 5.1 Baseline characteristics and their association with PNF
Univariate analysis
OR (95% CI) p
Donor related
 Age (years) 45 ± 16 1.017 (0.998 – 1.035) 0.076
 Sex (male) 205 (61%) 0.895 (0.513 – 1.559) 0.694
 Donor creatinine (μmol/L) 93 ± 38 1.002 (0.995 – 1.009) 0.612
 Maastricht category (uncontrolled) 91 (27%) 1.078 (0.594 – 1.955) 0.806
 Donor center (MUMC / other)b 34 / 66 % 1.052 (0.595 – 1.858) 0.862
Graft related
 Warm ischemia time (min) 26 ± 11 1.029 (1.004 – 1.054) 0.024
 Cold ischemia time (h)
 Of which machine perfusion time (h)
27 ± 6
21 ± 6
0.997 (0.955 – 1.041)
1.004 (0.961 – 1.049)
0.890
0.854
 Anastomosis time (min) 42 ± 17 1.015 (1.000 – 1.030) 0.051
 GST T4 (U/L/100g) 59.1 (37.5 – 91.6)a 1.004 (1.000 – 1.009) 0.043
 LDH T4 (U/L/100g) 495 (340 – 740)a 1.001 (1.001 – 1.002) 0.001
 H-FABP T4 (pg/L/100g) 55.2 (36.1 – 95.3)a 1.004 (1.000 – 1.007) 0.048
 Redox-active iron T4 
 (μmol/L/100g) (N = 187)
3.9 ± 1.1 1.522 (1.077 – 2.152) 0.017
 IL-18 (pg/mL/100g) (N = 299) 373 (226 – 600)a 1.001 (1.000 – 1.002) 0.001
 NGAL T4 (ng/mL/100g) (N = 290) 18.4 (10.2 – 29.1)a 0.996 (0.979 – 1.013) 0.323
 Renovascular resistance T0 1.06 ± 0.69 1.896 (1.306 – 2.752) 0.001
Recipient related
 Age (years) 51 ± 13 1.011 (0.990 – 1.033) 0.294
 Sex (male) 210 (63%) 0.854 (0.494 – 1.477) 0.572
 Re-transplantation (yes) 48 (14%) 0.911 (0.418 – 1.988) 0.815
 Total HLA mismatches 2.6 ± 1.1 0.906 (0.705 – 1.165) 0.443
 Transplant center (regional / export) 42 / 58% 1.000 (0.581 – 1.721) >0.999
 Kidney disease (renovascular / other) 26 / 74% 0.938 (0.486 – 1.807) 0.847
 Dialysis time (years) 3.1 ± 2.4 1.132 (1.022 – 1.254) 0.017
 Dialysis type (hemodialysis) 202 (61%) 1.170 (0.670 – 2.045) 0.581
 Peak PRA 4.1 ± 14.1 0.986 (0.948 – 1.026) 0.499
 Cyclosporine/tacrolimus/none (%) 28 / 68 / 4% 1.136 (0.612 – 2.109) 0.687
 Anti-metabolite (yes) 208 (62%) 0.601 (0.350 – 1.031) 0.065
 Sirolimus (yes) 60 (18%) 1.132 (0.572 – 2.240) 0.722
 Induction therapy (yes) 42 (13%) 1.105 (0.501 – 2.437) 0.805
a Expressed as median (interquartile range).
b MUMC: Maastricht University Medical Center.
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Discarded kidneys
GST and LDH concentrations (in U/L/100 g) at T4 of discarded kidneys were 
higher than that of transplanted kidneys (median 101.3 vs. 59.1; p<0.001 and 682.7 
vs. 495.8; p<0.001, respectively). Compared with the transplanted kidneys with PNF, 
GST was significantly higher in the discarded kidneys (median 65.6 vs. 101.3; p<0.001, 
respectively). A paired-samples test, however, showed no significant difference in 
GST (N = 25) and LDH (N = 22) concentrations between discarded kidneys and their 
contralateral transplanted kidney (median, 80.0 vs. 88.2 for GST and 715.2 vs. 726.0 
for LDH; p=0.989 and p=0.506, Wilcoxon signed rank test, respectively). 
Table 5.2  Differences in biomarker concentration of functioning kidneys and 
kidneys with PNF.
No PNF PNF p
GST (U/L/100 g)a 55.7 (36.5 – 87.7) 65.6 (48.1 – 100.7) 0.034
LDH (U/L/100 g)a 477.5 (330.4 – 679.6) 631.3 (417.3 – 870.9) 0.002
H-FABP (pg/L/100 g)a 53.9 (36.1 – 94.3) 67.3 (35.8 – 142.9) 0.176
Redox-active iron (μmol/L/100 g) 3.8 ± 1.1 4.3 ± 1.1 0.015
IL-18 (pg/mL/100 g)a 357.6 (225.7 – 533.5) 472.9 (227.0 – 933.4) 0.031
NGAL (ng/mL/100 g)a 17.6 (10.2 – 29.2) 19.3 (10.4 – 26.1) 0.953
a Expressed as median (interquartile range).
Short-term graft function
Of the transplanted kidneys, 67 kidneys developed PNF (20%), 205 kidneys 
DGF (61%), and 63 kidneys IF (19%).
The perfusate concentrations of the different biomarkers at T4 of functioning 
kidneys and kidneys with PNF are shown in Table 5.2. In separate multivariate analyses 
of biomarker concentrations at T4, only LDH and IL-18 were independent risk factors 
for PNF and LDH, redox-active iron and IL-18 were independent risk factors for DGF 
(Table 5.3). 
 The ROC-curves of all individual biomarker concentrations are shown 
in Figure 5.1A and 5.1B with the AURC and 95%CI shown between brackets. The 
predictive values of LDH and redox-active iron at T4 for PNF were highest but poor. 
Adding biomarker concentrations to a multivariate model with clinical risk factors 
only (donor age, donor category, WIT, CIT, anastomosis time, and renovascular 
resistance at T0) with an AURC of 0.686, 95% CI 0.612 – 0.760 (graph not shown), 
showed a modest improvement for LDH, redox-active iron and IL-18 (Figure 5.1C and 
5.1D).
THE VALUE OF PERFUSATE BIOMARKER CONCENTRATION OF MACHINE PERFUSED DCD KIDNEYS
79 
Figure 5.1 Receiver operating characteristics (ROC)-curve for PNF: (A) individual GST, LDH and 
H-FABP concentrations at T4, (B) individual redox-active iron, IL-18 and NGAL concentrations at T4, 
(C) ROC-curve of the multivariate model with individual biomarkers (GST, LDH and H-FABP); other 
variables are donor age, donor category (uncontrolled/controlled), warm ischemia time, cold ischemia 
time, anastomosis time and renovascular resistance at T0 and (D) multivariate model with individual 
biomarkers (redox-active iron, IL-18 and NGAL), with the same variables as (C). The number in brackets 
indicates the area under the curve for each line and the accompanying 95%CI.
 Redox-active iron and LDH concentrations were weakly correlated with 
perfusate haemoglobin concentration (r=.216, p=0.004 and rs=.362, p<0.001, 
respectively), indicating that iron and LDH release from erythrocytes still present in 
the graft after flush-out may represent a minor contribution to the perfusate redox-
active iron and LDH concentration. 
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Table 5.3  Multivariate analysis for primary non-function, delayed graft function, 
and graft failurea
Odds ratio (95% CI) p
Risk of PNF (biomarker concentration at T4)
 GST 1.004 (0.998 – 1.009) 0.161
 LDH 1.001 (1.000 – 1.002) 0.005
 H-FABP 1.002 (0.998 – 1.007) 0.280
 Redox-active iron 1.462 (0.974 – 2.195) 0.067
 IL-18 1.001 (1.000 – 1.002) 0.003
 NGAL 0.999(0.980 – 1.018) 0.919
Risk of DGF (biomarker concentration at T4)
 GST 1.006 (0.999 – 1.013) 0.112
 LDH 1.002 (1.001 – 1.004) 0.007
 H-FABP 1.007 (1.000 – 1.014) 0.064
 Redox-active iron 1.532 (1.045 – 2.245) 0.029
 IL-18 1.003 (1.001 – 1.004) 0.002
 NGAL 1.000 (0.982 – 1.018) 0.994
Hazards ratio (95% CI) p
Risk of graft failure within the first year 
posttransplantb
 GST 0.993 (0.978 – 1.008) 0.348
 LDH 0.998 (0.996 – 1.001) 0.223
 H-FABP 0.987 (0.969 – 1.005) 0.165
 Redox-active iron 0.999 (0.552 – 1.808) 0.997
 IL-18 1.000 (0.998 – 1.002) 0.996
 NGAL 0.996 (0.961 – 1.032) 0.819
a  For each biomarker, a separate multivariate analysis was done. Only odds ratios and p-values for the specific 
biomarker are given. Other variables in each model were donor age, donor category (uncontrolled/controlled), warm 
ischemia time, cold ischemia time, anastomosis time, and renovascular resistance at T0.
b Cox proportional hazards model of functional kidneys, censored for death with a functioning graft.
Long-term graft survival
The median follow-up after transplantation was 6.8 (IQR 4.0 – 9.3) years. 
Death censored graft survival at 1 and 5 years after transplantation was 76% and 
68%, respectively. 
 In multivariate Cox proportional hazards models, biomarker concentrations 
were not significantly associated with the risk of graft failure in the first year after 
transplantation (Table 5.3).
THE VALUE OF PERFUSATE BIOMARKER CONCENTRATION OF MACHINE PERFUSED DCD KIDNEYS
81 
 Only LDH was significantly correlated with eGFR at one year after 
transplantation (rs=-.177; p=0.006). Other biomarkers showed a non-significant 
negative correlation with eGFR (data not shown), except for redox-active iron 
(rs=.023, p=0.785).
Figure 5.2 shows the graft survival of all transplanted kidneys for biomarker 
concentrations below and above the mean or median. For GST, LDH and H-FABP, 
a concentration above the median resulted in a significantly shorter graft survival. 
Graft survival was equivalent for kidneys with redox-active iron, IL-18, and NGAL 
concentrations below or above the mean or median. Additionally, Cox proportional 
hazards model was used to see whether this effect of biomarker concentrations 
above the median persisted after correction for potential confounders. None of the 
biomarkers remained significant in this analysis (data not shown).
DISCUSSION
Kidneys from DCD donors are a valuable extension of the donor pool, but have 
higher rates of DGF and, in some studies, PNF compared to kidneys from DBD donors 
(4, 19, 20). Despite higher rates of DGF and PNF, recipients of DCD kidneys have better 
survival rates than patients who continue dialysis treatment while waiting for a kidney 
from a DBD donor (21). The long-term graft survival of functioning DCD kidneys is 
similar to kidneys from DBD donors and between uncontrolled and controlled DCD 
kidneys; also, the recipient survival does not differ significantly (20, 22). 
It remains a challenge to reduce the PNF rate of transplanted kidneys without 
the discard of too many viable organs. PNF is associated with unnecessary risks of 
surgery and immunosuppression and recipients may become sensitized to donor 
antigens, which decreases the opportunities for retransplantation (19). Interventions 
to reduce the risk of PNF include organ preservation by rapid laparotomy and 
direct aortic cannulation for controlled DCD donors, selection of kidneys from old 
DCD donors by histological assessment of pre-implantation biopsies, and careful 
management of recipient hemodynamics during transplantation to ensure adequate 
reperfusion of the graft (16, 23, 24). Machine perfusion offers the opportunity for pre-
transplantation viability assessment of the procured kidney and includes perfusion 
characteristics and perfusate biomarker concentrations. However, the predictive 
value of perfusate biomarkers to assess PNF remains unknown. Although Moers et al. 
(2012) concluded that perfusate biomarker concentrations should not lead to kidney 
discard, the PNF percentage in this study, 2.3% overall and 2.7% in 75 DCD kidneys, 
makes predictive value assessment for PNF, the most important reason for kidney 
discard, virtually impossible (12).
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Figure 5.2 Kaplan-Meier graft survival curves of all transplanted machine perfused DCD kidneys. 
Graft survival of kidneys with A) GST, B) LDH, C) H-FABP, D) redox-active iron, E) IL-18 and F) NGAL 
concentrations below and above the mean or median concentration at T4, all censored for recipient 
death with a functioning graft.
In Maastricht, all procured DCD kidneys were machine preserved for study 
purposes, regardless of their condition, and included very marginal kidneys, which 
explains the high discard rate. Kidneys were not discarded because of machine 
perfusion characteristics: the data were not provided to the recipients’ nephrologists, 
who decided to accept an organ for transplantation. 
 GST, an enzyme localized in the renal tubules, has been frequently used for 
viability testing (9, 10, 12). Also our group has shown a correlation between machine 
perfusate GST concentration and short-term kidney function (10). However, when 
kidneys with high GST concentrations showed a favorable outcome, we discontinued 
its use for viability testing. Therefore, only kidneys transplanted since 1997 were 
included in this study. 
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 In this study, LDH and IL-18 showed a significant association with early kidney 
function. LDH is a nonspecific cellular injury marker which is found in almost all body 
tissues. LDH measured in machine perfusate is either released by the perfused kidney 
or by hemolytic erythrocytes from the capillaries of the perfused kidneys (25). DCD 
kidneys sustain a period of warm ischemia with stasis of blood in the organs. This may 
be associated with a relatively high concentration of erythrocytes and blood clots 
in the capillaries after a poor initial flush after cardiac arrest. This may explain the 
relatively good association of LDH and the initial graft function in this study, because 
only DCD kidneys were included. In the present study, a weak correlation between 
LDH and hemoglobin was found. In other studies, with mainly kidneys from brain-
dead donors, LDH was not correlated with early post-transplant outcome (12). 
 H-FABP is a cytosolic protein localized in the distal tubules and is involved 
in transportation of free fatty acids from cytosol to mitochondria for catabolism. 
H-FABP has been associated with early release following tissue injury to the kidneys 
(11). Its clinical value as perfusate viability marker is relatively unknown. 
 Redox-active iron has been implicated in the pathophysiology of I/R injury in 
several organ systems. Redox-active iron is released during I/R injury and is believed to 
catalyze the formation of oxygen-free radicals, which are known to induce apoptotic 
and necrotic cell death and subsequent inflammatory responses (26). In the present 
study, redox-active iron was strongly associated with PNF in the univariate analysis, 
but did not remain significantly associated when corrected for confounders. 
 IL-18 is a pro-inflammatory cytokine produced by macrophages and other 
cell types present in the kidney during I/R injury and contributes to inflammatory 
reactions such as modulation of macrophage activity. IL-18 may promote immune- or 
nonimmune-mediated tissue damage via a multitude of mechanisms (27, 28). 
 NGAL, also known as lipocalin-2, is generally expressed in several human 
tissues, including the kidney. NGAL expression is induced in injured epithelia and has 
recently been discovered as a novel biomarker of acute kidney injury (29). However, 
in this study, NGAL concentration was not associated with short-term graft function.
 Enzymes released after cell death relate to each other. However, most 
biomarkers represent a measure of different processes of I/R injury, including cell 
death and inflammation, and biomarkers are present in different cells. Depending on 
the severity of the injury and the period of time afterwards, the association between 
I/R injury and biomarker concentration may vary.
 There are several potential confounders that may influence the reliability of 
these biomarkers in this study, including the volume of preservation fluid used during 
in situ perfusion, before procurement, and the volume and period of flushing on the 
back-table. This will also result in a certain amount of wash-out of these biomarkers 
before these kidneys are connected to the perfusion machine.
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 The concentration of biomarkers of machine perfused kidneys also depends 
on the proportion of the kidney which is perfused and thus flow through the kidney. 
When parts of the renal microcirculation are occluded by thrombosis or oedema, the 
flow (mL/min/100 g) will be relatively low, which results in poor washout of biomarkers 
released from damaged cells. We have shown previously that renovascular resistance 
itself was associated with short-term graft function (30). Furthermore, it is unknown 
if age affects the perfusate biomarker concentration. This is difficult to assess as 
age itself is an important risk factor for poor kidney function in DCD kidneys (31). 
Additionally, results may be biased by the unknown outcome of discarded kidneys. 
However, there are no possibilities to correct for this potential confounder. 
 All tested biomarkers, except for NGAL, were associated with PNF in the 
univariate analyses. As all these biomarkers were associated with PNF, separate 
multivariate analyses were done to correct for confounding factors. LDH and IL-18 
remained significantly associated with PNF in the multivariate analyses. Associations 
with DGF are less important, and have little clinical implications, because long-term 
survival rates of DCD kidneys with DGF do not significantly differ from DCD kidneys 
with IF (3, 32-34). The predictive value of individual biomarkers for PNF was poor. 
Only redox-active iron and IL-18 improved to ‘fair’ after including clinically relevant 
confounders in a multivariate analysis. 
 We have shown for the first time that the diagnostic accuracy of the 
commonly used perfusate biomarkers GST, LDH, and H-FABP and newly assessed 
biomarkers redox-active iron, IL-18, and NGAL in predicting viability of DCD kidneys 
is poor. These biomarkers should not lead to discard of DCD kidneys. Presently, there 
are no other potential viability markers which have shown an improvement in the 
assessment of kidney viability.
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ABSTRACT
Background: Donation after cardiac death (DCD) has shown to be a valuable 
extension of the donor pool despite a higher percentage of primary non-function 
(PNF). Limiting the incidence of PNF is of vital importance. Renovascular resistance is 
believed to predict graft outcome; however, the literature is inconsistent. Therefore, 
we studied whether renovascular resistance is associated with PNF and whether this 
parameter should be used to discard donor kidneys.
Methods: All transplanted DCD kidneys preserved by machine perfusion at our 
center between 1993 and 2007 were analyzed (N = 440). The effects of renovascular 
resistance on PNF, delayed graft function (DGF), and graft and patient survival were 
examined using multivariate analyses; predictive quality by calculating the area 
under the curve (AUC). 
Results: We showed that renovascular resistance at the start of machine 
perfusion was significantly and independently associated with PNF (OR 2.040, 95% CI 
1.362 – 3.056; p=0.001), and DGF (OR 2.345, 95% CI 1.110 – 4.955; p=0.025). Predictive 
quality was moderate (0.609, 95% CI 0.538 – 0.681). Graft and patient survival were 
not associated with renovascular resistance.
Conclusion: Renovascular resistance is an independent risk factor for PNF in 
DCD kidneys; however, the predictive value is relatively low.
Published as
E.E. de Vries, E.R.P. Hoogland, B. Winkens, M.G.J. Snoeijs, L.W.E. van Heurn. Renovascular resistance of machine-
perfused DCD kidneys is associated with primary non-function. Am J Transplant 2011;11(12):2685-91
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INTRODUCTION
Kidney transplantation is the treatment of choice for patients with end stage 
renal disease (1-3). The increasing demand for organ donors has led to the use of 
alternative sources of grafts to expand the donor pool. One of these alternatives 
includes organs from donation after cardiac death (DCD). These kidneys suffer from 
a period of warm ischemia between cardiac arrest and cold flushing. As a result a 
higher percentage of kidneys suffer from primary non-function (PNF) and delayed 
graft function (DGF) (4-6).
In recent years, kidney preservation by hypothermic machine perfusion has 
experienced renewed interest. In addition to the intended benefit of improved 
tissue preservation, machine perfusion also provides the opportunity to determine 
perfusion parameters including perfusion pressure, perfusion flow and renovascular 
resistance. These parameters have been advocated to predict graft function after 
transplantation (7-10). The assessment of organ viability is especially important in 
marginal kidneys with their increased risk of developing PNF. However, the value of 
machine perfusion parameters to predict PNF is relatively unknown, as the incidence 
of PNF after transplantation is generally low. DGF, as an alternative outcome measure, 
is less useful because DGF does not affect long-term survival in DCD kidneys (4-6, 11-
14). 
In a large group of marginal machine perfused DCD kidneys in which 
perfusion parameters were not used to discard the organs, we primarily studied 
whether renovascular resistance is independently associated with PNF and whether 
renovascular resistance can be safely used to discard donor kidneys. Additionally, we 
studied whether renovascular resistance is associated with DGF and long term graft 
and patient survival.
MATERIALS AND METHODS
All DCD kidneys, which were machine perfused at our center between 
March 1993 and May 2007 and were transplanted in the Eurotransplant region, as 
well as their contralateral kidney, were included in this study. This group consisted 
of (1) kidneys procured at our center, (2) kidneys taken to our center for machine 
preservation until transplanted elsewhere, or (3) kidneys procured elsewhere, but 
machine perfused until transplanted at our center. Kidneys were either accepted 
or discarded, based on donor characteristics, warm ischemia time, macroscopic 
appearance or anatomical variances of the graft. Kidneys were procured from donors 
after cardiac death according to the Maastricht DCD categories (15-17). Maastricht 
categories 1 and 2 together were classified as uncontrolled. Collection, storage and 
use of patient data were performed in agreement with the code of conduct “use of 
data in health research” from the Dutch federation of biomedical scientific societies; 
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ethics approval was not required. Donor, graft, machine perfusion and recipient 
characteristics were prospectively documented. The predonation GFR was estimated 
by the abbreviated Modification of Diet in Renal Disease formula (MDRD) (18). The 
following graft characteristics were recorded: warm ischemia time, the period from 
circulatory arrest or stop of resuscitation until the initial cold flush of the kidneys; cold 
ischemia time, the period between the initial flush and the start of first anastomosis 
of the recipient operation; and the anastomosis period, the time to complete both 
vascular anastomoses. Short-term graft function after transplantation was classified 
as 1) PNF: inadequate renal function necessitating continuation of dialysis or 
retransplantation; 2) DGF: renal function which was ultimately life sustaining but 
required temporary dialysis after transplantation; and 3) IF: immediate renal function 
without the need of postoperative dialysis. Recipients were followed up for graft 
and patient survival. GFR was reported 3 months after transplantation and yearly 
thereafter. The allograft failure date was defined as the date of return to dialysis or 
retransplantation, whichever comes first. 
Preservation
After organ recovery, kidneys were weighed and machine preserved on a 
Gambro PF-3B pulsatile perfusion machine (Gambro, Lund, Sweden) with Belzer’s 
hypothermic machine preservation UW gluconate solution at a mean temperature of 
4°C. Added to the solution were 40 IU of insulin, 200,000 U of penicillin and 16 mg of 
dexamethasone. After connection of the kidney to the machine, perfusion flow was 
set to a systolic pressure of 55 mmHg, which was maintained during the first 60 min 
by adjusting machine flow. After 60 min, the renal flow was kept constant. Flow and 
pressure parameters were recorded at the start of machine perfusion, and after 1, 2 
and 4 h of perfusion (T0, T1, T2 and T4, respectively). The renovascular resistance was 
calculated by dividing mean pressure by the registered flow and was corrected for 
kidney weight (mmHg/ml/min per 100 g kidney weight). During machine perfusion, 
pH was adjusted to values >7.10, using sodium bicarbonate. 
The immunosuppressive regimen evolved over the study period as different 
trials were conducted. Immunosuppression was mainly based on a combination of 
a calcineurin inhibitor (cyclosporine or tacrolimus) and prednisolone. Depending of 
the protocol at the time, these were combined with azathioprine, mycophenolate 
mofetil, sirolimus or daclizumab in recipients with an increased immunological risk 
(e.g., HLA immunization and retransplants). 
Statistics
Continuous variables were presented as mean ± standard deviation unless 
noted otherwise. Categorical variables were presented as absolute numbers and 
percentages. Renovascular resistance of discarded kidneys was compared with the 
resistance of all transplanted kidneys and kidneys with PNF, using an independent 
samples t-test, and compared with their contralateral kidneys using a paired samples 
t-test. Multivariate logistic regression analysis was performed to identify whether 
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renovascular resistance is an independent risk factor for PNF and DGF, correcting 
for known prognostic factors and significant variables from the univariate analyses. 
To avoid multicollinearity only renovascular resistance with the lowest p-value in 
univariate analyses was included in the model. The effect of renovascular resistance 
at each time point and the renovascular resistance area under the curve (AUC) on 
PNF and DGF were determined by univariate logistic regression analyses. Predictive 
measurements were performed by calculating a ROC curve. Positive and negative 
predictive values were computed using the predictive probability with maximum 
combination of sensitivity and specificity from the ROC curve, i.e. the point closest 
to the [1,1]-corner. We performed a Cox proportional hazard model to assess the 
association between renovascular resistance and graft survival in functioning grafts, 
censored for recipient death with a functioning graft, and patient survival. The 
long-term effects were visualized by the Kaplan-Meier curves, where renovascular 
resistance groups were created based on randomly chosen rounded numbers of 
renovascular resistance (in mmHg/ml/min/100 g) at T0 (group 1: <1, group 2: 1-1.99, 
group 3: ≥2). A linear mixed model was used to analyze the association between 
renovascular resistance at T0 and GFR, since it accounts for missing values due to graft 
failures or recipient death and for the repeated measurements within each recipient. 
p-Values equal or lower than 0.05 were considered statistically significant. Statistical 
analysis was performed with SPSS for Windows version 16.0.
RESULTS
Patients
Between March 1993 and May 2007, 440 machine perfused DCD kidneys from 
293 donors were transplanted in 439 patients; 2 kidneys were transplanted as a dual 
transplant. One hundred forty-six donors (50%) had both kidneys machine perfused 
and transplanted, from 108 donors (37%) only one kidney was machine perfused 
and from 39 donors (13%) both kidneys were perfused but only one kidney was 
transplanted. Kidney discard (N = 39) was based on vascular anatomy (N = 8), no 
suitable recipient (N = 8), macroscopic appearance (N = 12), machine malfunction (N 
= 2), cancelled surgery due to recipients problems (N = 2), or unknown (N = 7). Donor, 
graft and recipient characteristics are summarized in Table 6.1. Mean donor age was 
45 ± 16 years. Most kidneys were from controlled Maastricht category 3 (N = 285) or 
category 4 (N = 19) donors. The mean warm and cold ischemia times were 26 min 
and 28 h, respectively. The mean kidney weight was 235 g. Donors and recipients 
predominantly comprised men (63% men; for donors and recipients).
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Table 6.1  Baseline characteristics and their association with primary non-function
Univariate analysis Multivariate analysis
OR (95% CI) p OR (95% CI) p
Renovascular resistance 
T0
(mmHg/ml/min/100 g)
1.08 ± 0.60 1.972 (1.346-2.890) <0.001 2.040 (1.362-3.056) 0.001
Transplantation yeara 1.009 (0.942-1.081) 0.793
1993-1997 106 (24%)
1998-2002 225 (51%)
2003-2007 108 (25%)
Donor related
Age (year) 45 ± 16 1.019 (1.003-1.035) 0.023 1.016 (0.997-1.036) 0.106
Sex (male) 271 (63%) 0.979 (0.596-1.610) 0.935
Pre-donation eGFR
(ml/min/1.73m2)
76 ± 31 0.996 (0.988-1.004) 0.350 0.998 (0.988-1.008) 0.699
Maastricht category
(uncontrolled)
135 (31%) 1.029 (0.614-1.724) 0.914 1.145 (0.586-2.235) 0.692
Graft related
Warm ischemia time 
(min) 26 ± 11 1.027 (1.005-1.048) 0.014 1.023 (0.999-1.049) 0.062
Cold ischemia time (h) 28 ± 8 1.015 (0.986-1.045) 0.310 1.030 (0.987-1.075) 0.174
Anastomosis time (min) 43 ± 20 1.002 (0.990-1.014) 0.709
Recipient related
Age (year) 50 ± 14 1.015 (0.997-1.034) 0.105 1.012 (0.989-1.035) 0.303
Sex (male) 271 (63%) 1.004 (0.613-1.645) 0.988
Re-transplantation 367 (15%) 1.174 (0.583-2.362) 0.653
Duration of dialysis 
(year) 3.5 ± 2.7 1.097 (1.012-1.189) 0.024 1.006 (0.999-1.014) 0.103
Total mismatches 3 ± 1 0.958 (0.770-1.191) 0.698
PRA > 5% (N = 168) 18 (11%) 4.339 (0.554-33.965) 0.162
Cyclosporine/ 
tacrolimus/none
150/24/48
(34/55/11%)
0.828 (0.488-1.404) 0.483
Induction therapy 56 (15%) 0.992 (0.464-1.686) 0.983
Sirolimus 66 (15%) 0.884 (0.464-1.686) 0.709
Antimetaboliteb 254 (58%) 1.187 (1.157-3.025) 0.011 1.736 (0.978-3.080) 0.060
Renovascular resistance T
0
: renovascular resistance at the start of machine perfusion.  
a As continuous variable in the univariate analysis.  
b Azathioprine or mycophenolate mofetil.
Short-term graft outcome
Nine patients (2%) were lost to follow up or died before short-term graft 
function could be defined. Kidneys transplanted in these patients were excluded 
from analysis. Among the others, 84 recipients developed PNF (19.5%), 262 recipients 
DGF (61%) and 84 recipients IF (19.5%). Resistance in all groups decreased during 
machine preservation (Figure 6.1, Table 6.2).
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Table 6.2  Univariate logistic regression analysis for the risk of A) Primary non-function 
(PNF), and B) delayed graft function (DGF) in machine perfused kidneys.
A N Non PNF (N = 346) N
PNF
(N = 84) OR (95% CI) p
RR T0 318 1.02 ± 0.03 74 1.32 ± 0.11 1.972 (1.346 to 2.890) <0.001
RR T1 342 0.92 ± 0.02 84 1.12 ± 0.07 1.916 (1.263 to 2.906) 0.002
RR T2 341 0.87 ± 0.02 83 1.04 ± 0.07 1.835 (1.182 to 2.850) 0.007
RR T4 342 0.81 ± 0.02 83 0.94 ± 0.05 1.891 (1.122 to 3.188) 0.017
AUC 314 0.89 ± 0.02 72 1.09 ± 0.07 2.240 (1.353 to 3.709) 0.002
B N IF(N = 84) N
DGF
(N = 262) OR (95% CI) p
RR T0 78 0.90 ± 0.04 240 1.06 ± 0.03 2.368 (1.212 to 4.628) 0.012
RR T1 82 0.82 ± 0.04 260 0.95 ± 0.03 2.390 (1.156 to 4.942) 0.019
RR T2 81 0.78 ± 0.04 260 0.89 ± 0.03 2.327 (1.088 to 4.978) 0.029
RR T4 81 0.73 ± 0.04 261 0.83 ± 0.02 2.302 (1.025 to 5.168) 0.043
AUC 76 0.80 ± 0.04 238 0.92 ± 0.03 2.580 (1.155 to 5.766) 0.021
RR: Renovascular resistance in mmHg/mL/min/100g; AUC: area under the curve; IF: immediate function.
Reported values are mean ± standard error of the mean.
Renovascular resistance (in mmHg/ml/min/100 g) at T0 of discarded kidneys was 
higher than that of transplanted kidneys, 1.340 vs. 1.085 (p=0.021) and comparable 
with kidneys with PNF 1.340 vs. 1.325 (p=0.930). A paired samples t-test, however, 
showed no significant difference in renovascular resistance between discarded kidneys 
(N = 39) and their contralateral transplanted kidneys (1.340 vs. 1.178, respectively; 
p=0.412). 
Figure 6.1 Renovascular resistance and its association with primary non-function (PNF), delayed graft 
function (DGF) and immediate function (IF). Data are presented as means and standard error of the 
mean.
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Renovascular resistance at each time point and renovascular resistance AUC 
were significantly associated with PNF, where the association was strongest at T0 with 
an odds ratio of 1.972 (95% CI 1.346 to 2.890; p<0.001) (Table 6.2A). Other factors 
significantly associated with PNF in the univariate analyses include donor age (OR 
1.019, 95% CI 1.003 to 1.035; p=0.023), warm ischemia time (OR 1.027, 95% CI 1.005 
to 1.048; p=0.014), recipients’ duration of dialysis (OR 1.097, 95% CI 1.012 to 1.189; 
p=0.024), and whether or not an antimetabolite is given (OR 1.187, 95% CI 1.157 to 
3.025; p=0.011) (Table 6.1). In the multivariate analyses, renovascular resistance at T0 
(OR 2.040, 95% CI 1.362 to 3.056; p=0.001) remained a significant risk factor for PNF. 
Table 6.3 shows the categorized renovascular resistance at T0 and its accompanying 
increasing percentage of PNF.
Table 6.3  Renovascular resistance values and their accompanying percentage of 
primary non-function.
Renovascular resistance T0 
(mmHg/ml/min/100 g) ≥0.5 ≥1.0 ≥1.5 ≥2.0 ≥2.5 ≥3.0
N 369 160 61 26 12 7
Primary non-function 19% 25% 26% 38% 58% 85%
The area under the ROC curve (AURC), sensitivity, specificity, positive and 
negative predictive value were determined for (a) renovascular resistance at T0 
alone, (b) a model including donor age, pre-donation eGFR, Maastricht category 
and warm ischemia time, and (c) model b combined with renovascular resistance at 
T0 (Table 6.4). The AUC of renovascular resistance alone was moderate (0.609, 95% 
CI 0.538 to 0.681). By adding renovascular resistance to model b, the AUC slightly 
increased (model b: 0.636; 95%CI 0.570 to 0.702 vs. model c: 0.654; 95% CI 0.585 to 
0.723).
Table 6.4 Predictive values of renovascular resistance (RR) at T0.
AUC (95% CI) (c statistic) Sensitivity Specificity PPV NPV
Model a: RR alone 0.609 (0.538 to 0.681) 0.554 0.623 0.255 0.857
Model b (without RR) 0.636 (0.570 to 0.702) 0.524 0.694 0.297 0.855
Model c (with RR) 0.654 (0.585 to 0.723) 0.528 0.729 0.314 0.868
Model b: donor age, pre-donation eGFR, Maastricht category, and warm ischemia time; Model c: donor age, pre-donation 
eGFR, Maastricht category, warm ischemia time, and renovascular resistance. RR: renovascular resistance; PPV: positive 
predictive value; NPV: negative predictive value.
In functioning kidneys univariate analyses showed that renovascular resistance 
at each time point and renovascular resistance AUC were significantly associated with 
DGF (Table 6.2B). The same multivariate analysis as described above was repeated to 
determine risk factors for DGF. Renovascular resistance at T0 was an independent risk 
factor for DGF (OR 2.345, 95% CI 1.110 to 4.955; p=0.025).
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Long-term survival
The median period of follow up after transplantation was 7.2 (range 0 to 16.2) 
years, including 21 patients (4.8%) with incomplete follow-up. These patients were 
censored after a median follow up time of 2.7 years (range 0 to 11.3). Graft survival 
at 1 and 5 years after transplantation was 74% and 60%, respectively. Mean GFR of 
functioning grafts was 36 ± 18 ml/min/1.73 m2 at 3 months, and 43 ± 19 ml/min/1.73 
m2 at 5 years after transplantation. Patient survival was 76% and 67% after 1 and 
5 years, respectively. Linear mixed models showed that the trend in GFR was not 
influenced by renovascular resistance at T0 (p=0.875). Resistance at T0 was also not 
significantly related to graft survival (p=0.199) or patient survival (p=0.203).
Figure 6.2 shows graft survival of all transplanted grafts, delayed functioning 
and immediate functioning grafts, with resistance categorized in groups. Apparent 
differences in graft survival between the three resistance groups are mainly caused 
by PNF rate. Patient survival was similar in all groups (Figure 6.2B).
Figure 6.2 Graft and patient survival curves after transplantation of machine perfused donation 
after cardiac death (DCD) kidneys categorized by renovascular resistance in mmHg/ml/min/100g 
(RR), visualized by the Kaplan-Meier curves. (A) Graft survival, in (A1) all transplanted grafts and (A2) 
delayed functioning grafts and (A3) immediate functioning grafts, all censored for recipient death with 
functioning graft, and (B) patient survival.
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DISCUSSION
The use of DCD kidneys provides a valuable extension of the donor pool 
to meet the constantly growing number of patients on the waiting list for kidney 
transplantation. Despite the higher percentages of PNF and DGF (5, 19), patients who 
receive a DCD kidney have better survival rates than patients who continue dialysis 
treatment while waiting for a kidney from a donor after brain death (DBD) (20). 
Moreover, DCD kidneys that overcome the early posttransplantation period function 
as long as DBD kidneys. Contrary to DBD kidneys, DGF in DCD kidneys hardly, if at 
all, affects graft survival (4, 5, 13, 14, 21). Therefore it is essential to select kidneys 
that will never function from those which will either function immediately or after 
some time. The primary aim of the study was to determine if renovascular resistance, 
measured during machine perfusion, could provide additional information deciding 
which kidneys should be discarded and which kidneys have a good chance to 
eventually function. 
The two major methods of preservation are cold storage and machine 
perfusion. Machine perfusion, generally used for extended criteria donors, has two 
potential advantages over cold storage. First, it may improve marginal kidneys by 
preventing interstitial edema, decreasing oxidative stress, improving ATP availability 
upon reperfusion and by washing out thrombi and harmful metabolic products (22, 
23). Two recently published randomized controlled trials comparing both preservation 
methods showed conflicting results. Moers et al. (2000) demonstrated the benefit 
of machine perfusion compared to cold storage in DCD and DBD kidneys with a 
reduced risk of DGF and improved graft survival in the first year after transplantation 
(24), whereas Watson et al. (2000) described that machine perfusion does not offer 
advantages over cold storage for DCD kidneys (25). Secondly, machine perfusion 
allows measurement of pre-transplantation parameters such as perfusion flow, 
pressure and renovascular resistance, providing information about the quality of the 
graft. The evidence that renovascular resistance is a valuable predictor of transplant 
outcome is poor although several resistance cut off points have been described (10, 
26). In Maastricht, from 1993, all procured DCD kidneys were preserved by machine 
perfusion regardless of preprocurement conditions, a group including very marginal 
kidneys with a high PNF rate. Therefore we were able to study variables associated 
with PNF including renovascular resistance by performing multivariate analyses.
Our results show that renovascular resistance at the start of machine perfusion 
(T0) is independently associated with PNF. Mean renovascular resistance decreases 
over time and its decline is more pronounced in PNF kidneys implying that the 
discriminatory value of renovascular resistance decreases towards transplantation. 
This is in line with results of Brook et al. (2000)(27) showing that only early renovascular 
resistance until 60 min of machine perfusion accurately reflects differences in warm 
ischemia time in porcine kidneys. In human kidney transplantation the value of 
renovascular resistance at T0 as discriminative time point has not been previously 
described. Earlier studies only report the mean value of perfusion parameters (8, 9, 
26, 28), or values at T4 (10, 29). Our finding, that recommends the use of renovascular 
RENOVASCULAR RESISTANCE OF MACHINE PERFUSED DCD KIDNEYS IS ASSOCIATED WITH PRIMARY NON-FUNCTION
99 
resistance at T0, could be advantageous because early viability assessment enables to 
decide in an early stage whether or not to use the kidney for transplantation.
The predictive quality of renovascular resistance is moderate and the decision 
to either accept or discard a kidney remains multifactorial. Nevertheless, we think 
that renovascular resistance can be a valuable parameter next to other factors to 
decide whether to transplant a kidney or not. Moreover, in our series, 6 out of 7 
kidneys with a renovascular resistance at T0 of >3.0 mmHg/ml/min/100 g resulted in 
PNF, which is unacceptably high because transplantation of nonviable kidneys results 
in unnecessary risk of surgery and immunosuppression, and sensitizes the recipient 
for future transplants (30). Kidneys with DGF had a higher renovascular resistance 
than immediately functioning kidneys; this finding, however, should not have clinical 
implications, as long-term survival rates of DCD kidneys with DGF do not significantly 
differ from DCD kidneys with IF (4, 5, 13, 19, 20, 31).
The reported mean renovascular resistance in the present study is higher than 
values reported by others. First, this may be caused by the relatively poor quality of the 
perfused DCD kidneys, which becomes apparent from the relatively high percentage 
of PNF. Second, we have corrected the renovascular resistance for kidney weight, 
which generally implies a two to threefold increase of the measured resistance value.
We showed that differences in graft survival among transplanted grafts were 
mainly caused by the presence of PNF. In functioning kidneys there was no statistical 
association between graft survival and renovascular resistance at T0; neither was 
patient survival associated with renovascular resistance. These findings indicate that 
renovascular resistance is particularly useful in predicting PNF. 
There could have been a selection bias, if kidneys in our series were discarded 
based on renovascular resistance, but renovascular resistance was not a parameter to 
discard kidneys for transplantation. All kidneys were accepted for transplantation by 
the recipient’s nephrologists, based on the combination of donor, graft and recipients 
characteristics. They were not informed of machine preservation parameters. 
Resistance of the discarded kidneys was equivalent to the resistance of transplanted 
contralateral kidneys. However, the number of kidneys that could be compared was 
too small to draw firm conclusions from this finding. Furthermore, unobserved arterial 
leakage during perfusion may have affected flow and pressure registration. This 
could have resulted in an underestimation of the measured renovascular resistance 
in poorly functioning kidneys. Moreover, the number of variables included into the 
analysis was limited to optimize statistical accuracy. This implies that other possibly 
relevant risk factors were not included in the multivariate risk analysis. 
In conclusion, we demonstrated that renovascular resistance at the start of 
machine perfusion is an independent risk factor for PNF; however, the predictive 
value is relatively low.
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ABSTRACT
Background: Kidney donation after cardiac death leads to vascular damage as a 
result of warm ischemia, affecting renovascular circulating volume. Novel ultrasound 
dilution techniques may be used to measure renovascular circulating volumes during 
hypothermic machine perfusion of donor kidneys.
Methods: Renovascular circulating volumes of machine perfused porcine 
kidneys were repeatedly measured by ultrasound dilution at different perfusion 
pressures (30, 40, 50, and 60 mmHg), durations of perfusion (1 and 24 hours) and 
warm ischemia times (15 and 45 min). Validity of ultrasound dilution was assessed by 
comparing volume changes after clamping of renal artery branches.
Results: Repeatability of ultrasound dilution measurements of renovascular 
circulating volumes was good (mean coefficient of variation: 7.6%). Renovascular 
circulating volumes significantly increased with higher perfusion pressures, remained 
constant over time, and significantly decreased with longer warm ischemia times. 
Changes in ultrasound dilution measurements after renal artery branch clamping did 
not correlate with changes in actual perfused volumes.
Conclusions: Ultrasound dilution is a reproducible method to assess renovascular 
circulating volumes in machine-perfused kidneys, which is susceptible to changes 
in warm ischemia times. Future studies should evaluate the value of renovascular 
volume in pretransplantation kidney viability testing.
Published as
E.E. de Vries, T.C. van Smaalen, J. Boer, E.R.P. Hoogland, N.M. Krivitski, M.G.J. Snoeijs, L.W.E. van Heurn. Measurement 
of renovascular circulating volume during hypothermic organ perfusion. Transplantation 2013;95(9):1100-4
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INTRODUCTION
Kidney transplantation in patients with end-stage renal disease leads to 
superior life expectancy and better quality of life compared to dialysis (1). In the past 
decades, there is an increasing shortage of donor kidneys. Organs from donors after 
cardiac death (DCD) have become generally accepted to expand the donor pool and 
meet the demand for additional donor kidneys. However, transplantation of DCD 
kidneys is associated with an increased incidence of initial graft dysfunction (2, 3).
The higher incidence of graft dysfunction in DCD kidneys, compared with 
kidneys from donation after brain death (DBD) donors, can be attributed to the 
prolonged period of warm ischemia before organ procurement. This period of warm 
ischemia leads to more capillary damage resulting from thrombosis, vasoconstriction, 
and edema, and may consequently result in a decreased renovascular circulating 
volume. Therefore, pre-implantation renovascular circulating volume of the kidney 
may be associated with the severity of warm ischemic injury and could be a valuable 
predictor of transplantation outcome. 
The dilution technique is used to measure circulating volume in hemodialyzer 
fibre bundles. It determines the dilution of an injected saline bolus with ultrasound 
flow probes before and after transit of the dialyzer. In hemodialyzer volume 
assessment, this technique is accurate, and its results are reproducible (4-6). The same 
technique can be used to measure renovascular circulating volume in donor kidneys. 
Renovascular circulating volume may be a valuable viability marker in ischemically 
damaged donor kidneys if measured before transplantation. Therefore, we studied 
the dilution technique to measure renovascular circulating volume in machine-
perfused porcine kidneys and determined if renovascular circulating volume is 
associated with warm ischemia time.
MATERIALS AND METHODS
The experiments were carried out with porcine kidneys, which were recovered 
from a regional slaughterhouse. Pigs were between 6 and 7 months of age and had 
a mean weight of 105 kg. In the highly standardized slaughtering process, the time 
from death until recovery of the kidneys took exactly 15 minutes. After receiving 
an ‘en bloc’ pair of kidneys, kidneys were separated and then flushed with 0.5 L 
of Histidine-Tryptophan-Ketoglutarate (HTK) preservation solution for 20 minutes at 
the site. For transport to the preservation laboratory, kidneys were temporarily stored 
on ice. Two hours after recovery, kidneys were connected to a pulsatile perfusion 
machine (LifePort Kidney Transporter, model number LKT-100-P, Organ Recovery 
Systems, Des Plaines, IL, USA) and perfused with 500 mL University of Wisconsin (UW) 
solution. During machine perfusion, pressure (mmHg), flow (mL/min), and resistance 
(mmHg/mL/min) were recorded using the Lifeport Kidney Transporter.
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According to national legislation, study approval by the local animal 
experiments committee (DEC) was not required. Our study did not interfere with the 
standardized slaughtering process; kidneys were obtained after death.
Dilution technique
Renovascular circulating volume was assessed with the dilution technique. This 
technique has been described in detail before by others (6). Briefly, the renovascular 
circulating volume was measured with a dilution monitor (HD02 haemodialysis Flow-
QC monitor, Transonic Systems Inc, Ithaca, NY) through two reusable ultrasound flow 
probes (Transonic H4E Flow Probes) installed at 2 cm distance from the kidney on 
the arterial tube and on a tube connected to the renal vein. The dilution monitor 
was connected to a computer installed with HD02 Dialysis Monitoring Software 
(Figure 7.1). The system was calibrated for UW solution. To obtain measurements, 
we injected a saline bolus of 2 mL into the arterial injection port. The indicator is 
first sensed by the arterial sensor that records the time and volume of injection. The 
indicator then travels through the renovascular system and is recorded by the venous 
sensor on the renal vein. The venous sensor measures the change in concentration of 
saline in the preservation fluid and the transit time through the renovascular system. 
The renovascular circulating volume is calculated by the equation V = Q x MTT. In this 
equation, Q is defined as the flow in the system, and MTT (mean transit time) as the 
average transit time of the indicator. The first bolus was injected one hour after the 
start of perfusion (T1) to ensure a balanced state of perfusion. The additional volume 
within the tubing between vein or artery and sensors was kept constant by placing 
the sensors at a fixed distance from the kidney.
Figure 7.1 Schematic research setting. Sensors were placed in the perfusion machine on the arterial 
(A) tube, and venous (V) tube, connected to the renal vein. The dilution monitor was connected to a 
computer installed with HD02 Dialysis Monitoring Software.
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Flow measurements
To assess the correlation between measured flow by ultrasound flow probes 
and derived from roller pump speed, we performed simultaneous measurements 
of flow in six kidneys using pressures of 40, 50 and 60 mmHg. In total, 87 paired 
measurements were performed. Given the very strong correlation between flow 
measured by ultrasound flow probes and that derived from roller pump speed, only 
flow data derived from roller pump speed was used in the calculations.
Repeatability and validation
To verify repeatability in measuring renovascular circulating volume, we 
performed sets of six measurements at different perfusion pressures (30, 40, 50 and 
60 mmHg) in 9 kidneys. Per kidney and per pressure, six boluses of saline were injected 
at one hour after the start of perfusion (T1) and after 24 hours of machine perfusion 
(T24). A total of 426 measurements (71 data sets) were performed. In addition, of 
all measurements in this dataset, we plotted the correlation of measured volume 
against flow as well as volume against resistance.
Although the dilution technique has shown to be accurate in estimating 
perfused volume in dialyzer circuits, there is no gold standard of measuring 
renovascular circulating volume. Therefore, we verified validity of the dilution 
technique by comparing volume ratio and weight ratio in six partially perfused 
kidneys after the repeatability measurements were performed, at a pressure of 60 
mmHg. One of the renal arterial branches was clamped, and the measurements 
repeated. Next, a bolus of methylene blue was injected into the system, colouring the 
perfused part of the vascular system. The colored tissue was macroscopically divided 
from the non-colored tissue, and the percentage of the weight of each part was 
assessed. Validity was determined by comparing the renovascular circulating volume 
ratio and weight ratio of perfused and non-perfused parts of the kidney. 
Effect of warm ischemia time on renovascular circulating volume
To assess the effect of warm ischemia on renovascular circulating volume, we 
performed measurements in five kidney pairs. Each pair contained a kidney exposed 
to a mean of 15 minutes and a kidney exposed to a mean of 45 minutes of warm 
ischemia. After retrieval, this was realized by immediate cannulation of one of the 
renal arteries of the ‘en-bloc’ kidneys and connecting only this kidney to the perfusion 
fluid for initial flush. After the initial flush (20 min), kidneys were separated; the first 
kidney was stored on melting ice, and the contralateral kidney was stored at room 
temperature until 45 minutes of warm ischemia and then flushed. Measurements 
were performed after one hour of machine perfusion and after 24 hours (T1 and T24) 
with a perfusion pressure of 40 mmHg.
Data analysis
Continuous variables are presented as mean ± standard deviations (SD) if 
normally distributed (histogram). Correlation coefficients were calculated with the 
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Pearson test for normally distributed variables, and with the Spearman test otherwise. 
To determine repeatability, the coefficient of variation (CV) was calculated as the 
ratio of mean volume and standard deviation per dataset. Paired sample t-test was 
used to calculate the significance of differences between time points. Renovascular 
volume differences after clamping were calculated using the Wilcoxon signed-rank 
test. We used a paired-samples t-test to analyze differences between the 15 and 45 
minutes WIT groups. 
Data analysis was performed using SPSS 18.0 and Microsoft Excel 2007 for 
Windows. A p-value below 0.05 was considered evidence of a significant difference.
RESULTS
Flow measurements
The correlation between perfusate flow measured by ultrasound flow probes 
and derived from roller pump speed was very strong (R=0.97, 95% CI 0.95-0.98, 
p<0.001; Figure 7.2). Mean perfusate flow derived from roller pump speed was 11.0 ± 
8.0 mL higher than that by measured by ultrasound flow probes.
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Figure 7.2 Correlation of flow between the machine perfusion system and ultrasound flow probes 
using Spearman correlation coefficient.
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Repeatability and validation 
In one kidney, the series of measurements at a pressure of 30 mmHg at T1 failed 
because flow was too low. The mean CV of renovascular circulating volume measured 
by ultrasound dilution was 7.6 ± 6.2 % (Table 7.1). The CV did not significantly change 
with different durations of perfusion (1 and 24 hour; mean CV 6.8 ± 4.5% and 8.4 ± 
7.5%, respectively; p=0.166). The mean CV at a perfusion pressure of 30 mmHg was 
higher than at 40 mmHg (p=0.007), but did not significantly change compared to 
other pressures (40 vs. 50 mmHg; p=0.229; 50 vs. 60 mmHg; p=0.978). Excluding the 30 
mmHg measurements from the analyses showed a decrease of mean CV and SD from 
7.6 ± 6.2% to 6.2 ± 3.6%. Correlation of all volume measurements with flow and with 
resistance was good (rs=.921 and rs=.766, respectively) (Figure 7.3). 
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Figure 7.3 Correlation of flow (mL/min) (A) and resistance (mmHg/mL/min (B) measurements with 
renovascular circulating volume (mL).
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Table 7.1 Characteristics of measurements at different pressures
P (mmHg) Time N V(mL)
CV
(%)
Q
(mL/min)
R
(mmHg/mL/min)
30
T1 8*6=48 15.3 ± 4.8 11.5 ± 6.7 37.5 ± 9.6 0.76 ± 0.20
T24 9*6=54 15.9 ± 8.2 12.8 ± 12.3 39.6 ± 15.3 0.78 ± 0.31
40
T1 9*6=54 18.9 ± 6.2 6.8 ± 2.1 46.4 ± 11.4 0.82 ± 0.19
T24 9*6=54 21.0 ± 8.1 7.1 ± 6.8 51.7 ± 18.9 0.79 ± 0.30
50
T1 9*6=54 21.8 ± 6.6 4.9 ± 2.3 55.9 ± 11.2 0.85 ± 0.18
T24 9*6=54 23.4 ± 7.9 6.6 ± 2.5 62.9 ± 22.4 0.81 ± 0.28
60
T1 9*6=54 25.2 ± 7.7 4.7 ± 2.1 64.9 ± 13.3 0.88 ± 0.18
T24 9*6=54 24.9 ± 8.1 6.9 ± 3.8 75.1 ± 24.3 0.79 ± 0.24
Variables are expressed as mean ± SD. N = number of measurements; V = volume (mL); CV = coefficient of variation (%); Q = 
flow (mL/min); R = resistance (mmHg/mL/min). 
Renovascular circulating volumes measured by ultrasound dilution decreased 
after clamping of one of the renal arterial branches (from 25.6 ± 8.9 mL to 16.3 ± 7.6 
mL; p=0.028). However, these changes in renovascular circulating volume were not 
correlated with changes in actual perfused volume as measured by methylene blue 
staining (Figure 7.4).
Effect of perfusion pressure, duration of perfusion, and warm ischemia time on 
renovascular circulation volume
Per pressure (30, 40, 50 and 60 mmHg), renovascular circulating volume 
measured by ultrasound dilution did not differ between T1 and T24 (p=0.557, p=0.084, 
p=0.126 and p=0.833, respectively; Table 7.1). Renovascular circulating volume 
increased significantly with every 10 mmHg increase of pressure at T1 and for the 
increase from 30 mmHg to 40 mmHg at T24. Increasing the duration of hypothermic 
perfusion from 1 hour to 24 hours did not change renovascular circulating volumes 
(mean renovascular circulating volume 20.4 ± 7.3 mL and 21.5 ± 8.7 mL, respectively; 
p=0.078).
The mean renovascular circulating volumes of kidneys with 15 minutes of 
warm ischemia were higher than those of kidneys with 45 minutes of warm ischemia 
(34.1 ± 6.0 mL vs. 26.8 ± 5.3 mL, respectively; p=0.005) at T1, but did not significantly 
differ at T24 (36.7 ± 11.4 mL vs. 27.3 ± 8.0 mL, respectively; p=0.059).
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Figure 7.4 Correlation of volume/weight ratios of kidneys before and after clamping one of the arterial 
branches and methylene blue staining. The dotted line represents equality of both circulatory volume and 
weight ratio.
DISCUSSION
Organs from DCD donors have rapidly increased the deceased donor pool, but 
suffer from warm ischemic injury, resulting in a higher incidence of postoperative 
graft dysfunction. Pretransplantation assessment of DCD kidneys to select viable 
grafts for transplantation is crucial to obtain the best results after transplantation. 
Warm ischemia can lead to microvascular damage, affecting renovascular circulating 
volume. The dilution technique is a relatively simple method to measure intravascular 
volume and has not been used before in transplant surgery. As intravascular volume 
may be associated with organ viability, the dilution technique is a potentially 
valuable method to use in organ viability assessment. Therefore, we determined the 
repeatability and the validity of this technique, and we assessed the effect of warm 
ischemia on renovascular circulating volume in machine-perfused porcine kidneys. 
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In 1897, the dilution technique was introduced for cardiac output measurement 
(7). More recently, this method has been applied to measure regional blood flow in 
heart and lungs, and this application has gained a wide acceptance (8). Since 1995, 
a modification of the dilution technique has been used to measure shunt flow, 
recirculation, and cardiac output during hemodialysis (4, 9). This study is the first that 
applies the dilution technique to measure renovascular volume of machine-perfused 
kidneys. Given the importance of pretransplantation viability testing in DCD kidneys, 
we have studied the feasibility of the dilution technique to measure renovascular 
circulating volume as a new potential viability marker. 
We have shown that the dilution technique is a reproducible technique to 
measure renal blood flow in machine-perfused porcine kidneys. The repeatability 
of the dilution method was good, with an acceptable CV of 7.6%.  Repeatability did 
not change with duration of perfusion, but did show changes at different perfusion 
pressures. CV at a pressure of 30 mmHg showed a significantly higher value compared 
with 40 mmHg, indicating that measurements at low pressure and flow are less 
reliable. This is probably due to equipment adjustments and should be optimized. 
If one of the renal arterial branches of the kidney was clamped, measured 
renovascular volume decreased for all kidneys. Nonetheless, a correlation between 
volume and weight ratio could not be demonstrated. In four of six kidneys, volume 
and weight ratio measurements after clamping one arterial branch were almost 
equivalent, but ratios in two other kidneys were slightly off the line of equality of 
ratios. One of the limitations is that, in all six kidneys, between 30 to 50% of the 
kidney was excluded from perfusion. Moreover, it is not possible to assess if differences 
between volume and weight ratio measurements are caused by differences in the 
initial perfusion of one kidney. One part of a kidney may be better perfused with a 
higher intravascular volume than another. 
We think that pretransplantation viability assessment by the dilution 
technique could have advantages as compared to viability assessment by machine 
perfusion. Machine perfusion has two potential advantages over cold storage. 
First, machine perfusion improves early graft function compared to cold storage 
by preventing interstitial edema, decreasing oxidative stress, improving adenosine 
triphosphate (ATP) availability, and washing out thrombi and metabolic products 
(10-16). Second, machine perfusion allows early viability assessment by measuring 
perfusion characteristics, including flow, pressure and renovascular resistance, or 
biomarkers (17-22). However, recent studies show that the value of these parameters 
to predict kidney transplant outcome is limited (21, 23, 24). Machine perfusion 
characteristics could be influenced by leakage from the arterial connection resulting 
from atherosclerosis of the patch or by leakage from small arterial branches that have 
been damaged during procurement. In the dilution technique, however, leakage 
cannot influence the measurements, because an exact bolus of saline is assessed. 
However, the theoretical advantage of the dilution technique in viability testing has 
to be proven in clinical practice.
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Renovascular volume decreased after a prolonged period of warm ischemia. 
This may be explained by the manifestation of edema. Cellular volume regulation 
depends on mechanisms that require sodium-potassium ATPase activity, which 
is limited by decreased ATP during ischemia (25, 26). The significant differences 
between renovascular circulating volumes between short and long ischemia did not 
sustain until 24 hours of machine perfusion. This is in line with previous studies, which 
demonstrate that perfusion differences decrease over time (23, 27). In this study, 
we only compared different warm ischemia times at a machine perfusion pressure 
of 40 mmHg. This is the maximum perfusion pressure used at our and many other 
transplantation centers to avoid microvascular injury. Higher perfusion pressures may 
open capillaries, with better perfusion, but are also associated with vascular injury 
caused by shear stress (28-30). The finding that renovascular circulating volume is 
associated with warm ischemia time confirms our hypothesis on the relevance of 
renovascular circulating volume.
Further studies are necessary to assess the value of the dilution technique and 
renovascular volume measurements in human transplantation. Sterile flow probes 
for the renal artery and vein are available, which makes testing in human kidneys 
possible. The assessment of the effect of different pharmacological interventions 
during machine perfusion including vasodilating and antithrombolytic drugs on 
circulating volume could be a future application of the dilution technique.
We conclude that the dilution technique is a reproducible way to assess 
renovascular circulating volume in machine-perfused porcine kidneys, and that the 
technique is suitable to detect differences in warm ischemia time.
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ABSTRACT
Pretransplant assessment of kidney graft viability may help clinicians to decide 
whether to accept or discard a kidney for transplantation. With the increasing 
demand for donor kidneys and the increased use of marginal kidneys, the need of 
viability markers has increased to pursue superior transplant outcomes. Hypothermic 
machine perfusion (HMP) provides the theoretical opportunity to assess the viability 
of donor kidneys. We discuss the novel developments in viability testing during HMP 
and address the future prospects.
HMP viability testing has focused on the analysis of machine perfusion 
parameters and perfusate biomarkers. Renal resistance and the biomarkers lactate 
dehydrogenase, aspartate transaminase, glutathione-S-transferase, N-acetyl-b-D-
glucosaminidase, heart-type fatty acid binding protein, lipid peroxidation products, 
redox-active iron and IL-18 are correlated with transplant outcome in terms of 
development of delayed graft function or graft survival. However, they all lack 
adequate predictive value for transplant outcome. New techniques including contrast-
enhanced ultrasound, three-dimensional ultrasound and magnetic resonance 
spectrometry are promising methods to test kidney viability during HMP, but their 
value has to be established. The introduction of normothermic machine perfusion 
offers other promising opportunities for viability testing.
Machine perfusion characteristics and perfusate biomarkers have been 
extensively studied. They often correlate with the transplant outcome, but the present 
viability tests are not reliable predictors of transplant outcome. New developments 
in kidney graft viability assessment are necessary to have a chance of being clinically 
useful in the future.
Published as
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INTRODUCTION
Selection of suitable kidneys for transplantation is important to reduce the risk 
of primary non-function (PNF) and delayed graft function (DGF) after transplantation, 
which is associated with an increased risk of graft loss, acute rejection, longer 
hospital stay and high costs (1-4). The shortage of donors and the increasing use of 
marginal donors make donor kidney selection even more important. Although donor 
characteristics, including age and associated disease, and procurement methods are 
associated with kidney transplant function, there are no true kidney viability markers. 
Predicting the kidney function and assessing the chance of graft survival prior to 
transplantation remain difficult. Because of the increasing use of marginal kidneys, 
there is an urgent need for better pretransplant viability tests to avoid the risk of 
poor outcome after transplantation.
Hypothermic machine perfusion (HMP) is a technique to preserve donor 
kidneys. It has many advantages over cold storage. In theory, continuous pulsatile 
flow through the kidney can provide nutrients and oxygen to the kidney and it can 
eliminate metabolic byproducts and toxins. It decreases vasospasm and protects 
the endothelium, possibly because of flow-dependent genes. Furthermore, HMP 
offers the opportunity to apply therapeutic interventions, like the addition of 
pharmacological agents (5, 6). In a preclinical animal study, HMP was superior to 
cold storage in terms of functional recovery, oxidative stress, tissue histology and 
inflammatory parameters (7). In human kidney transplantation, there is highlevel 
evidence that HMP is associated with a decreased risk of DGF, improved 1-year and 
3-year graft survival, although the last was only proven for donation after brain 
death (DBD) kidneys and not for donation after cardiac death (DCD) kidneys (8-11).
HMP offers a good opportunity to test the viability of deceased-donor kidneys. 
In the past, machine viability testing has been used to decide whether kidneys should 
be discarded or not. Many have evaluated perfusate biomarker concentration and 
machine perfusion parameters as a tool to estimate graft viability. However, its use 
was often only justified by the argument that the results of transplantation had 
improved after the introduction of machine perfusion viability testing. Highquality 
evidence was usually not available (4). Recent literature provides more information 
about the association of machine perfusion viability testing and kidney function after 
transplantation and even more importantly, about its predictive value.
MACHINE PERFUSION PARAMETERS
During machine perfusion, pressure, flow and renal resistance are easily 
monitored. There is no common opinion about the best perfusion pressure of 
kidneys and used pressures vary between 20 and 60 mmHg (12, 13). Because pressure 
measurements are directly subjected to their manual setting, perfusion pressure 
itself has no role in outcome prediction or viability testing. Renal flow, although 
more often used than pressure, encounters similar problems. Flow depends on the 
CHAPTER 8
122
manual pressure settings, making a cut-off value for flow itself not reliable in clinical 
decision-making (14). Therefore, renal resistance (the ratio of perfusion pressure and 
renal flow) is used for viability testing instead.
It is estimated that approximately 15% of all machine-perfused kidneys in 
the USA are discarded, partly because of high renal resistance (15). However, little 
information is known about the predictive value of renal resistance and other 
machine perfusion characteristics on transplant outcome or its use in selecting kidneys 
for transplantation (12, 14, 16, 17). Two studies have addressed the use of renal 
resistance as a viability marker without being biased by donor kidney selection prior 
to transplantation, that is, discarding kidneys because of too high renal resistance or 
low flow (18, 19). 
The first study included 336 hypothermic machine-perfused DCD and DBD 
kidneys of the European machine perfusion trial (8). High renal resistance at the end 
of machine perfusion was an independent risk factor of DGF (OR 38.1; 95% CI 1.56–
934; P=0.026) and for 1-year graft failure (HR 12.33; 95% CI 1.11–136.85; p=0.004). 
However, the predictive value of renal resistance on DGF was poor (AURC = 0.58) (18). 
The second study included 440 hypothermic machine-perfused DCD kidneys. 
This study showed a significant and independent association of renal resistance at the 
beginning of HMP with PNF (OR 2.040; 95% CI 1.362–3.056; p=0.001) and DGF (OR 
2.345; 95% CI 1.110–4.955; p=0.025). However, the predictive value for PNF was poor 
(AURC 0.609) (19). This study focused on PNF instead of DGF, as DGF does not affect 
long-term survival in DCD kidneys (20).
BIOMARKERS
Machine perfusion enables viability testing by analyzing the washout of 
enzymes in the perfusate. These biomarkers include released contents of damaged 
cells leaked into the interstitial space, free-radical-mediated molecules, measures of 
antioxidant status or inflammation-associated proteins.
A large variety of biomarkers have been advocated as possible markers of 
kidney injury: lactate dehydrogenase (LDH), alanine aminopeptidase (Ala-AP), 
glutathione-S-transferase (GST) in different isoforms, aspartate transaminase (AST), 
lipid peroxidation products (LPOP), heart-type fatty acid binding protein (H-FABP), 
lactate, electrolytes, gas pressure (pO2 and pCO2), pH, osmolarity, N-acetyl-b-D-
glucosaminidase (NAG), redox-active iron, malondialdehyde (MDA), total antioxidant 
status (TAS), glucose, acid phosphatase, neutrophils gelatinase-associated lipocalin 
(NGAL), interleukin 18 (IL-18) and proteomics. The most important and recently 
studied biomarkers are discussed below (Table 8.1) (21-25).
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LDH was correlated with PNF in some studies and more often with DGF only, 
although its predictive value for DGF was poor (AURC 0.60) (4, 21). Very recently, 
these findings were confirmed in an unselected cohort of 335 DCD kidneys. LDH 
was associated with PNF as well as DGF in a multivariate analysis, corrected for 
confounding variables. However, diagnostic accuracy for the development of PNF was 
poor (AURC = 0.699) (22).
Table 8.1            Perfusate biomarkers
Biomarker Origin Marker of DCD/DBD kidneys1
Predictive 
value for2
References
DGF PNF
LDH
Cytoplasm of various body 
cells, including brush border 
of proximal renal tubule.
Non-specific cellular 
injury 
DCD, 
DBD Poor Poor (21, 22, 29)
Ala-AP Intestine and brush border of proximal renal tubule Tubular injury
DCD, 
DBD Poor - (21)
Total GST
Cytoplasm of various body 
cells, including proximal and 
distal renal tubule
Tubular injury DCD, DBD Poor Poor (21, 22, 26, 29) 
Alpha-GST
Cytoplasm of various body 
cells, including proximal renal 
tubule
Proximal tubular 
injury
DCD, 
DBD - - (26)
Pi-GST
Cytoplasm of various body 
cells, including distal renal 
tubule
Distal tubular injury DCD, DBD - - (26)
LPOP Various body cells Oxidative stress DCD, DBD - - (26)
H-FABP
Heart, small intestine, skeletal 
muscle and distal renal 
tubules.
Ischemic cellular 
injury
DCD, 
DBD Poor Poor (21, 22)
AST Several tissues, including renal parenchymal cells
Parenchymal cell 
injury
DCD, 
DBD Poor - (21)
Redox-
active iron Several organ systems
Ischemia/
reperfusion injury DCD - Fair
3 (22, 29)
NAG
Lysosomes of various tissues, 
including proximal renal 
tubule
Acute oxidative 
stress
DCD, 
DBD Poor - (21)
NGAL Several tissues, Renal tubular epithelial cells
Tubular epithelial 
injury DCD - Poor (22)
IL-18 Produced by macrophages and other cell types
Inflammatory 
reactions during 
ischemia/
reperfusion injury
DCD - Fair3 (22)
Perfusate 
Proteomes Unknown
Ischemic acute renal 
injury   DCD - - (31)
 
1 Kidneys on which a predictive value was based on.
2 Predictive value was derived from the area under the receiver operating curve of univariate analyses of individual 
biomarkers (1: perfect; 0.9-1: excellent; 0.8-0.9 good; 0.7-0.8 fair; <0.7: poor).
3 Predictive value after multivariate analysis.
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Ala-AP is a biomarker used in acute kidney injury and rarely described in a 
pretransplant setting. Ala-AP was correlated with DGF, however with a poor predictive 
value (AURC 0.57) (21, 26).
GST represents a family of cytosolic, microsomal and membrane-bound 
enzymes [total GST (tGST)], of which two of the eight cytoplasmic classes identified 
are of major interest. Alpha-GST, found in the proximal renal tubule, and p-GST, 
found in the distal renal tubule, are released during ischemia. Proximal tubules are 
metabolically more active, thus making a-GST in theory a more promising biomarker 
(26-28). Total GST concentration was elevated in DGF and PNF kidneys, but with poor 
predictive values for DGF (AURC 0.67) (21) and PNF (AURC 0.58) (22). Analysis of GST 
in HMP perfusates of 111 kidneys from donors older than 55 years showed that p-GST 
was not suitable to predict DGF. Alpha-GST had a better positive predictive value than 
tGST (71.4 and 37.5%, respectively), but is more expensive and time-consuming to 
measure. After multivariate analysis, none did seem to be an independent predictor 
of DGF after transplantation (24).
LPOP is a combination of products released after oxidative stress (24). 
LPOP concentration is proposed to be an index for the effects of reactive oxygen 
species, which are thought to play a major role in ischemic injury (3, 29, 30). LPOP 
concentration was an independent predictor of DGF after transplantation (OR 2.026; 
95% CI 1.129–3.637; p=0.018) (24).
H-FABP was addressed in two studies. It is involved in the uptake of fatty 
acid from the cytosol to the mitochondria (28). H-FABP was noted to have a poor 
predictive value for DGF (AURC 0.64) (21) and PNF (AURC 0.56) (22).
AST showed a significant association with DGF after transplantation with a 
poor predictive value (AURC 0.61) (21).
Perfusate redox-active iron concentration was significantly higher in DCD 
kidneys than in DBD kidneys, explained by the increased ischemic injury of DCD 
kidneys. Perfusate concentration in DCD kidneys was significantly associated with 
DGF and PNF, with increased risk of DGF (OR 1.532; 95% CI 1.045–2.245; p=0.029) and 
PNF (OR 1.68; 95% CI 1.13–2.49; p=0.01). The predictive value for PNF in a univariate 
analysis was poor (AURC 0.625), but increased to fair (AURC 0.701) in a multivariate 
analysis (22, 23).
NAG was addressed in one high-quality study. The perfusate sample was taken 
at the end of machine perfusion and showed a poor predictive value for DGF (AURC 
0.64) (21).
NGAL is expressed in a wide variety of tissues, including renal tubular 
epithelium, and rapidly expressed after the injury of tubular epithelium (27). NGAL 
has been used as a biomarker for acute renal injury; the concentration in perfusate 
of machine-perfused porcine kidneys was proportionate to the amount of prior 
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warm ischemic injury (31). Recently, it has been studied as a viability predictor in DCD 
kidneys. Although perfusate concentration was associated with transplant outcome, 
its predictive value for PNF was poor (AURC 0.503) (22).
The proinflammatory cytokine IL-18 has been addressed once. In DCD kidneys, 
it was associated with an increased risk of PNF and DGF (OR 1.001; 95% CI 1.000–1.002; 
p=0.003 and OR 1.003; 95% CI 1.001–1.004; p=0.002, respectively). Its predictive value 
for PNF in a univariate analysis was poor (AURC 0.591), but increased to fair (AURC 
0.700) in a multivariate analysis (22).
A proteomics study of machine perfusate of 18 kidneys (6 DBD, 6 controlled DCD 
and 6 uncontrolled DCD kidneys) identified 19 unique proteins with the use of two-
dimensional difference gel electrophoresis and mass spectrometry. In DCD kidneys, 
two unidentified proteins were significantly upregulated and one protein, identified 
as haptoglobin, was significantly downregulated, compared with DBD kidneys. 
Furthermore, two proteins were upregulated in PNF kidneys and 1 protein, identified 
as a1-antitrypsin, was upregulated in DGF kidneys. Thus, this study introduced a series 
of novel biomarkers of ischemic acute renal injury in human donor kidneys. However, 
their diagnostic value in viability testing has to be determined in future studies (25).
NOVELTIES IN VIABILITY TESTING
In past decades, machine perfusion viability testing mainly focused on perfusate 
biomarkers and machine perfusion parameters. Contrast-enhanced ultrasound (CEUS) 
and three dimensional ultrasound (3DUS) have recently been introduced as a new 
technique for assessing renal transplant perfusion during HMP. Five pig kidneys were 
procured after a period of 30 min of warm ischemia and placed on a hypothermic 
perfusion machine. Following a bolus injection of a contrast solution (tiny bubbles 
of inert gas, which pass through the capillary bed but not through the interstitial 
space or blood–brain barrier and which increase ultrasound signal return), 2D and 3D 
ultrasound scans were performed. These techniques were fast, well tolerated, aseptic 
and noninvasive methods to assess perfusion of the kidney before transplantation 
(32). In the future, this might be useful to assess organ viability, in addition to 
machine perfusion parameters like flow and renal resistance, albeit their value has to 
be assessed in large human cohorts first.
Magnetic resonance spectrometry (MRS) has been studied before to assess 
ischemic injury and viability of kidneys on cold storage (33-37). Recently, MRS has 
been used to assess viability during HMP with a newly developed magnetic resonance 
compatible perfusion machine (38-40). This machine has been used to oxygenate 
porcine kidneys during hypothermic preservation and to measure chemical shifts 
during HMP with the use of 1H and 31P-MRS. 31P-MRS showed to be a valuable tool 
to assess ATP levels in kidneys without warm ischemia, if appropriate O2 tension was 
CHAPTER 8
126
applied to the preservation medium. MRS during HMP may also be useful to study 
preservation conditions and warm ischemic effects in a clinical setting (40). Although 
the number of kidneys studied until now is limited, the idea of measuring ATP levels 
is interesting and promising as it is a measure of energy depletion after ischemic 
injury. Its value to predict organ viability has to be proven.
FUTURE PROSPECTS
Kidney viability testing has benefited from the introduction of HMP, although 
the predictive value of machine perfusion resistance and of different perfusate 
biomarkers is too low to obtain a useful predictor of kidney transplant outcome. 
Normothermic machine perfusion (NMP) may provide new and other opportunities 
to assess the quality of a donor organ before transplantation. Furthermore, NMP may 
ameliorate ischemic damage and resuscitate the organ instead of doing further harm 
and preventing the graft from injury during the preservation period (41).
The Leicester group showed in a porcine kidney autotransplant model that 
after a period of 20 h of HMP, kidneys can be safely perfused with NMP for two 
hours with autologous blood (42). Thereafter, they perfused a human kidney with 
a warm solution of cross-matched packed red cells with crystalloids, nutrients and 
some medication, shortly before transplantation, which shows that short-term NMP 
is feasible in a clinical setting (43). Now NMP seems feasible and well tolerated, 
it may have large potential to improve machine perfusion viability testing. The 
major advantage of NMP to test organ viability is the possibility of measuring 
functional parameters, like diuresis and creatinine clearance. In a normothermic 
setting with normal kidney metabolism, cellular injury may be diagnosed by cellular 
dysfunction instead of by markers of cell death, ischemia or inflammation. Functional 
measurements may provide key parameters of kidney viability and may be more 
accurate and useful in transplant outcome prediction than any of aforementioned 
viability markers (44, 45).
CONCLUSION
We conclude that machine perfusion viability testing has not offered clinicians 
the expected tools to assess kidney viability before transplantation. Currently 
available viability tests during HMP are not reliable enough to decide to discard a 
donor kidney prior to transplantation. New biomarkers and novel techniques may 
provide tests with better predictive value than the tests used today, but their value 
has to be proven. Viability testing during normothermic perfusion offers a novel 
opportunity to assess the quality of a donor kidney, as the function of metabolically 
active organs is tested, instead of surrogate indicators of kidney injury.
MACHINE PERFUSION VIABILITY TESTING – A REVIEW
127 
REFERENCES
1.  Yarlagadda SG, Coca SG, Formica RN, Jr., Poggio ED, Parikh CR. Association between delayed graft function 
and allograft and patient survival: a systematic review and meta-analysis. Nephrol Dial Transplant. 2009 
Mar;24(3):1039-47. 
2.  Huang Y, Samaniego M. Preemptive kidney transplantation: Has it come of age? Nephrologie & 
therapeutique. Nov;8(6):428-32. 
3.  Perico N, Cattaneo D, Sayegh MH, Remuzzi G. Delayed graft function in kidney transplantation. Lancet. 
2004 Nov 13-19;364(9447):1814-27. 
4.  Bhangoo RS, Hall IE, Reese PP, Parikh CR. Deceased-donor kidney perfusate and urine biomarkers for 
kidney allograft outcomes: a systematic review. Nephrol Dial Transplant. 2012 Aug;27(8):3305-14. 
5.  Yuan X, Theruvath AJ, Ge X, Floerchinger B, Jurisch A, Garcia-Cardena G, et al. Machine perfusion or 
cold storage in organ transplantation: indication, mechanisms, and future perspectives. Transpl Int. 2010 
Jun;23(6):561-70. 
6.  Taylor MJ, Baicu SC. Current state of hypothermic machine perfusion preservation of organs: The clinical 
perspective. Cryobiology. 2010 Jul;60(3 Suppl):S20-35. 
7.  Vaziri N, Thuillier R, Favreau FD, Eugene M, Milin S, Chatauret NP, et al. Analysis of machine perfusion 
benefits in kidney grafts: a preclinical study. Journal of translational medicine. 2011;9:15. 
8.  Moers C, Smits JM, Maathuis MH, Treckmann J, van Gelder F, Napieralski BP, et al. Machine perfusion or 
cold storage in deceased-donor kidney transplantation. N Engl J Med. 2009 Jan 1;360(1):7-19. 
9.  Moers C, Pirenne J, Paul A, Ploeg RJ, Machine Preservation Trial Study G. Machine perfusion or cold storage 
in deceased-donor kidney transplantation. N Engl J Med. 2012 Feb 23;366(8):770-1. 
10.  Treckmann J, Moers C, Smits JM, Gallinat A, Maathuis MH, van Kasterop-Kutz M, et al. Machine perfusion 
versus cold storage for preservation of kidneys from expanded criteria donors after brain death. Transpl Int. 
2011 Jun;24(6):548-54. 
11.  Gallinat A, Moers C, Treckmann J, Smits JM, Leuvenink HG, Lefering R, et al. Machine perfusion versus cold 
storage for the preservation of kidneys from donors >=65 years allocated in the Eurotransplant Senior 
Programme. Nephrol Dial Transplant. 2012 Dec;27(12):4458-63. 
12.  Patel SK, Pankewycz OG, Weber-Shrikant E, Zachariah M, Kohli R, Nader ND, et al. Effect of increased 
pressure during pulsatile pump perfusion of deceased donor kidneys in transplantation. Transplantation 
proceedings. 2012 Sep;44(7):2202-6. 
13.  Doorschodt BM, Schreinemachers MC, Behbahani M, Florquin S, Weis J, Staat M, et al. Hypothermic 
machine perfusion of kidney grafts: which pressure is preferred? Annals of biomedical engineering. 2011 
Mar;39(3):1051-9. 
14.  Mozes MF, Skolek RB, Korf BC. Use of perfusion parameters in predicting outcomes of machine-preserved 
kidneys. Transplantation proceedings. 2005 Jan-Feb;37(1):350-1. 
15.  Sung RS, Christensen LL, Leichtman AB, Greenstein SM, Distant DA, Wynn JJ, et al. Determinants of discard 
of expanded criteria donor kidneys: impact of biopsy and machine perfusion. Am J Transplant. 2008 
Apr;8(4):783-92. 
16.  Dikdan GS, Mora-Esteves C, Koneru B. Review of randomized clinical trials of donor management and 
organ preservation in deceased donors: opportunities and issues. Transplantation. 2012 Sep 15;94(5):425-
41. 
17.  Patel SK, Pankewycz OG, Nader ND, Zachariah M, Kohli R, Laftavi MR. Prognostic utility of hypothermic 
machine perfusion in deceased donor renal transplantation. Transplantation proceedings. 2012 
Sep;44(7):2207-12. 
18.  Jochmans I, Moers C, Smits JM, Leuvenink HG, Treckmann J, Paul A, et al. The prognostic value of renal 
resistance during hypothermic machine perfusion of deceased donor kidneys. Am J Transplant. 2011 
Oct;11(10):2214-20. 
19.  de Vries EE, Hoogland ER, Winkens B, Snoeijs MG, van Heurn LW. Renovascular resistance of machine-
CHAPTER 8
128
perfused DCD kidneys is associated with primary nonfunction. Am J Transplant. 2011 Dec;11(12):2685-91. 
20.  Renkens JJ, Rouflart MM, Christiaans MH, van den Berg-Loonen EM, van Hooff JP, van Heurn LW. Outcome 
of nonheart-beating donor kidneys with prolonged delayed graft function after transplantation. Am J 
Transplant. 2005 Nov;5(11):2704-9. 
21.  Moers C, Varnav OC, van Heurn E, Jochmans I, Kirste GR, Rahmel A, et al. The value of machine perfusion 
perfusate biomarkers for predicting kidney transplant outcome. Transplantation. 2010 Nov 15;90(9):966-
73. 
22.  Hoogland ER, de Vries EE, Christiaans MH, Winkens B, Snoeijs MG, van Heurn LW. The Value of 
Machine Perfusion Biomarker Concentration in DCD Kidney Transplantations. Transplantation. 2013 Feb 
27;95(4):603-10. 
23.  de Vries B, Snoeijs MG, von Bonsdorff L, Ernest van Heurn LW, Parkkinen J, Buurman WA. Redox-active iron 
released during machine perfusion predicts viability of ischemically injured deceased donor kidneys. Am J 
Transplant. 2006 Nov;6(11):2686-93. 
24.  Nagelschmidt M, Minor T, Gallinat A, Moers C, Jochmans I, Pirenne J, et al. Lipid peroxidation products in 
machine perfusion of older donor kidneys. The Journal of surgical research. 2013 Apr;180(2):337-42. 
25.  Snoeijs MG, Pulinx B, van Dieijen-Visser MP, Buurman WA, van Heurn LW, Wodzig WK. Characterization of 
the perfusate proteome of human donor kidneys. Annals of clinical biochemistry. 2013 Mar;50(Pt 2):140-6. 
26.  Gok MA, Pelsers M, Glatz JF, Bhatti AA, Shenton BK, Peaston R, et al. Comparison of perfusate activities 
of glutathione S-transferase, alanine aminopeptidase and fatty acid binding protein in the assessment of 
non-heart-beating donor kidneys. Annals of clinical biochemistry. 2003 May;40(Pt 3):252-8. 
27.  Waring WS, Moonie A. Earlier recognition of nephrotoxicity using novel biomarkers of acute kidney injury. 
Clinical toxicology. 2011 Oct;49(8):720-8. 
28.  Balfoussia D, Yerrakalva D, Hamaoui K, Papalois V. Advances in machine perfusion graft viability assessment 
in kidney, liver, pancreas, lung, and heart transplant. Exp Clin Transplant. 2012 Apr;10(2):87-100. 
29.  Siedlecki A, Irish W, Brennan DC. Delayed graft function in the kidney transplant. Am J Transplant. 2011 
Nov;11(11):2279-96. 
30.  Kosieradzki M, Kuczynska J, Piwowarska J, Wegrowicz-Rebandel I, Kwiatkowski A, Lisik W, et al. Prognostic 
significance of free radicals: mediated injury occurring in the kidney donor. Transplantation. 2003 Apr 
27;75(8):1221-7. 
31.  Jochmans I, Monbaliu D, Pirenne J. Neutrophil gelatinase-associated lipocalin, a new biomarker candidate 
in perfusate of machine-perfused kidneys: a porcine pilot experiment. Transplantation proceedings. 
Nov;43(9):3486-9. 
32.  Stenberg B, Talbot D, Khurram M, Kanwar A, Ray C, Mownah O, et al. A new technique for assessing renal 
transplant perfusion preoperatively using contrast-enhanced ultrasound (CEUS) and three-dimensional 
ultrasound (3DUS)--a porcine model pilot study. Ultraschall in der Medizin. 2011 Dec;32 Suppl 2:E8-13. 
33.  Beckmann N, Hof RP, Rudin M. The role of magnetic resonance imaging and spectroscopy in transplantation: 
from animal models to man. NMR Biomed. 2000 Oct;13(6):329-48. 
34.  Hauet T, Mothes D, Goujon JM, Caritez JC, Le Moyec L, Carretier M, et al. Evaluation of normothermic 
ischemia and simple cold preservation injury in pig kidney by proton nuclear magnetic resonance 
spectroscopy. The Journal of surgical research. 1997 Mar;68(2):116-25. 
35.  Hauet T, Mothes D, Goujon JM, Caritez JC, Carretier M, Eugene M. Evaluation of injury preservation in pig 
kidney cold storage by proton nuclear magnetic resonance spectroscopy of urine. The Journal of urology. 
1997 Mar;157(3):1155-60. 
36.  Kurkova D, Herynek V, Gintelova J, Taborsky P, Hajek M. Potential of 31P magnetic resonance spectroscopy 
in monitoring the viability of human renal grafts stored in Euro-Collins perfusion solution. Physiological 
research / Academia Scientiarum Bohemoslovaca. 1995;44(5):327-32. 
37.  Bretan PN, Jr., Baldwin N, Novick AC, Majors A, Easley K, Ng T, et al. Pretransplant assessment of renal 
viability by phosphorus-31 magnetic resonance spectroscopy. Clinical experience in 40 recipient patients. 
Transplantation. 1989 Jul;48(1):48-53. 
38.  Buchs JB, Buhler L, Morel P. A new disposable perfusion machine, nuclear magnetic resonance compatible, 
MACHINE PERFUSION VIABILITY TESTING – A REVIEW
129 
to test the marginal organs and the kidneys from non-heart-beating donors before transplantation. 
Interactive cardiovascular and thoracic surgery. 2007 Aug;6(4):421-4. 
39.  Buchs JB, Lazeyras F, Ruttimann R, Nastasi A, Morel P. Oxygenated hypothermic pulsatile perfusion versus 
cold static storage for kidneys from non heart-beating donors tested by in-line ATP resynthesis to establish 
a strategy of preservation. Perfusion. 2011 Mar;26(2):159-65. 
40.  Lazeyras F, Buhler L, Vallee JP, Hergt M, Nastasi A, Ruttimann R, et al. Detection of ATP by “in line” 31P 
magnetic resonance spectroscopy during oxygenated hypothermic pulsatile perfusion of pigs’ kidneys. 
Magma. 2012 Oct;25(5):391-9. 
41.  Hosgood SA, Nicholson HF, Nicholson ML. Oxygenated kidney preservation techniques. Transplantation. 
2012 Mar 15;93(5):455-9. 
42.  Hosgood SA, Barlow AD, Yates PJ, Snoeijs MG, van Heurn EL, Nicholson ML. A pilot study assessing the 
feasibility of a short period of normothermic preservation in an experimental model of non heart beating 
donor kidneys. The Journal of surgical research. 2011 Nov;171(1):283-90. 
43.  Hosgood SA, Nicholson ML. First in man renal transplantation after ex vivo normothermic perfusion. 
Transplantation. 2011 Oct 15;92(7):735-8. 
44.  Hosgood SA, Nicholson ML. Normothermic kidney preservation. Current opinion in organ transplantation. 
2011 Apr;16(2):169-73. 
45.  Vogel T, Brockmann JG, Coussios C, Friend PJ. The role of normothermic extracorporeal perfusion in 
minimizing ischemia reperfusion injury. Transplantation reviews. 2012 Apr;26(2):156-62. 
130
131 
CHAPTER 9
THE VALUE OF DONOR 
NGAL IN PREDICTING 
SHORT-TERM GRAFT 
FUNCTION
CHAPTER 9
132
ABSTRACT
Background: Donation after cardiac death (DCD) may greatly expand the donor 
pool, but concerns about warm ischemic injury before organ recovery have resulted 
in reluctance to use DCD kidneys for transplantation. An accurate tool to assess renal 
injury before donation is lacking. We explored the diagnostic value of donor plasma 
NGAL concentration as a predictor of early postoperative graft function after kidney 
transplantation.
Methods: All deceased donor kidneys procured or transplanted at the 
Maastricht University Medical Center were included in this study. Plasma NGAL 
concentration was determined in whole donor EDTA-blood of DCD donors and 
donation after brain-dead (DBD) donors. Correlations of NGAL concentration with 
donor characteristics and graft function after transplantation were assessed.
Results: A total of 101 kidneys entered analysis. NGAL concentration was not 
significantly different between DCD and DBD donors (p=0.333). NGAL concentration 
correlated with donor creatinine (rs=.451, p<0.001), but did not correlate with graft 
function after transplantation (p=0.267). For functioning DCD kidneys, a significant 
difference in NGAL concentration between kidneys with delayed graft function 
(DGF) and immediate function (IF) was observed (p=0.049). NGAL concentration 
did not correlate with estimated glomerular filtration rate at 1 and 2 years after 
transplantation (p=0.216 and p=0.941, respectively). 
Conclusion: We have shown that donor NGAL concentration correlated with 
donor plasma creatinine. Additionally, NGAL concentrations between DGF and IF of 
DCD kidneys were significantly different. Its value to predict transplantation outcome 
is limited. 
Published as
E.R. Pieter Hoogland, Maarten G.J. Snoeijs and L.W. Ernest van Heurn. Plasma neutrophil gelatinase-associated 
lipocalin of deceased donors as a predictor of posttransplantation kidney function. Manuscript submitted.
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INTRODUCTION
For patients with end-stage renal disease, kidney transplantation offers better 
life expectancy and quality of life compared to dialysis therapy. Due to the shortage 
of donor kidneys, marginal grafts have increasingly been accepted for transplantation 
over the past decade. However, concerns about early graft dysfunction due to warm 
ischemic injury before organ recovery have resulted in a general reluctance to expand 
the use of DCD kidneys to its full potential. The extent of ischemic injury suffered 
by these kidneys varies widely and does not necessarily correspond to the period of 
absolute warm ischemia, because inconsistent renal perfusion during cardiopulmonary 
resuscitation and withdrawal of supportive treatment and the variable efficacy 
of renal cooling during in situ preservation also contribute to the ischemic injury. 
Therefore, accurate assessment of the extent of ischemic injury before implantation 
is needed and may increase the confidence to transplant DCD kidneys (1).
 Several studies have focused on the assessment of perfusate biomarker 
concentrations of machine-perfused kidneys as potential viability markers before 
transplantation (2-7). Others have focused on machine perfusion characteristics, such 
as renovascular resistance (8, 9). However, these tests are unreliable predictors of 
transplantation outcome (10). Biomarker viability testing of donor kidneys before 
procurement is not or only rarely done and may be a valuable tool to estimate the 
viability of donor kidneys. 
The protein neutrophil gelatinase-associated lipocalin (NGAL), also known as 
lipocalin-2, has recently been discovered as a novel biomarker of acute kidney injury 
(11). In kidney transplantation, NGAL concentration in recipient urine on the first 
postoperative day held remarkable diagnostic accuracy for the prediction of delayed 
graft function (AURC 0.90) (12). Furthermore, the intensity of immunohistochemical 
staining for NGAL in kidney biopsies taken at reperfusion correlated with graft 
function (13). The concentration of NGAL increases dramatically in response to 
tubular injury and precedes the elevation of classical biomarkers for kidney damage, 
such as serum creatinine (14). This study therefore aims to examine the diagnostic 
value of plasma NGAL concentration in the organ donor for early postoperative graft 
function after kidney transplantation.
MATERIALS AND METHODS
Study design
All deceased donor kidneys in our procurement area and deceased donor 
kidneys transplanted at our transplantation center from March 2009 until May 2011 
were included in this study. Plasma NGAL concentration was determined in whole 
EDTA blood, routinely drawn for tissue typing, virological screening and other 
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laboratory tests. In uncontrolled DCD donors, blood samples were taken during 
or after resuscitation, during which ischemia injury already occurred. In controlled 
DCD and DBD donors, blood samples were taken prior to cardiac arrest and organ 
preservation, respectively. Plasma NGAL concentration (in ng/mL) was determined by 
trained personnel. The medical staff involved in the donation and transplantation 
process was blinded for NGAL measurements. A small sample of left-over EDTA blood 
stored at room temperature was examined with the Triage MeterPro fluorescence-
immunoassay (Alere, Tilburg, The Netherlands), within 24 hours after sampling. 
The assay device is a single-use plastic cartridge that contains an NGAL-specific 
monoclonal antibody conjugated to a fluorescent NGAL antigen immobilized on a 
solid phase. The test is performed by pipetting a small sample (250 mL) of EDTA 
blood onto a port in the cassette where a filter separates cells from plasma. The 
plasma then reacts with the fluorescent antibody conjugates and flows through the 
test device by capillary action. NGAL present in the specimen prevents binding of 
the fluorescent conjugates to the solid phase on the detection zone, such that the 
NGAL concentration is inversely related to the fluorescence detected. The cassette is 
then inserted into the Triage MeterPro, a portable fluorescence spectrometer, and 
quantitative measurements of NGAL concentration in the range from 60 to 1300 ng/
mL are displayed on the meter screen.
The NGAL assay used had a lower limit of detection of 60 ng/mL, and 
manufacturer quoted 95th percentile of 149 ng/mL. Because of the lower detection 
limit, groups with different NGAL concentrations were created (<60, 60-149 and >149 
ng/mL).
All kidneys from uncontrolled donors after cardiac death (Maastricht category 
I and II) and selected kidneys from controlled donors after cardiac death (Maastricht 
category III) were preserved with machine pulsatile perfusion and perfusion 
characteristics were recorded. Early postoperative graft function of the kidneys 
from all deceased donors was categorized as immediate function (IF; no dialysis 
necessary after transplantation), delayed graft function (DGF; temporary dialysis 
therapy initiated in the first week after transplantation) or primary non-function 
(PNF; inadequate renal function, necessitating continuation of dialysis treatment 
or retransplantation). Glomerular filtration rate at 3 months and 1 year was 
estimated from serum creatinine using the MDRD formula (15). All clinical data were 
anonymously extracted from a prospectively kept database intended for internal 
quality control. 
The primary endpoint of this study was the correlation between plasma NGAL 
concentration in organ donors and early postoperative graft function. Secondary 
endpoints were the correlation of plasma NGAL concentration with glomerular 
filtration rate at 3 months and 1 year after transplantation and with perfusion 
characteristics during organ preservation.
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Ethics
This study did not need approval from an institutional review board. 
Collection, storage and use of tissue and patient data are performed in agreement 
with the codes of conduct ‘Use of data in health research’ and ‘Proper secondary use 
of human tissue’ put forward by The federation of Dutch medical scientific societies 
(http://www.federa.org/). Furthermore, use of leftover donor samples for transplant 
research is in line with the Dutch act on organ donation.
Statistical analyses
Continuous variables are presented as mean ± standard deviation (SD) if 
normally distributed, and as median and inter-quartile range (IQR) otherwise. 
Categorical variables are presented as percentages.
Baseline donor, preservation, and recipient characteristics were compared 
between donor types (DCD vs. DBD) with independent-samples t-tests for 
approximately normally distributed continuous variables, with Mann-Whitney U-tests 
if the distribution clearly deviated from normality and with chi-square tests for 
categorical variables. Donor creatinine and recipient’s eGFR were compared between 
NGAL groups (<60, 60-149 and >149 ng/mL) with independent-samples t-tests.
Correlations between NGAL and both donor creatinine and estimated GFR 
(eGRF), calculated with the abbreviated modification of diet in renal disease equation 
(MDRD), were evaluated with Spearman’s test.
Graft survival censored for recipient death with a functioning graft was 
calculated with the Kaplan-Meier method; the log-rank test was used to compare the 
survival curves of the specific biomarker concentration between the different NGAL 
concentration groups.
All analyses were performed using Statistical Package for the Social Sciences 
(SPSS) software version 20.0; a p-value ≤ 0.05 was considered statistically significant.
RESULTS
Donor kidneys
Baseline donor, graft, and recipient characteristics are summarized in Table 
9.1. Between March 2009 and May 2011, 52 donation procedures from deceased 
donors were carried out in our region (101 procured kidneys), of which 10 were 
uncontrolled (Maastricht category I and II) DCD donors (19 kidneys), 15 controlled 
(category III) DCD donors (30 kidneys) and 27 DBD donors (52 kidneys). 84 kidneys 
CHAPTER 9
136
from these donors were transplanted in the Eurotransplant region. Two kidneys were 
transplanted en bloc and were analyzed as 1. A total of 17 kidneys (13 uncontrolled 
DCD kidneys, 4 controlled DCD kidneys) were discarded, based on (vascular) anatomy 
(N = 3), macroscopic appearance (N = 4), a tumor found during organ procurement (N 
= 2), or if there were no suitable recipients (N = 8). Additionally, 17 kidneys procured 
elsewhere were transplanted at our center.   	
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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Figure 9.1 NGAL concentration, divided in groups, and the accompanying donor creatinine 
concentration
Donor creatinine was significantly higher in the ’60-149’ ng/mL (mean 97.5 ± 
35.4 µmol/L, p<0.001, N = 21) and ‘>149’ ng/mL (mean 105.0 ± 68.3 µmol/L, p=0.004, N 
= 20) NGAL groups compared with the ‘<60’ ng/mL group (mean 59.5 ± 24.2 µmol/L, 
N = 24) (Figure 9.1). Donor NGAL significantly correlated with donor creatinine, rs = 
.451, p<0.001. Donor creatinine concentration values were missing in 4 cases. 
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Table 9.1 Baseline donor, graft, and recipient characteristics
DCD DBD p
Donor related
 Donor age 53 ± 13 52 ± 15 0.713
 Donor sex (male) 58% 65% 0.584
 Donor Creatinine (μmol/L) 78 ± 35 93 ± 59 0.230
 Donor center  (MUMC/other)1 69 / 31% 79 / 21% 0.340
 Uncontrolled / controlled DCD kidneys 14.3 / 85.7% - -
Graft related
 Warm ischemia time (min)2 19.3 ± 5.8 - -
 Cold ischemia time (min) 19 ± 4 15 ± 5 0.006
 Anastomosis time (min) 40 ± 18 34 ± 9 0.227
 NGAL (% <60/60-149/>149 ng/mL) 28.6/42.9/28.6% 41.2/26.5/32.4% 0.333
 Shortterm graft function (% PNF / DGF / IF) 5.1 / 74.4 / 20.5 7.5 / 35.8 / 56.6 0.001
Recipient related
 Recipient age 57 ± 11 54 ± 16 0.194
 Recipient sex (male) 67% 66% 0.953
 Transplant center (regional  / export) 52 / 48% 17 / 83% <0.001
 
1 MUMC: Maastricht University Medical Center.
2 Warm ischemia time of DCD kidneys only.
Discarded and non-functioning kidneys 
NGAL concentrations of discarded kidneys were not significantly different 
from concentrations of transplanted kidneys, however, a trend towards significance 
was observed (Pearson’s chi-square p=0.071), with higher NGAL concentrations in 
the discarded kidneys. NGAL concentrations of kidneys that eventually functioned 
were not significantly different than of transplanted kidneys with PNF (Pearson’s chi-
square p=0.375), however, the number of kidneys with PNF was low (N = 6).
Short-term graft function
Short-term graft function was significantly different between DCD and DBD 
kidneys (PNF: 5.1% vs. 7.5%, DGF: 74.4% vs. 35.8%, IF: 20.5% vs. 56.6%, respectively, 
p=0.001). NGAL concentrations were not associated with short-term graft function 
overall (Pearson’s chi-square p=0.267). Separated analyses for DCD kidneys only and 
DBD kidneys only showed no association between NGAL concentrations and short-
term graft function for DCD kidneys (Pearson’s chi-square p=0.109) and DBD kidneys 
(Pearson’s chi-square p=0.232).
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For functioning kidneys (PNF kidneys excluded), there was no difference 
in NGAL concentrations between kidneys with DGF and IF in all kidneys together 
(Pearson’s chi-square p=0.116). NGAL concentrations did not correlate with eGFR at 3 
months after transplantation (rs=0.080, p=0.481). Separated analyses for DCD kidneys 
showed a significant difference in NGAL concentrations between DGF and IF (Pearson’s 
chi-square p=0.049), with a higher NGAL concentration being more common in the IF 
kidneys and a NGAL concentration of 60-149 being more common in the DGF kidneys. 
No correlation was found between NGAL concentrations and eGFR at 3 months after 
transplantation (rs=0.184, p=0.284). The same analyses for DBD kidneys only showed 
no significant difference between DGF and IF (p=0.961), and no correlation between 
NGAL concentrations and eGFR at 3 months after transplantation (rs=0.019, p=0.903).
After excluding donor kidneys with a NGAL concentration below the detection 
limit of 60 ng/mL, statistical analyses were repeated with NGAL concentration as a 
continuous variable. Also in these analyses, there were no significant differences 
between NGAL concentrations and short-term graft function and no significant 
correlation between NGAL and eGFR at 3 months (data not shown).
Long-term graft function and survival
eGFR was not significantly different between NGAL groups at one year after 
transplantation (Figure 9.2), and NGAL concentration did not correlate with eGFR at 
1 and 2 years after transplantation (rs=.150, p=0.216, N = 70, and rs=.016, p=0.941, 
N = 25). 
Figure 9.2 NGAL concentration, divided in groups, and renal function denoted in eGFR at one year 
after transplantation.
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Figure 9.3 shows graft survival of all transplanted kidneys, censored for 
recipient death with a functioning graft. Graft survival at 1 and 2 years after 
transplantation was not significantly different for the different NGAL groups, kidneys 
with PNF included.
 Again, after excluding donor kidneys with a NGAL concentration below 
the detection limit of 60 ng/mL, statistical analyses were repeated with NGAL 
concentration as a continuous variable. No correlations were found between NGAL 
concentrations and eGFR at 1 and 2 years after transplantation (r=0.194, p=0.206, N 
= 44, and r=-.272, p=0.308, N = 16, respectively).
Machine perfused kidneys
A total of 22 kidneys were machine perfused. GST and LDH concentrations 
at 4 hours after start of machine perfusion were available from 18 kidneys. Donor 
NGAL did not correlate with GST and LDH levels at 4 hours after the start of machine 
perfusion (rs=.433, p=0.073 and rs=.107, p=0.672) and with renovascular resistance at 
the start of machine perfusion (rs=.132, p=0.626, N = 16). 
DISCUSSION
Donation after cardiac death has the potential to greatly expand the number 
of organ donors and thereby the kidneys available for transplantation. However, the 
use of these donors is limited due to the reluctance of many transplantation centers 
to use kidneys with acute ischemic injury that are at increased risk of early graft 
dysfunction. 
 Expanding the donor pool safely requires the selection and discard of 
donor kidneys with an unacceptable high risk of early graft dysfunction and the 
development of tools to assess kidney graft quality prior to transplantation. Graft 
quality can be assessed at two distinct stages during the donation process: prior to 
procurement and during preservation (16). For the first stage, different risk scores for 
donors have been developed (17-19). However, all existing donor risk scores have a 
low predictive accuracy and therefore, it is not appropriate to discard kidneys based 
on risk scores (16). 
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Figure 9.3 Kaplan-Meier graft survival curves for NGAL concentrations divided in groups.
 Quality assessment during preservation can be performed by means of pre-
transplantation kidney biopsies (16, 20). Pre-transplantation kidney biopsies are 
mostly evaluated in older donors (21). In these donors, glomerular sclerosis is, among 
others, an important predictor for graft survival (22).
Viability testing of machine-perfused kidneys includes perfusion dynamics and 
perfusate biomarker concentration. Many studies have tried to identify potential 
viability markers, of which glutathione S-transferase (GST) and lactate dehydrogenase 
(LDH) are best known (6, 23, 24). However, the predictive value of perfusate 
biomarkers to assess PNF remains unknown or poor (16). Machine perfusion dynamics 
(e.g. renovascular resistance) are associated with kidney function, but the predictive 
value is too low to be useful to discard kidneys for transplantation on its value alone 
(8, 16).
NGAL, also known as lipocalin-2, has recently been discovered as a biomarker 
of acute kidney injury (11). Moreover, NGAL released during hypothermic machine 
perfusion of porcine kidneys that were exposed to different warm ischemia times, 
seemed to be proportionate to the degree of injury due to warm ischemia, suggesting 
that NGAL is released from ischemically damaged kidneys, independent of neutrophil 
activation (25). These findings were not confirmed in machine-perfused human 
kidneys, showing a poor predictive value of NGAL for transplantation outcome (24).
THE VALUE OF DONOR NGAL IN PREDICTING SHORT-TERM GRAFT FUNCTION
141 
The predictive value of donor NGAL prior to organ donation has never been 
assessed in DCD donors, and it is unknown whether or not donor plasma NGAL 
concentration is associated with transplantation outcome in these donor kidneys. 
Therefore, we measured NGAL concentrations in both DCD (uncontrolled Maastricht 
category I and II donors and controlled Maastricht category III donors) and DBD donors 
and examined the value of donor plasma NGAL levels to predict post-transplant graft 
function. In this study, we showed that donor plasma NGAL concentration significantly 
correlated with donor creatinine, meaning we can detect (acute) kidney injury in the 
donor. However, this has no direct consequences for the recipients, because kidneys 
from donors with relatively high serum creatinine levels show comparable results 
compared with kidneys from donors with lower serum creatinine levels (26-28). This 
is in line with a study on DBD kidneys only (29). Only for functioning DCD kidneys, a 
significant difference was observed for NGAL concentrations between kidneys with 
DGF and IF. 
A limitation of this study is the detection limit of the NGAL assay, with 
NGAL concentrations below the detection limit in 43 kidneys. NGAL concentrations 
were categorized in groups, which limited statistical power. However, the kidneys 
with highest NGAL concentration theoretically have the worst outcome after 
transplantation, and this is the group we are interested in for potential discard. 
Therefore, the assay sufficed to detect the relevant differences in NGAL concentration.
We have shown that donor NGAL concentrations prior to organ recovery 
are not associated with graft function after transplantation of both DCD and DBD 
kidneys, however, for functioning DCD kidneys only, a significant difference was 
found for NGAL concentrations between kidneys with DGF and IF. Although it is a 
valuable biomarker for kidney injury in intensive care patients, its value as a predictor 
in kidney transplantation outcome is limited.
CHAPTER 9
142
REFERENCES
1.  Snoeijs MGJ, Pulinx B, Van Dieijen-Visser MP, Buurman WA, Van Heurn LWE, Wodzig WKWH. Characterization 
of the perfusate proteome of human donor kidneys. Annals of clinical biochemistry. 2013;50(2):140-6..
2.  Daemen JW, Oomen AP, Janssen MA, van de Schoot L, van Kreel BK, Heineman E, et al. Glutathione 
S-transferase as predictor of functional outcome in transplantation of machine-preserved non-heart-
beating donor kidneys. Transplantation. 1997 Jan 15;63(1):89-93. 
3.  Balupuri S, Talbot D, El-Sheikh M, Snowden C, Manas DM, Kirby J, et al. Comparison of proteolytic enzymes 
and glutathione S-transferase levels in non-heart-beating donors’ (NHBD) kidney perfusates. Clin Chem 
Lab Med. 2000 Nov;38(11):1099-102. 
4.  Gok MA, Pelsers M, Glatz JF, Bhatti AA, Shenton BK, Peaston R, et al. Comparison of perfusate activities 
of glutathione S-transferase, alanine aminopeptidase and fatty acid binding protein in the assessment of 
non-heart-beating donor kidneys. Annals of clinical biochemistry. 2003 May;40(Pt 3):252-8. 
5.  Gok MA, Pelsers M, Glatz JF, Shenton BK, Peaston R, Cornell C, et al. Use of two biomarkers of renal ischemia 
to assess machine-perfused non-heart-beating donor kidneys. Clinical chemistry. 2003 Jan;49(1):172-5. 
6.  Jochmans I, Lerut E, van Pelt J, Monbaliu D, Pirenne J. Circulating AST, H-FABP, and NGAL are early and 
accurate biomarkers of graft injury and dysfunction in a preclinical model of kidney transplantation. Annals 
of surgery. 2011 Nov;254(5):784-91; discussion 91-2. 
7.  Moers C, Varnav OC, van Heurn E, Jochmans I, Kirste GR, Rahmel A, et al. The value of machine perfusion 
perfusate biomarkers for predicting kidney transplant outcome. Transplantation. 2010 Nov 15;90(9):966-
73. 
8.  de Vries EE, Hoogland ER, Winkens B, Snoeijs MG, van Heurn LW. Renovascular resistance of machine-
perfused DCD kidneys is associated with primary nonfunction. Am J Transplant. 2011 Dec;11(12):2685-91. 
9.  Mozes MF, Skolek RB, Korf BC. Use of perfusion parameters in predicting outcomes of machine-preserved 
kidneys. Transplantation proceedings. 2005 Jan-Feb;37(1):350-1. 
10.  van Smaalen TC, Hoogland ER, van Heurn LW. Machine perfusion viability testing. Current opinion in organ 
transplantation. 2013 Apr;18(2):168-73. 
11.  Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, et al. Neutrophil gelatinase-associated lipocalin 
(NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet. 2005 Apr 2-8;365(9466):1231-8. 
12.  Parikh CR, Jani A, Mishra J, Ma Q, Kelly C, Barasch J, et al. Urine NGAL and IL-18 are predictive biomarkers 
for delayed graft function following kidney transplantation. Am J Transplant. 2006 Jul;6(7):1639-45. 
13.  Mishra J, Ma Q, Kelly C, Mitsnefes M, Mori K, Barasch J, et al. Kidney NGAL is a novel early marker of acute 
injury following transplantation. Pediatric nephrology (Berlin, Germany). 2006 Jun;21(6):856-63. 
14.  Magnusson NE, Hornum M, Jorgensen KA, Hansen JM, Bistrup C, Feldt-Rasmussen B, et al. Plasma 
neutrophil gelatinase associated lipocalin (NGAL) is associated with kidney function in uraemic patients 
before and after kidney transplantation. BMC nephrology. 2012;13:8. 
15.  Poge U, Gerhardt T, Palmedo H, Klehr HU, Sauerbruch T, Woitas RP. MDRD equations for estimation of GFR 
in renal transplant recipients. Am J Transplant. 2005 Jun;5(6):1306-11. 
16.  Jochmans I, Pirenne J. Graft quality assessment in kidney transplantation: not an exact science yet! Current 
opinion in organ transplantation. 2011 Apr;16(2):174-9. 
17.  Nyberg SL, Baskin-Bey ES, Kremers W, Prieto M, Henry ML, Stegall MD. Improving the prediction of donor 
kidney quality: deceased donor score and resistive indices. Transplantation. 2005 Oct 15;80(7):925-9. 
18.  Schold JD, Kaplan B, Baliga RS, Meier-Kriesche HU. The broad spectrum of quality in deceased donor 
kidneys. Am J Transplant. 2005 Apr;5(4 Pt 1):757-65. 
19.  Rao PS, Schaubel DE, Guidinger MK, Andreoni KA, Wolfe RA, Merion RM, et al. A comprehensive risk 
quantification score for deceased donor kidneys: the kidney donor risk index. Transplantation. 2009 Jul 
27;88(2):231-6. 
20.  Metzger RA, Delmonico FL, Feng S, Port FK, Wynn JJ, Merion RM. Expanded criteria donors for kidney 
transplantation. Am J Transplant. 2003;3 Suppl 4:114-25. 
THE VALUE OF DONOR NGAL IN PREDICTING SHORT-TERM GRAFT FUNCTION
143 
21.  Snoeijs MG, Buurman WA, Christiaans MH, van Hooff JP, Goldschmeding R, van Suylen RJ, et al. Histological 
assessment of preimplantation biopsies may improve selection of kidneys from old donors after cardiac 
death. Am J Transplant. 2008 Sep;8(9):1844-51. 
22.  Remuzzi G, Cravedi P, Perna A, Dimitrov BD, Turturro M, Locatelli G, et al. Long-term outcome of renal 
transplantation from older donors. N Engl J Med. 2006 Jan 26;354(4):343-52. 
23.  Bhangoo RS, Hall IE, Reese PP, Parikh CR. Deceased-donor kidney perfusate and urine biomarkers for 
kidney allograft outcomes: a systematic review. Nephrol Dial Transplant. 2012 Aug;27(8):3305-14. 
24.  Hoogland ER, de Vries EE, Christiaans MH, Winkens B, Snoeijs MG, van Heurn LW. The Value of Machine 
Perfusion Biomarker Concentration in DCD Kidney Transplantations. Transplantation. 2013 Jan 4. 
25.  Jochmans I, Monbaliu D, Pirenne J. Neutrophil gelatinase-associated lipocalin, a new biomarker candidate 
in perfusate of machine-perfused kidneys: a porcine pilot experiment. Transplantation proceedings. 
Nov;43(9):3486-9. 
26.  Barlow AD, Metcalfe MS, Johari Y, Elwell R, Veitch PS, Nicholson ML. Case-matched comparison of long-
term results of non-heart beating and heart-beating donor renal transplants. The British journal of surgery. 
2009 Jun;96(6):685-91. 
27.  Matsuno N, Konno YN, Jyojima Y, Akashi I, Iwamoto H, Hama K, et al. Machine perfusion preservation 
for kidney grafts with a high creatinine from uncontrolled donation after cardiac death. Transplantation 
proceedings. 2010 Jan-Feb;42(1):155-8. 
28.  Navarro AP, Sohrabi S, Wilson C, Sanni A, Wyrley-Birch H, Vijayanand D, et al. Renal transplants from 
category III non-heart-beating donors with evidence of pre-arrest acute renal failure. Transplantation 
proceedings. 2006 Oct;38(8):2635-6. 
29.  Hollmen ME, Kyllonen LE, Inkinen KA, Lalla ML, Merenmies J, Salmela KT. Deceased donor neutrophil 
gelatinase-associated lipocalin and delayed graft function after kidney transplantation: a prospective 
study. Critical care (London, England). 2011;15(3):R121. 
144
145 
CHAPTER 10
THE EFFECT OF ANTI-
MINCLE ON KIDNEY 
INJURY
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ABSTRACT
Background: Ischemia-reperfusion injury is one of the problems in kidney 
transplantation with kidneys from donors after cardiac death. The macrophage-
inducible C-type Lectin (Mincle) receptor is an important target to reduce inflammatory 
response after cell death. It is involved in the mediation of the inflammatory response 
to ischemia-reperfusion injury, and Mincle-specific antibody was associated with less 
infiltration of neutrophils after massive thymocyte death. 
Methods: The effects of Mincle on renal ischemia-reperfusion injury and 
inflammatory response were studied in an ischemia-reperfusion model in mice, using 
25 minutes of ischemia and 24 hours of reperfusion. The Mincle-receptor was blocked 
with a Mincle-specific antibody (anti-Mincle) and compared with animals, which 
received rat IgG as control group. 
Results: Kidney function (creatinine 232 ± 34 vs. 211 ± 22 µmol/L, p=0.200 
and BUN 61.2 ± 5.6 vs. 58.2 ± 5.9, p=0.355, respectively), histological injury and the 
number of infiltrated neutrophils were similar between both groups. 
Conclusion: Blocking the Mincle-receptor with specific anti-Mincle antibodies 
does not inhibit the inflammatory response in mice kidneys after ischemia and 
reperfusion and does not contribute to lesser renal injury and better renal function.
Published as
E.R.P. Hoogland, M.G.J. Snoeijs, B. de Vries, C.J. Peutz- Kootstra, W.A. Buurman, T. Saito, L.W.E. van Heurn. The effect of 
anti-Mincle on kidney injury. Manuscript submitted.
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INTRODUCTION
Organ donation from donation after cardiac death (DCD) donors inevitably 
leads to ischemia and reperfusion from cardiac arrest until reperfusion after 
transplantation. Ischemia-reperfusion (I/R) leads to a complex series of events, including 
generation of inflammatory mediators, leukocyte infiltration and, depending on the 
severity of the injury, ultimately to cell death by either necrosis or apoptosis (1, 2). 
Studies using animal models have demonstrated that the inflammatory responses to 
I/R exacerbates organ injury after transplantation (2). 
Acute kidney injury (AKI) is a frequent complication in patients on the intensive 
care unit (ICU), after cardiac surgery, and after ischemia and reperfusion (I/R) in renal 
transplantation with kidneys obtained from donors after cardiac death. AKI is a 
syndrome of abrupt loss of kidney function, often with oliguria, which is strongly 
associated with increased early and long-term patient morbidity and mortality (3). 
AKI occurs in up to 40% of adults after cardiac surgery, with 1-5% needing dialysis in 
whom the mortality rate approaches 80% (4). Pathophysiological mechanisms include 
diminished renal blood flow, loss of pulsatile flow, hypothermia, atheroembolism, 
and a generalised inflammatory response (4). In renal transplantation, AKI may result 
in primary non-function (PNF) and in delayed graft function (DGF), which may be 
associated with an increased risk of acute rejection and graft loss (5, 6). 
Therapies that target specific inflammatory responses to I/R are of major 
importance to minimize the incidence of PNF and DGF and to maximize the use of 
available DCD kidneys from the donor pool. Recently, it has been shown that the C-type 
lectin Mincle (macrophage-inducible C-type lectin) receptor recognizes a nuclear 
protein released by dead or dying cells and is involved in mediating inflammatory 
responses by the recruitment of neutrophils (7, 8). Yamasaki et al. developed a 
Mincle-specific monoclonal antibody (anti-Mincle) and showed that administering 
anti-Mincle results in less recruitment of neutrophils into the thymus after massive 
thymocyte necrosis induced by whole-body irradiation or dexamethasone treatment 
in mice. Given its great potential to reduce the inflammatory response after ischemia 
and reperfusion, we studied the effect of anti-Mincle on renal ischemia-reperfusion 
injury in mice. 
MATERIALS AND METHODS
Animals
Wild-type male C57BL/6J mice (8-10 weeks old, 20-25 g) were obtained from 
Charles River (L’arbresle Cedex, France). Animals were housed in standard laboratory 
cages with free access to food and water throughout the experiments. 
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Renal ischemia and reperfusion in mice
Mice were anesthetized with ketamine and xylazine (100 and 10 mg/kg 
subcutaneous, respectively). Body temperature was maintained at 37°C by a heating 
lamp and heating pad until the animals had recovered from anaesthesia. Under 
aseptic conditions, the animals underwent a laparotomy and 25 minutes of ischemia 
was induced by clamping the left renal pedicle using a non-traumatic vascular clamp 
(Fine Science Tools, cat. number 18055-05 curved clips), applied with a special clip 
applicator (Fine Science Tools, cat. number 18056-14). Upon clamp removal, the 
kidney was inspected for restoration of blood flow and the contralateral kidney 
was removed and stored for analysis. The abdomen was closed in two layers, 0.25% 
bupivacaine was applied topically for post-operative pain management and 1 mL 
pre-warmed PBS was given subcutaneously to prevent dehydration. Animals were 
euthanized 24 h after reperfusion, when blood was collected by puncture of the caval 
vein. The left kidney was recovered for further analysis. Blood was stored on ice in 
heparinised tubes until centrifugation at 900 g at 4°C for 10 min.
Administration of anti-Mincle and control antigens
The monoclonal antibodies to Mincle were created by and obtained from 
Yamasaki et al (7). Mice were randomly assigned to receive 0.5 mg anti-Mincle (N = 
8) intravenously one hour before start of ischemia, 0.5 mg rat IgG (BD Biosciences, 
Franklin Lakes, USA) isotype control (N = 8) or were sham-operated (N = 5).
Histological assessment of renal tissue
Renal tissue was formalin-fixed and embedded in paraffin. Tissue sections 
were stained with periodic acid-Schiff for blinded assessment of renal injury by two 
experienced nephropathologists. Tubular dilatation, casts and debris, brush border 
loss and necrosis at the corticomedullary junction were scored in 8 - 10 fields at 400x 
magnification on a scale of 0 to 5 (0 is normal; 1 involves <10% of cortex; 2 involves 
10–25% of cortex; 3 involves 25–50% of cortex; 4 involves 50–75% of cortex; and 5 
involves >75% of cortex) (9). 
To quantify renal neutrophil infiltration, tissue sections were incubated 
with polyclonal rabbit anti-human myeloperoxidase (MPO) antibodies as described 
previously (5). Neutrophil infiltration was assessed quantitatively by counting the 
number of positive cells at the corticomedullary junction at 200x magnification over 
5 - 10 fields by two blinded investigators.
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Renal function
Serum creatinine and blood urea nitrogen (BUN) concentrations were 
measured in the clinical chemistry laboratory.
Statistical analysis
Continuous variables are presented as mean and standard deviation if normally 
distributed, and as median and inter-quartile range (IQR) otherwise. Independent 
samples t-tests were used to compare continuous variables between experimental 
groups and Mann-Whitney U test was used for nonparametric values. All analyses 
were performed using Statistical Package for the Social Sciences (SPSS) software 
version 20.0 for Windows, and a p-value < 0.05 was considered statistically significant.
Figure 10.1 Kidney function of kidneys subjected to 25 minutes of ischemia and 24 hours of 
reperfusion in sham-operated mice (N = 5), mice subjected to rat IgG (N = 6) and anti-Mincle (N 
= 8). (A) Serum creatinine concentration is equal to the isotype control group (rat IgG). (B) Blood 
urea nitrogen concentration is equal to the isotype control group. * p <0.001 compared to sham-
operated mice.
Ethics
In vivo experiments were approved by the local laboratory animal review 
boards (DEC 2011-012) and were conducted in accordance with the NIH principles of 
laboratory animal care. 
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RESULTS
Effect of anti-Mincle on renal function and ischemia and reperfusion injury
Two mice in the rat IgG control group died at the end of the ischemic period. 
Temporary renal ischemia induced severe kidney dysfunction as indicated by increased 
plasma concentrations of creatinine and BUN at 24 hours after reperfusion in both 
the anti-Mincle as the rat IgG control group (creatinine 232 ± 34 vs. 211 ± 22 µmol/L 
and BUN 61.2 ± 5.6 vs. 58.2 ± 5.9, respectively) (Figure 10.1). Mice treated with anti-
Mincle experienced a similar extent of renal dysfunction after I/R compared with the 
rat IgG control group (p=0.200 for creatinine and p=0.355 for BUN).
Figure 10.2 Histological assessment of renal injury of sham-operated mice (N = 5) and mice treated 
with rat IgG (N = 6) and anti-Mincle (N = 8). Tubular dilatation, casts deposition, brush border loss 
and necrosis were blindly scored by an experienced nephropathologist on a scale of 0 to 5 (9). P < 
0.001 for the anti-Mincle and rat IgG group compared to the sham-operated group.
Furthermore, substantial renal injury was observed on histological assessment 
of tissue sections after I/R, indicated by tubular dilatation, cast deposition, brush 
border loss and necrosis at the corticomedullary junction (Figure 10.2). Renal injury 
after I/R was equivalent in mice treated with anti-Mincle compared with the control 
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group (p=0.721 for tubular dilatation, cast deposition, brush border loss and necrosis). 
Effect of anti-Mincle on neutrophil infiltration
Influx of neutrophils into the kidney occurs relatively early after reperfusion 
and exacerbates ischemic acute renal injury (5). In this study, renal ischemia and 
reperfusion resulted in accumulation of neutrophils around the injured tubules at 
the corticomedullary junction (Figure 10.3A). The extent of neutrophil infiltration 
was similar for the anti-Mincle and the rat IgG control group (Figure 10.3B and 10.3C)
(Mann-Whitney U p=0.770).
Figure 10.3 Neutrophil infiltration into the kidney. Mice treated with anti-Mincle (A) have a similar 
extent of neutrophil infiltration into the kidney compared with the IgG control group (B). Data are 
presented as median and inter-quartile range (C).
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DISCUSSION
Ischemia and reperfusion of deceased donor kidneys is an inevitable 
consequence of renal transplantation, which frequently leads to acute kidney injury 
(AKI). AKI is a serious clinical complication with high mortality, morbidity and costs 
(10, 11). Interventions that protect kidneys from ischemia-reperfusion injury may 
improve early graft function in particularly kidneys from donors after cardiac death, 
which suffer prolonged ischemia before transplantation.
Ischemia-reperfusion leads to a complex series of events, including generation 
of inflammatory mediators, leukocyte infiltration and, depending on the severity of 
the injury, ultimately in cell death by either necrosis or apoptosis (12, 13). Inefficient 
clearance of apoptotic cells leads to necrosis, which is characterized by the disruption 
of cellular membranes and the release of cytoplasmic and nuclear components (8). 
The receptors and mechanisms that lead to inflammation after necrotic cell death 
are poorly understood. In instances of sterile inflammation, neutrophil recruitment is 
mediated by the release of ‘danger signals’ or damage-associated molecular pattern 
molecules (DAMPs) from disrupted cells and tissues (14). Understanding the role of 
candidate DAMPs released from damaged cells could reveal novel drug targets for 
inhibiting the inflammatory response or promoting repair processes in (renal) I/R 
injury (15). As the knowledge and understanding of these molecules and pathways 
evolves, information on precise therapeutic targets will likely lead to improved 
outcomes after transplantation (15). 
The Toll-like receptor (TLR) family has been reported to recognize self-ligands 
released from necrotic cells. Some of the TLR-self ligand interactions have been shown 
to contribute to inflammatory disease (7). Another family of receptors that may be 
involved in sensing dead cells is the C-type lectins. Recent data show that the C-type 
lectin Mincle-receptor is involved in this process. Mincle recognizes the soluble factor 
spliceosome-associated protein 130 (SAP130), a nuclear protein released by necrotic 
cells, triggering inflammatory cytokine responses, which leads to the recruitment 
of neutrophils (7, 8). Although incompletely understood, renal tubular necrosis, 
apoptosis and inflammation during and after renal ischemia-reperfusion contribute 
significantly to the pathogenesis of ischemic acute kidney injury (11). Therefore, we 
studied whether blocking the Mincle-receptor with a Mincle-specific antibody would 
result in improved renal function and a less severe inflammatory response after 
ischemia-reperfusion compared with a control group.
Tissue injury activates the innate immune system and leads to infiltration of 
inflammatory cells into the damaged tissue (2). Influx of neutrophils into the kidney 
occurs relatively early after reperfusion and has been shown to exacerbate ischemic 
acute renal injury (16). 
Mice models of warm renal ischemia and reperfusion share important 
similarities with human ischemia-reperfusion injury (12) and have been used before 
by our research group (5, 17, 18).
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We studied the most optimal ischemia time in a pilot study. An ischemia time 
of 25 minutes provides the best association with AKI according to serum levels of 
creatinine and BUN in combination with histological assessment. Serum creatinine 
and BUN did not increase further with longer ischemia times. Therefore, a warm 
ischemia time of 25 minutes was used in the present study.
Male mice were used in this study, because female mice are more resistant to 
I/R induced kidney injury. This protection is believed to be caused by testosterone, 
which could be responsible for enhanced renal inflammation and endothelial and 
tubular cell injury (19).
 The current study is the first to investigate the involvement of the Mincle-
receptor in the inflammatory response after renal ischemia-reperfusion injury in mice. 
We show that renal function did not improve after ischemia-reperfusion and blocking 
the Mincle receptor. Additionally, no differences were seen in cellular damage and 
inflammation. 
 Our findings seem to contradict previously reported data on inflammatory 
responses after blocking of the Mincle-receptor (7). These conflicting findings may 
be caused by differences in the applied experimental models, in the difference of the 
studied organ, by unknown pathways by which post I/R inflammation is initiated, or 
the number of dead or dying cells triggering the Mincle-pathway.
We conclude that blocking the Mincle-receptor with specific anti-Mincle 
antibodies does not inhibit the inflammatory response in the kidney after ischemia 
and reperfusion and consequently does not contribute to minimize renal injury and 
better renal function.
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ABSTRACT
Background: F2-isoprostanes are formed by oxidative modification of 
arachidonic acid and are the gold standard for detection of oxidative stress in vivo. F2-
isoprostanes are biologically active compounds that signal through the thromboxane 
A2 (TP) receptor; infusion of F2-isoprostanes reduces glomerular filtration in the 
kidney by constricting afferent arterioles. We investigated whether endogenous F2-
isoprostanes contribute to the pathogenesis of ischemic acute kidney injury, which is 
associated with oxidative stress and reduced glomerular filtration.
Methods: TP-receptor knockout mice – that lack F2-isoprostanes and 
thromboxane A2 signalling – and wild-type control mice underwent 30 minutes of 
renal ischemia and 24 hours of reperfusion.
Results: Kidney dysfunction, histological injury and the number of infiltrated 
neutrophils were similar between the two mouse strains, whereas TP-receptor 
knockout mice had significantly more apoptotic cells and lipid peroxidation than their 
wild-type counterparts. F2-isoprostanes and thromboxane B2 were readily detectable 
in urine collections after surgery.
Conclusion: Our findings indicate that F2-isoprostanes and thromboxane 
A2 signalling do not contribute critically to the pathogenesis of ischemic acute 
kidney injury, and more generally provide evidence against a prominent role for F2-
isoprostanes signalling in exacerbating acute disease states associated with oxidative 
stress.
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L.W. Ernest van Heurn. Thromboxane receptor signalling in renal ischemia reperfusion injury. Free Rad Res 2011; 45(6): 
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THROMBOXANE RECEPTOR SIGNALLING IN EXPERIMENTAL RENAL ISCHEMIA REPERFUSION INJURY
159 
INTRODUCTION
Acute kidney injury is a frequent complication after ischemia and reperfusion 
due to cardiovascular surgery and hemorrhagic shock and is independently associated 
with increased in-hospital mortality (1). In renal transplantation, acute kidney injury 
results in delayed graft function which is associated with an increased incidence of 
acute rejection and graft loss (2). At reperfusion, reintroduction of oxygen to the 
ischemic kidney rapidly leads to the formation of reactive oxygen species that may 
damage cellular lipids, proteins and DNA when anti-oxidant defences have been 
exhausted. The resulting oxidative stress is an important cause of acute kidney 
injury, since administration of various anti-oxidants has been shown to attenuate 
renal dysfunction and histological injury in animal models of renal ischemia and 
reperfusion (3-5). 
 F2-isoprostanes are formed by oxidative modification of arachidonic acid in 
cell membranes. They are cleaved and released into the plasma by platelet-activating 
factor acetylhydrolase (6, 7). Measurement of plasma and urinary F2-isoprostanes 
has become accepted as the gold standard for detection of oxidative stress in vivo 
(8), and their production has been demonstrated in a rat model of renal ischemia 
and reperfusion (9). Interestingly, next to being accurate biomarkers of oxidative 
stress, F2-isoprostanes are biologically active compounds that signal through the 
thromboxane A2 (TP) receptor (10). Intra-arterial administration of F2-isoprostanes to 
rats and pigs results in dose-dependent reductions in renal blood flow and glomerular 
filtration rate due to vasoconstriction of afferent glomerular arterioles (9, 11). This 
renal vasoconstriction has also been observed in human acute kidney injury (12). 
 Taken together, the vasoconstrictive properties of locally produced F2-
isoprostanes may contribute to the reduction of glomerular filtration rate in ischemic 
acute kidney injury and may explain the protective effects of anti-oxidants in animal 
models of renal ischemia and reperfusion. To address this hypothesis, we studied the 
effects of genetic disruption of the TP-receptor – which eliminates F2-isoprostanes 
signalling (13) – in a mouse model of renal ischemia and reperfusion.
MATERIALS AND METHODS
Renal ischemia and reperfusion in mice
Homozygous TP-receptor knockout breeding pairs (backcrossed on C57BL/6J 
mice for 13 generations) were provided by dr. T.M. Coffman (14). Wild-type 
C57BL/6J mice were obtained from Charles River (L’arbresle Cedex, France). Animals 
were housed in standard laboratory cages with free access to food and water. In 
random order, male wild-type and TP-receptor knockout mice aged 9-11 weeks were 
anaesthetized with ketamine and xylazine (100 and 10 mg/kg s.c., respectively). 
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Body temperature was maintained at 37 ºC by a heating lamp until the animals had 
recovered from anaesthesia. Ischemia was induced by clamping the left renal pedicle 
for 30 minutes using a non-traumatic vascular clamp through a midline abdominal 
incision. The surgeon was blinded for mouse genotype. Upon clamp removal, the 
kidney was inspected for restoration of blood flow and the contralateral kidney 
was excised. The abdomen was closed in 2 layers, 0.25% bupivacaine was applied 
topically for post-operative pain management and 1 mL pre-warmed PBS was given 
subcutaneously to prevent dehydration. Animals were euthanized at 24 hours after 
reperfusion, when blood was collected by puncture of the vena cava. The left kidney 
was recovered for further analysis. Blood was stored on ice in heparanized tubes 
until centrifugation at 900 g at 4 ºC for 10 min. Plasma creatinine and blood urea 
nitrogen (BUN) concentrations were measured. In a separate set of experiments, the 
contralateral kidney was left in situ and the animals were housed in metabolic cages 
to collect urine for 24 hours before and after surgery.
Histological assessment of renal tissue
Renal tissue was formalin-fixed and stained with periodic acid-Schiff for blinded 
assessment of renal injury by an experienced nephropathologist. Tubular dilation, 
casts and debris, brush border loss and necrosis at the corticomedullary junction were 
scored in 10 fields at 400x magnification in a scale of 0 to 5 (0 is normal; 1 involves <10% 
of cortex; 2 involves 10-25% of cortex; 3 involves 25-50% of cortex; 4 involves 50-75% 
of cortex; and 5 involves >75% of cortex (15)).  For detection of neutrophils, 
tissue sections were incubated with polyclonal rabbit anti-human myeloperoxidase 
(MPO) antibodies (1:50 dilution; Hycult Biotech, Uden, The Netherlands) for 2 hours 
and with biotinylated polyclonal swine anti-rabbit IgG antibodies (1:500 dilution; 
Dako, Glostrup, Denmark) for 30 minutes. Endogenous peroxidase activity and 
non-specific binding were blocked with 0.6% H2O2 and 10% normal pig serum. 
After incubation with streptavidin and horseradish peroxidase conjugated biotin 
(Dako), slides were developed with H2O2 and AEC and were counterstained with 
haematoxylin. The number of positive cells at the corticomedullary junction were 
counted in 10 fields at 400x magnification by a blinded investigator.
 Apoptotic cells were detected by terminal deoxynucleotidyl transferase 
(TdT)-mediated dUTP nick-end labelling (TUNEL; in situ cell death detection kit; 
Roche Diagnostics, Indianapolis, IN) according to the manufacturer’s instructions (16). 
Before labelling, nuclei were permeabilized by incubating the tissue sections with 
300 µg/mL proteinase K (Sigma-Aldrich, St. Louis, MO) for 15 minutes. Endogenous 
peroxidase activity and non-specific binding were blocked with 0.6% H2O2 and 
3% bovine serum albumin. The slides were developed with H2O2 and AEC and the 
number of positive nuclei at the corticomedullary junction were counted in 10 fields 
at 400x magnification by a blinded investigator.
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TP-receptor genotyping
Genomic DNA was isolated from renal tissue according to the manufacturer’s 
instructions (Wizard genomic DNA purification kit; Promega, Madison, WI). DNA was 
amplified using the primers 5’-GGGGGTAGCTATGGTGTTC-3’ (for the wild-type allele), 
5’-CTTCCTCGTGCTTTACGGTA-3’ (for the mutant allele with PGK-neomycin insert) and 
5’-GTGAGAAGGGCCGTGTGAT-3’ (for both alleles) in 30 cycles at 94 ºC, 60 ºC and 72 
ºC (60 seconds each). The PCR product was run on a 1.2% agarose gel with a DNA 
basepair ladder. The predicted amplicon sizes from the wild-type and mutant alleles 
were 150 and 700 base pairs, respectively.
Measurement of urine thromboxane B2 and F2-isoprostanes
Urine was collected on ice for 24 hours before and after surgery, centrifuged 
at 900 g at 4 ºC for 10 minutes and stored at -80 ºC. Urinary thromboxane B2 and 
F2-isoprostanes concentrations were measured using commercially available enzyme 
immunoassays (Cayman Chemical, Ann Arbor, MI) according to the manufacturer’s 
instructions and were adjusted for urinary creatinine concentrations.
Measurement of tissue malondialdehyde
Malondialdehyde (MDA) was measured in homogenized renal tissue that was 
sampled and snap-frozen at 24 h after reperfusion and stored at −80°C until analysis. 
A 100 µL sample was added to 900 µL reagent (0.12 M 2-thiobarbituric acid, 0.32 M 
O-phosphoric acid, 0.68 mM butylated hydroxytoluene, 0.01% EDTA) and incubated 
for 1 hour at 100°C. MDA products were extracted with 500 µL butanol and their 
concentrations were determined by HPLC using a Nucleosil C18 column (150 X 3.2 
mm, 5 µm particle size; Supelco) eluted with 35% methanol in 25 mM phosphate 
buffer (pH 4.8). Detection was done by fluorescence using excitation at 532 nm and 
emission at 553 nm. Malonaldehyde bis(diethylacetal) was used as internal standard.
Laboratory animal use and ethical considerations
Assuming a standard deviation of plasma creatinine of 15% of the mean, 
10 mice per experimental group are necessary to detect a 20% difference between 
groups with statistical significance; we consider this difference to be biologically 
relevant. In vivo experiments were approved by local laboratory animal and national 
genetically modified organism review boards (DEC 2007-139 and GGO IG 07-110).
Statistical methods
Continuous variables are presented as mean and standard deviation. 
Independent samples t-test was used to compare continuous variables between 
experimental groups. For comparisons of continuous variables within experimental 
groups, paired samples t-test was used. p<0.05 was considered statistically significant.
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Figure 11.1 Kidney function is impaired to a similar extent in TP-receptor knockout (TP -/-) and wild-
type control mice (WT) after 30 minutes of renal ischemia and 24 hours of reperfusion (I/R). (A) Plasma 
creatinine concentration. (B) Blood urea nitrogen (BUN) concentration. Diamonds and lines represent 
individual mice and group means, respectively.
RESULTS
Effects of TP-receptor genotype on renal ischemia and reperfusion injury
Homozygous TP-receptor knockout mice and wild-type controls were randomly 
subjected to 30 minutes of renal ischemia (N = 10 per group) or sham surgery (N = 5 
per group). No complications occurred during surgery and all animals survived until 
euthanasia at 24 hours after reperfusion. Mean body weight of TP-receptor knockout 
and wild-type mice was 24±0.8 and 24±1.2 g, respectively, before surgery and 22±1.5 
and 23±1.0 g at euthanasia. TP receptor genotype of each animal was confirmed by 
PCR of genomic DNA (data not shown).
Temporary renal ischemia induced severe kidney dysfunction as indicated by 
increased plasma concentrations of creatinine and BUN at 24 hours after reperfusion 
(Figure 11.1). TP-receptor knockout and wild-type control mice experienced a similar 
extent of renal dysfunction after ischemia and reperfusion (p=0.73 for creatinine and 
p=0.19 for BUN). Furthermore, substantial renal injury was observed on histological 
assessment of tissue sections after ischemia and reperfusion, indicated by tubular 
dilatation, cast deposition, brush border loss and necrosis at the corticomedullary 
junction (Figure 11.2). In line with its effect on renal function, disruption of the TP-
receptor gene did not significantly reduce the extent of tissue injury after ischemia 
and reperfusion (p=0.58 for tubular dilatation, p=0.06 for cast deposition, p=0.32 for 
brush border loss and p=0.06 for necrosis).
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Figure 11.2 TP-receptor knockout (TP -/-) and wild-type control mice experience a similar extent of 
renal injury after 30 minutes of ischemia and 24 hours of reperfusion. Representative pictures of 
periodic acid-Schiff stained tissue sections at 400x magnification are shown. Tubular dilatation, casts 
deposition, brush border loss and necrosis were blindly scored by an experienced nephropathologist 
on a scale of 0 to 5 (15). Data are presented as mean and standard deviation.
Effect of TP-receptor genotype on neutrophil infiltration, apoptosis and lipid 
peroxidation
Tissue injury activates innate immunity and leads to infiltration of inflammatory 
cells into the damaged tissue (17). Influx of neutrophils into the kidney occurs 
relatively early after reperfusion and has been shown to exacerbate ischemic acute 
renal injury (18). In our experiment, renal ischemia and reperfusion resulted in massive 
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accumulation of neutrophils around the injured tubules at the corticomedullary 
junction (Figure 11.3A). The extent of neutrophil infiltration was similar for TP-
receptor knockout and wild-type control mice (p=0.96). Furthermore, after renal 
ischemia and reperfusion, tubular epithelial cells undergo apoptotic cell death which 
may aggravate acute kidney injury (19). In line with our other findings, disruption 
of the TP-receptor gene did not attenuate the induction of apoptosis in tubular 
epithelial cells at the corticomedullary junction after renal ischemia and reperfusion. 
On the contrary, TP-receptor knockout mice had significantly more apoptotic cells 
than their wild-type counterparts (p=0.01, Figure 11.3B). Finally, we measured MDA 
concentrations in renal tissue to study lipid peroxidation after ischemic acute kidney 
injury. Unexpectedly, renal MDA concentrations were significantly higher in TP-
receptor knockout mice that in wild-type animals, both at baseline (76 ± 23 vs 43 ± 11 
nmol/g, p=0.02) and at 24 hours after reperfusion (66 ± 25 vs 45 ± 7 nmol/g, p=0.02).
Production of F2-isoprostanes and thromboxane A2
Production of the TP-receptor ligands F2-isoprostanes and thromboxane A2 
increases after renal ischemia and reperfusion in rats (9, 20). Since genetic disruption 
of the TP-receptor did not alter the susceptibility to ischemic acute kidney injury in 
mice, we investigated whether TP-receptor ligands were present in our experimental 
model. In urine collections before and after temporary renal ischemia, F2-isoprostanes 
and thromboxane B 2 (the stable metabolite of thromboxane A2) concentrations from 
TP-receptor knockout and wild-type control mice were similar (Table 11.1). Urine 
thromboxane B2 concentrations increased by 44 ± 35% following renal ischemia and 
reperfusion (p=0.01), whereas urine F2-isoprostanes concentrations were constant 
(p=0.27). These findings confirm the presence of the two major TP-receptor ligands 
after renal ischemia and reperfusion.
Table 11.1         F2-isoprostanes and thromboxane B2 concentrations (ng/mg creatinine) in 
24-hour urine collections before and after renal ischemia and reperfusion.a
Before ischemia and 
reperfusion
After ischemia and 
reperfusion p
F2-ISOPROSTANES
Wild-type controls 4.1 ± 2.1 3.3 ± 0.8
0.27
TP-receptor knockouts 4.2 ± 1.3 3.4 ± 1.1
THROMBOXANE B2
Wild-type controls 8.8 ± 2.3 12.2 ± 3.1
0.01
TP-receptor knockouts 8.8 ± 2.3 11.5 ± 1.7
a Data are presented as mean (standard deviation). P-values represent comparisons of urine 
concentrations before and after renal ischemia and reperfusion after pooling of both mouse strains.
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DISCUSSION
The current study was designed to establish the biological effects of locally 
produced F2-isoprostanes in a mouse model of renal ischemia and reperfusion. We 
found that mice with genetic deletion of the TP-receptor – which eliminates F2-
isoprostanes and thromboxane A2 signalling (13) – suffered renal dysfunction of 
similar severity as wild-type mice with the same genetic background at 24 hours 
after reperfusion. Furthermore, the degree of histological injury and the number of 
neutrophils in the outer renal medulla were comparable between the two groups 
of mice. TP-receptor knockout mice had significantly more apoptosis and a trend 
towards less necrosis than their wild-type counterparts, suggesting a change in the 
mode of cell death after renal ischemia and reperfusion when TP signalling is lost. 
Taken together, however, F2-isoprostanes and thromboxane A2 signaling do not 
seem to contribute critically to the development of ischemic acute kidney injury.
 The biological effects of F 2-isoprostanes have been studied in various 
experimental models. Administration of synthetic F2-isoprostanes increases systemic 
blood pressure in rodents and causes vasoconstriction of human arteries and veins 
in vitro (13, 21, 22). The vasoconstrictive actions of F2-isoprostanes are particularly 
evident in the renal microcirculation: intrarenal arterial administration of 1 µg/kg/
min 15-F2-isoprostane acutely reduces glomerular filtration rate by 35% in pigs 
and 49% in rats, whereas systemic haemodynamic effects are not observed until 
administration of 10 µg/kg/min 15-F2-isoprostane (9, 11, 13). Other biological effects 
of F2-isoprostanes include stimulation of leukocyte adhesion to endothelium and 
proliferation of endothelial and vascular smooth muscle cells, promoting angiogenesis 
and atherosclerosis in vivo (23, 24). Conflicting reports have been published on the 
effects of F 2-isoprostanes on platelets, some groups finding increased activation 
of platelets, whereas others report that F 2-isoprostanes  prevent aggregation of 
platelets in vitro (13, 25). These paradoxical effects may be explained by partial 
agonistic activity of F 2-isoprostanes on TP-receptors or by the presence of a second, 
inhibitory F 2-isoprostanes  receptor on platelets (10).
It has been established that administration of synthetic F 2-isoprostanes 
causes a variety of biological that are highly comparable to the actions of other 
TP-receptor agonists. It has repeatedly been proposed that endogenous formation 
of F 2-isoprostanes as a result of oxidative stress may elicit similar effects, thereby 
contributing to the pathogenesis of conditions as diverse as ischemia-reperfusion 
injury, atherosclerosis, tumour angiogenesis and asthmatic bronchoconstriction. 
However, biological actions of synthetic F 2-isoprostanes have typically been observed 
after adding these compounds at concentrations two to three orders of magnitude 
greater than the physiological plasma concentrations of F 2-isoprostanes in healthy 
volunteers. At sites of oxidative stress, F 2-isoprostanes may nevertheless reach 
concentrations at which adverse biological effects have been observed (26). 
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Figure 11.3 TP-receptor knockout (TP -/-) mice have similar extent of (A) neutrophil infiltration 
into the kidney and (B) significantly more tubular epithelial cell apoptosis after 30 minutes of 
renal ischemia and 24 hours of reperfusion as compared to wild-type control mice. Representative 
pictures of myeloperoxidase (MPO) and terminal deoxynucleotidyl transferase (TdT)-mediated 
dUTP nick-end labeling (TUBEL) stained tissue sections at 400x magnification are shown. Tubular 
debris was diffusely positive for TUNEL staining and was not taken into account when quantifying 
apoptotic nuclei. Data are presented as mean and standard deviation; the asterisk indicates statistical 
significance (p=0.01).
 
  The current study is the first to investigate the pathogenic actions of 
locally produced F2-isoprostanes in renal ischemia-reperfusion injury. This experimental 
model is well suited for assessment of the biological effects of F2-isoprostanes, since 
oxidative stress plays an important role in the pathophysiology of ischemic acute 
kidney injury and because the actions of F2-isoprostanes are particularly evident in 
the renal microcirculation (9, 11). The haemodynamic effects of F2-isoprostanes are 
entirely mediated by TP-receptors that are expressed in the glomeruli and intrarenal 
arteries of human and rodent kidneys (27-29). Mice with genetic deletion of the 
TP-receptor are viable and are characterized by normal renal haemodynamics with 
attenuated renal vasoconstriction after administration of endotoxin or angiotensin-
II (14, 30, 31). In the current study, we found that ischemia and reperfusion induces 
acute kidney injury in TP receptor knockout mice to a similar extent as in wild-type 
mice, indicating that neither F2-isoprostanes nor thromboxane A2 signalling is 
critically involved in the pathophysiology of ischemic acute kidney injury. Our study 
does not account for potential TP-receptor-independent actions of F2-isoprostanes. 
It has been proposed that esterified F2-isoprostanes may cause cellular injury in the 
absence of TP-receptors by disruption of the fluidity and integrity of cell membranes, 
similar to other products of lipid peroxidation (32). 
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 Our findings seem to contradict previous experiments that have suggested 
thromboxane A2 signalling to contribute to the pathogenesis of ischemic acute 
kidney injury (33). Specific inhibitors of thromboxane A2 synthase have been shown 
to attenuate acute kidney injury in rodent models of renal ischemia and reperfusion 
(33). However, inhibition of thromboxane A2 synthesis increases the production of 
the vasodilator prostacyclin as a result of the increased availability of their common 
precursor prostaglandin H2 – a phenomenon termed endoperoxide shunting (34). 
Since the beneficial effects of thromboxane A2 synthase inhibitors on ischemic acute 
kidney injury were eliminated when prostacyclin synthesis was blocked (35), these 
effects may have been caused by an increase in prostacyclin signalling as a result 
of endoperoxide shunting rather than by a decrease in thromboxane A2 signalling. 
A separate study found that pharmacological inhibition of TP-receptor signalling 
attenuated renal dysfunction in a rat model of 60 minutes of renal ischemia followed 
by 6 hours of reperfusion (20). In contrast, we observed no effect of genetic deletion 
of TP-receptors on acute kidney injury after 30 minutes of renal ischemia and 24 
hours of reperfusion in mice. These conflicting findings may be caused by differences 
in the applied experimental models or by cross-reactivity of the drug used to inhibit 
TP-receptor signalling (36). 
 Finally, we observed increased lipid peroxidation in kidneys of TP-receptor 
knockout mice as compared to those of wild-type animals, both at baseline and after 
renal ischemia and reperfusion. This novel and unexpected finding suggests that TP-
receptor signalling by F2-isoprostanes may induce endogenous anti-oxidant defence 
mechanisms that limit lipid peroxidation in the kidney. It would be interesting to study 
this hypothesis on negative feedback on anti-oxidant regulation by F2-isoprostanes 
in future studies.
 Taken together, we conclude that F2-isoprostanes and thromboxane A2 
signalling do not contribute critically to the pathogenesis of ischemic acute kidney 
injury. Tissue injury due to ischemia and reperfusion is characterized by extensive 
oxidative stress and the biological actions of F2-isoprostanes are particularly evident 
in the renal microcirculation. Therefore, our findings more generally argue against 
a prominent role for F2-isoprostanes signalling in exacerbating acute disease states 
associated with oxidative stress.
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INTRODUCTION
Kidney transplantation is the treatment of choice for patients with end-stage 
renal disease. Due to the shortage of conventional brain-dead donor kidneys, and 
the increasing incidence of end-stage renal disease, waiting lists are still growing. 
Kidney donation from donors after cardiac death increases the number of available 
donor kidneys for transplantation. The pool of controlled donors after cardiac 
death is limited. The number of patients who die after failed resuscitation is much 
higher, but there is a general reluctance to use these donors for kidney donation and 
transplantation, because of a relatively high incidence of delayed graft function and 
primary non-function compared to conventional donors after brain death. Therefore, 
this thesis intends to describe the outcome of primarily uncontrolled DCD kidneys 
and to define clinically applicable methods to assess kidney viability and to reduce 
the incidence of primary non-function of DCD kidneys. In this chapter, we summarize 
and interpret the main findings of this thesis.
DEFINITION OF DONATION AFTER CARDIAC DEATH
Donation after cardiac death (DCD) refers to organ donation by deceased 
patients who do not meet strict criteria for brain death, but instead die from circulatory 
arrest after unsuccessful cardiopulmonary resuscitation (Maastricht category I and 
II) or after withdrawal of futile medical supportive treatment (Maastricht category 
III) (see also Table 1.1). The Maastricht categories were put together during the 
first international conference on non-heart-beating donation in Maastricht in 1995 
(1). Maastricht category I donors constitute of patients declared dead outside the 
hospital and are subsequently transferred to the hospital with the purpose of organ 
donation. Maastricht category II donors are patients who die in the hospital, mostly in 
the emergency department, after unsuccessful resuscitation. Both categories are also 
referred to as uncontrolled DCD donation, since both situations occur unexpectedly 
and require swift actions of the donation team. Maastricht category III donors are 
patients in intensive care units (ICU) who do not meet brain death criteria but suffer 
from severe neurological damage, which makes medical supportive treatment futile. 
These patients in whom cardiac arrest is awaited are referred to as controlled DCD 
donors. The latter category, Maastricht category IV, consists of brain-dead donors 
who die of unexpected cardiac arrest before organ procurement.
 In contrast to organs from brain-dead donors (donation after brain death, 
DBD), DCD kidneys suffer from warm ischemic injury during the period from 
circulatory arrest until organ preservation. This ischemic damage results in a relatively 
high incidence of primary non-function (PNF) and delayed graft function (DGF) after 
transplantation of the kidney, compared to kidney transplantation from conventional 
brain-dead donors (Chapter 2) (2). These early complications associated with DCD 
kidney transplantation have led to a general reluctance to use these kidneys for 
transplantation despite good results (Chapter 2) (3).
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RESULTS OF KIDNEY TRANSPLANTATION FROM DONORS 
AFTER CARDIAC DEATH
It is commonly known that kidney transplantation results in longer life 
expectancy and superior quality of life compared to dialysis treatment (4, 5). 
Therefore, kidney transplantation is the treatment of choice for many patients 
with end-stage renal disease (3). Procurement of kidneys from donors after cardiac 
death holds the potential to expand the donor pool 2.5 to 4 times (6). Only a small 
proportion of intensive care patients who are not brain-dead and in whom further 
medical treatment is considered to be futile, meet donor criteria. The number of 
patients who die after failed resuscitation is much higher (7) and are therefore a 
great potential to expand the donor pool. 
Snoeijs et al. studied the survival benefit of patients who received a kidney 
from a DCD donor compared to patients who stay on dialysis treatment and wait 
for a conventional kidney from a brain-dead donor, in a large cohort study, which 
included 2.575 patients who were registered on the Dutch waiting list for a first kidney 
transplantation (8). Graft failure during the first 3 months after transplantation was 
twice as likely for DCD kidneys as for DBD kidneys. However, standard-criteria DCD 
kidney transplantation was associated with a 56% reduced risk of mortality, compared 
with continuing dialysis treatment and waiting for a DBD kidney. This reduction in 
mortality translates into a 2.4-month additional expected lifetime during the first 4 
years after a kidney transplantation from a DCD donor. However, the long-term results 
of uncontrolled DCD kidney transplantation specifically remained to be established.
To address this issue, we studied the long-term outcome of uncontrolled DCD 
kidneys that were transplanted within the Eurotransplant region after being recovered 
in our organ procurement area from 1981 until 2009 and compared the results with 
controlled DCD kidney transplantation (Chapter 2). This study demonstrates that 
the initial function and long-term outcome of kidneys from uncontrolled DCDs is 
comparable with the outcome of kidneys from controlled donors. For both groups, a 
careful selection of both donor kidneys and recipients remains mandatory to reduce 
the risk of non-functioning grafts (7).
These findings show that uncontrolled DCD kidneys are a valuable expansion 
of the donor pool with good long-term results. However, drastic measures to reduce 
the percentage of primary non-function are necessary. It is not clear which factors 
influence the outcome of uncontrolled DCD kidney transplantation. Most studies 
which assessed DCD kidney transplantation outcomes analyzed either controlled 
DCD kidneys or uncontrolled and controlled DCD kidneys together. Because of the 
increased popularity, it is essential to know which uncontrolled DCD kidneys can 
be accepted for transplantation and which kidneys better can be discarded. To 
describe the opportunities and limits of uncontrolled DCD kidney transplantations, 
we assessed the results of our uncontrolled DCD program and determined which 
factors are associated with PNF or inferior graft function after transplantation 
of uncontrolled donor kidneys (Chapter 3). In this relatively large study with 135 
uncontrolled DCD kidneys we focused on the association of different donor, graft 
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and recipient characteristics with primary non-function. Only donor age shows to be 
an independent risk factor for PNF in the univariate analysis (OR 1.035, 95%CI 1.004–
1.068, p=0.028) and remains strongly associated with PNF in the multivariate analysis 
(OR 1.064, 95%CI 1.013 – 1.118, p=0.014). Further analysis of donor age, using the 
ROC-curve and its accompanying table, showed the strongest association with PNF 
from an age of 54 years and older with an odds ratio of 2.857 (95% CI 1.242 – 6.571; 
p=0.013). Kidneys from donors of 54 years and older have a higher percentage of PNF 
compared with younger donor kidneys (35% vs. 16%, p=0.012, respectively). However, 
the predictive value of donor age is poor with an area under the receiver operating 
characteristics curve of 0.640, 95%CI 0.553–0.721. From Chapter 3, it cannot be 
excluded that there are more risk factors for poor uncontrolled DCD kidney function 
than old donor age. Despite the relatively high percentage of primary non-function, 
which increases the power to identify potential risk factors and, compared to other 
studies, the large group of uncontrolled DCD kidney transplantations, the number of 
analyzed donor kidneys remains relatively small to identify all possible risk factors for 
primary non-function. Taken together, Chapter 3 shows that donor age is associated 
with graft function of uncontrolled DCD kidneys and therefore, donor age remains 
an important criteria which may influence the decision to either accept or discard an 
uncontrolled DCD kidney.
PITFALLS OF KIDNEY TRANSPLANTATION FROM DONORS 
AFTER CARDIAC DEATH
Even though DCD kidney transplantation confers a survival benefit to 
wait-listed dialysis patients, the relatively high percentage of never functioning 
grafts provides a strong incentive to improve the current practice of DCD kidney 
transplantation.
Kidneys from DCD donors have higher risks of developing PNF and DGF compared 
to kidneys from DBD donors (8-10). Delayed graft function is a serious complication 
of kidney transplantation. It often leads to prolonged hospital stay, increased costs, 
increased risks of graft loss and recipients have to stay on dialysis treatment until 
the transplanted kidney regains function. However, DGF is not the most important 
parameter in DCD kidney transplantation, since it has little clinical implications, as 
long-term survival rates of DCD kidneys with DGF do not significantly differ from 
DCD kidneys with IF (2, 11-13). PNF on the other hand is a major complication, which 
is associated with the unnecessary risk of surgery, immunosuppression and recipients 
may become sensitized to donor antigens which decreases the opportunities for 
retransplantation (14).
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IMPROVEMENTS IN DCD KIDNEY TRANSPLANTATION
As primary non-function is a serious complication of kidney transplantation, 
measures to reduce the incidence of PNF to a minimum are of major importance. To 
make optimal use of DCD kidneys without increasing the percentage PNF, studies 
have been performed to identify potential risk factors for primary non-function and 
methods to reduce the chance on PNF. 
The Maastricht University Medical Center (MUMC) started a kidney 
transplantation program in 1980. At that moment, only excellent donor kidneys from 
young, brain-dead donors were used for transplantation. While the waiting list for 
kidney transplantation was growing, the number of organ donors remained stable. 
Therefore, the need for additional sources of organ donors became more important 
and the pool of donor organs was expanded by the use of kidneys from donors after 
cardiac death. In the early years of the transplant program, DCD kidneys were only 
used occasionally. However, the demand for donor organs increased and DCD kidney 
transplantation was stimulated. We started using organs from older DCD donors 
and with longer periods of warm ischemia for transplantation. In the early nineties, 
25% of the deceased donors were DCD donors. Unfortunately, the expansion of the 
donor pool with more marginal kidneys was accompanied with an increase in primary 
non-function. Therefore, we evaluated the quality of care at our center and assessed 
if improvements could be made to reduce the high rate of primary non-function 
without the reduction in the number of DCD donors (Chapter 4).
 Potential risk factors for primary non-function that were analyzed included 
donor age, DCD category, warm ischemia time and duration of cold ischemia time. 
Previous studies from our group showed that DCD kidneys from donors aged 60 years 
or older showed a higher incidence of PNF and inferior graft survival compared to 
kidneys from younger donors (15), uncontrolled DCD donors were no significant 
risk factor for primary non-function (Chapter 2), prolonged in situ preservation was 
associated with a higher percentage of primary non-function and direct cannulation 
of the aorta was superior to in situ preservation for controlled donors (16, 17). 
Based on these data, changes in our transplantation program were 
implemented in order to reduce the incidence of primary non-function. These 
changes included firstly routine biopsies for donor kidneys older than 60 years of age. 
In donors older than 60 years, the decision to transplant a kidney, to use both kidneys 
as dual transplant or to discard the donor kidney was made with the help of pre-
implantation histology. Secondly, donor kidneys with ISP insertion time longer than 
30 minutes were generally discarded. Thirdly, for controlled DCD donors, direct aortic 
cannulation rather than ISP became the preservation method of choice. Fourthly, 
extra attention was paid to emphasize the importance of shorter CIT by reducing 
waiting time for operating theatre availability. Due to these implemented changes, 
we were able to reduce the incidence of primary non-function of DCD kidneys back 
to 5%, without the reduction in the number of DCD donors. This percentage is 
equivalent with results of other groups (9, 10, 18). 
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Taken together, a liberal approach to accept marginal DCD donors for 
transplantation may contribute to a more widespread strategy to transplant DCD 
kidneys with a reduction of the number of patients on the waiting list with the 
dialysis associated mortality. However, such strategy requires careful monitoring of 
transplant outcome to guarantee that results remain within the limits of acceptable 
practice.
DIAGNOSTIC TOOLS TO ASSESS GRAFT VIABILITY OF KIDNEYS 
FROM DONORS AFTER CARDIAC DEATH
Pre-transplant assessment of kidney graft viability may help clinicians to 
decide whether to accept or discard a kidney for transplantation. Proper selection of 
suitable kidneys for transplantation is important to reduce the risk of primary non-
function and delayed graft function after transplantation, which is associated with 
an increased risk of graft loss, acute rejection, longer hospital stay and high costs 
(19-22). Additionally, without reliable tools to assess graft viability, potential viable 
kidneys may be discarded. Therefore, diagnostic tools to assess graft viability before 
transplantation are of major importance.
Viability assessment of machine perfused kidneys
In recent years, kidney preservation by hypothermic machine perfusion has 
experienced renewed interest. In addition to the intended benefit of improved 
tissue preservation, machine perfusion also provides the opportunity to assess organ 
viability with the help of perfusion parameters and biomarkers in the perfusate (23, 
24). Perfusate biomarkers glutathione S-transferase (GST) and lactate dehydrogenase 
(LDH) are promising or accepted tools to accept or discard kidneys for transplantation 
(25-27). However, most studies which assess the value of perfusate biomarkers 
as predictors of organ viability assessed this in selected kidneys and described the 
improvement of the results of DCD kidney transplantation after the introduction 
of perfusate biomarkers to assess organ viability, or included a limited number of 
kidneys with an a priori good prognosis and therefore lack power (Chapter 5).
 In Chapter 5, we evaluated the predictive value of the potential biomarkers 
GST, LDH, heart-type fatty acid binding protein (H-FABP), redox-active iron, 
interleukin (IL)-18 and neutrophil gelatinase-associated lipocalin (NGAL) of a large 
(N = 335) unselected group of DCD kidneys with a relative poor prognosis and a high 
incidence of graft failure. In this cohort, only LDH and IL-18 were associated with PNF 
in the multivariate analysis (OR 1.001, 95% CI 1.000 – 1.002, p=0.005 and 1.001, 95% 
CI 1.000 – 1.002, p=0.003, respectively). However, the diagnostic accuracy for primary 
non-function was ‘poor’ for all biomarkers. Therefore, the diagnostic accuracy of the 
perfusate biomarkers GST, LDH, H-FABP, redox-active iron, IL-18 and NGAL should not 
lead to the discard of DCD kidneys.
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 Next to the assessment of perfusate biomarkers, machine perfusion also 
provides the opportunity to determine perfusion parameters, including perfusion 
pressure, renal flow and renovascular resistance. These parameters have been 
advocated to predict graft function after transplantation (28-31). However, the value 
of machine perfusion characteristics to predict primary non-function was relatively 
unknown. Therefore, we assessed the value of renovascular resistance in predicting 
organ viability in a large cohort of marginal machine perfused DCD kidneys in which 
perfusion characteristics were not used to discard the organs (Chapter 6). We showed 
that renovascular resistance at the start of machine perfusion was significantly and 
independently associated with primary non-function (OR 2.040, 95% CI 1.362 – 3.056, 
p=0.001). However, the predictive quality was moderate. Therefore, marginal kidneys 
should not be discarded based on renovascular resistance only.
 The period of warm ischemia can lead to capillary damage due to thrombosis, 
vasoconstriction and oedema and may consequently result in a decreased renovascular 
circulating volume. Therefore, pre-implantation renovascular circulating volume of 
the kidney may be associated with the severity of warm ischemic injury and could 
be a valuable predictor of transplant outcome. The dilution technique is used to 
measure circulating volume in hemodialyzer fibre bundles. It determines the dilution 
of an injected saline bolus with ultrasound flow probes before and after transit of 
the dialyzer. In hemodialyzer volume assessment this technique is accurate and its 
results reproducible (32-35). The dilution technique is a relatively simple method to 
measure intravascular volume and has not been used before in transplant surgery. 
Therefore we determined the repeatability and the validity of this technique and we 
assessed the effect of warm ischemia on renovascular circulating volume in machine 
perfused porcine kidneys (Chapter 7). This technique is a reproducible way to assess 
renovascular circulating volume of machine perfused porcine kidneys and is suitable 
to detect differences in warm ischemia time. However, further studies are necessary 
to assess the value of the dilution technique and renovascular volume measurements 
in human transplantation.
Unfortunately, the ‘viability tests’ for machine perfused DCD kidneys described 
in this thesis and other recent studied potential viability markers have insufficient 
diagnostic accuracy to be clinically useful in deciding whether to transplant or discard 
DCD kidneys that have suffered from warm ischemia (Chapter 8). Assessment of 
renovascular circulating volume of machine perfused kidneys with the hemodialyzer 
technique may be a valuable tool to assess organ viability but future studies in human 
kidney transplantation are necessary.
Viability assessment of kidneys before organ procurement
Viability testing of machine perfused kidneys has been extensively studied. 
Machine perfusion characteristics and perfusate biomarkers often correlate with 
the transplant outcome, but the present viability tests are not reliable predictors 
of transplant outcome. Viability assessment of kidneys before organ procurement, 
however, has been studied less. 
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The protein neutrophil gelatinase-associated lipocalin (NGAL), also known 
as lipocalin-2, has recently been discovered as a novel biomarker of acute kidney 
injury (36). The concentration of NGAL increases dramatically in response to tubular 
injury and precedes the elevation of classical biomarkers for kidney damage, such 
as serum creatinine (37). Therefore, we measured NGAL concentrations in both 
DCD (uncontrolled Maastricht category I and II donors and controlled Maastricht 
category III donors) and DBD donors and examined the value of donor plasma NGAL 
to predict post-transplant graft function (Chapter 9). We have shown for the first 
time that donor NGAL concentrations prior to organ recovery are not associated with 
graft function after transplantation, however, for functioning DCD kidneys only, a 
significant difference was found for NGAL concentrations between kidneys with DGF 
and IF. Although it is a valuable biomarker for kidney injury in intensive care patients, 
its value as a predictor in kidney transplantation outcome is limited.
TREATMENT OF ISCHEMIC ACUTE KIDNEY INJURY IN ANIMAL 
MODELS
DCD kidney transplantation is currently limited to kidneys that have suffered 
relatively short periods of warm ischemia. Reducing renal injury after ischemia and 
reperfusion holds the potential to reduce the incidence of early graft dysfunction 
and as a result it may contribute to an expansion of the donor pool with kidneys 
which have suffered prolonged ischemic injury. Therefore, we have studied novel 
potential therapies for ischemic acute kidney injury in experimental mice models with 
the eventual goal to improve early graft function in DCD kidney transplantation.
Ischemia-reperfusion leads to a complex series of events, including generation 
of inflammatory mediators, leukocyte infiltration and, depending on the severity of 
the injury, ultimately cell death by either necrosis or apoptosis (38, 39). Inefficient 
clearance of apoptotic cells leads to necrosis, which is characterized by the disruption 
of cellular membranes and the release of cytoplasmic and nuclear components 
(40). The mechanisms that lead to inflammation after necrotic cell death are poorly 
understood. Recent data show that C-type lectin Mincle is involved in this process. 
Mincle recognizes the soluble factor spliceosome-associated protein 130 (SAP130), a 
nuclear protein released by necrotic cells, triggering inflammatory cytokine responses, 
which leads to the recruitment of neutrophils (40, 41). Although incompletely 
understood, renal tubular necrosis, apoptosis and inflammation during and after renal 
ischemia-reperfusion contribute significantly to the pathogenesis of ischemic acute 
kidney injury (42). Taken together, blocking the Mincle receptor may result in a less 
severe inflammatory response, leading to less severe injury after nonhomeostatic cell 
death. Therefore, we studied the effect of anti-Mincle on renal ischemia-reperfusion 
injury in mice in Chapter 10. The effects of Mincle on renal ischemia-reperfusion injury 
and inflammatory response were studied in an ischemia-reperfusion model in mice, 
using 25 minutes of ischemia and 24 hours of reperfusion. The Mincle-receptor was 
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blocked with a Mincle-specific antibody (anti-Mincle) and compared with animals 
receiving rat IgG as control group. Kidney function (creatinine 232 ± 34 vs. 211 ± 22 
µmol/L, p=0.200 and BUN 61.2 ± 5.6 vs. 58.2 ± 5.9, p=0.355, respectively), histological 
injury and the number of infiltrated neutrophils were similar between both groups. 
In conclusion, blocking the Mincle-receptor with specific anti-Mincle antibodies does 
not inhibit the inflammatory response in mice kidneys after ischemia and reperfusion 
and does not contribute to lesser renal injury and better renal function.
During cold ischemia and at reperfusion, generation of reactive oxygen 
species is considered to contribute significantly to ischemic acute kidney injury,  it 
causes renal vasoconstriction and damages cellular lipids, proteins and DNA, leading 
to tubular epithelial cell death, when there is no anti-oxidant defense (43-45). In 
Chapter 11 we studied the pathophysiology of vasoconstriction due to oxidative stress 
and a possible method to prevent this. We described that oxidative modification 
of arachidonic acid in cell membranes leads to formation of stable F2-isoprostanes 
that are cleaved and released into the plasma and then possess biological activity by 
signaling through the thromboxane A2 receptor (46, 47). Previous studies showed a 
reduction in renal blood flow and glomerular filtration rate due to vasoconstriction 
of afferent glomerular arterioles after administration of F2-isoprostanes to rats and 
pigs (48, 49). Mice with genetic disruption of the Thromboxane A2 receptor, which 
eliminates F2-isoprostanes signaling, were not protected from ischemic acute kidney 
injury when compared to wild-type mice, though F2-isoprostanes were detected in 
urine collections after surgery. Therefore, we think that F2-isoprostanes signaling 
does not have a great impact on the pathogenesis of ischemic acute kidney injury.
FUTURE PERSPECTIVES IN DCD KIDNEY DONATION AND 
TRANSPLANTATION
Targeted interventions to organ damage due to brain death or ischemia may 
reduce or attenuate ischemia-reperfusion injury after transplantation. Modifying 
inflammatory reactions and innate immunity may play an important role in this in 
the future. Novel treatment strategies may improve the quality of the organs, and 
so increase the number of organs that can be safely accepted for transplantation. 
Interventions can be applied in the donor, but also between organ procurement and 
transplantation during cold machine preservation or during warm preservation. In 
the latter, the metabolism is higher which theoretically enables better modification 
of the organ.
As described in Chapter 8 normothermic machine perfusion (NMP) may 
provide new and other opportunities to assess the quality of a donor organ before 
transplantation. Furthermore, NMP may ameliorate ischemic damage and resuscitate 
the organ instead of doing further harm and preventing the graft from injury during 
the preservation period (50). The major advantage of NMP to test organ viability 
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is the possibility of measuring functional parameters, like diuresis and creatinine 
clearance .
CONCLUSION
In the current thesis, we describe the utilization of organs from donors after 
cardiac death, especially uncontrolled Maastricht category II donors, the long-term 
results and ways to improve transplant outcome. Despite the higher incidence of 
primary non-function of uncontrolled DCD kidneys, long-term results are equal to 
controlled DCD kidneys. The risk of primary non-function can be reduced by identifying 
marginal organ donors by age, histological assessment of pre-implantation biopsies 
of old donor kidneys, donor category, WIT and CIT, justifying the expansion of the 
donor pool with uncontrolled donors to reduce the still growing waiting list for 
renal transplantations and stimulating the implementation of uncontrolled kidney 
donation programs.
Ischemia-reperfusion leads to a complex series of events. Therefore, treatment 
of ischemically damaged kidneys is likely to require a combination of interventions 
targeting different pathophysiological pathways. In this thesis, possible treatments 
of single elements of the pathophysiology of ischemia-reperfusion were studied, 
with no positive effects. A combination of interventions however, may be successful 
in future studies. 
With the results presented in this thesis the use of kidneys from DCD donors, 
especially uncontrolled DCD donors, may be further expanded. However, major 
efforts should continue to be made to improve the quality of DCD kidneys and 
thereby expand the utilization of this large pool of donor kidneys to its full potential.
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INLEIDING
Niertransplantatie is de voorkeursbehandeling bij patiënten met eindstadium 
nierfalen. Door het tekort aan de conventionele hersendode nierdonoren en een 
toenemende incidentie van eindstadium nierfalen, blijven de wachtlijsten voor 
niertransplantatie groeien. Naast nierdonatie van hersendode donoren, kan 
orgaandonatie na hartstilstand het aantal beschikbare donornieren vergroten. 
Voornamelijk orgaandonatie na een niet-succesvolle reanimatie kan tot een forse 
toename in het aantal donoren leiden. In tegenstelling tot nieren van hersendode 
donoren, worden organen van donoren na hartstilstand blootgesteld aan een 
periode van afwezige doorbloeding; warme ischemie. Hierdoor ontstaat acute 
nierschade, waardoor er na transplantatie een verhoogde kans op vertraagde 
transplantaatfunctie of primaire non-functie. Hierdoor is terughoudendheid 
opgetreden bij de acceptatie van deze nieren voor transplantatie. In dit proefschrift 
worden de lange termijnresultaten beschreven van voornamelijk nierdonatie na een 
niet-succelvolle reanimatie. Tevens worden klinisch toepasbare methoden gezocht 
om de kans op primaire non-functie te verkleinen.  
DEFINITIE VAN ORGAANDONATIE NA HARTSTILSTAND
Donatie na hartstilstand verwijst naar orgaandonatie bij patiënten die 
niet voldoen aan strikte hersendoodcriteria, maar die komen te overlijden door 
een hartstilstand na niet-succesvolle reanimatie (Maastricht categorieën I en II), 
of na het staken van een medisch zinloze behandeling bij patiënten met ernstige 
hersenschade (Maastricht categorie III) (zie tabel 1.1). Deze Maastricht-categorieën 
zijn samengesteld tijdens het eerste internationale congres over orgaandonatie 
na hartstilstand in Maastricht in 1995 (1). Maastricht categorie I donoren bestaan 
uit patiënten die buiten het ziekenhuis overleden worden verklaard en vervolgens 
voor orgaandonatie naar het ziekenhuis worden vervoerd. Maastricht categorie 
II donoren zijn patiënten die binnen het ziekenhuis, meestal op de spoedeisende 
hulp, overlijden na een niet-succesvolle reanimatie. Beide categorieën worden 
ook wel ‘ongecontroleerde donoren’ genoemd, aangezien in beide situaties het 
overlijden onverwacht optreedt en er snel en adequaat gehandeld moet worden 
door het donatieteam. Maastricht categorie III donoren zijn patiënten op de afdeling 
intensieve zorg (IC) die niet voldoen aan de hersendoodcriteria, maar bij wie door 
ernstig hersenletsel verdere medische behandeling zinloos is. Bij deze patiënten, ook 
wel ‘gecontroleerde donoren’ wordt de behandeling gestaakt en wordt hartstilstand 
afgewacht De laatste categorie, Maastricht categorie IV, zijn hersendode patiënten 
die onverwacht aan een hartstilstand komen te overlijden voor de geplande 
orgaandonatie.
In tegenstelling tot organen van hersendode donoren, lijden organen van 
donoren na hartstilstand aan een periode van afwezige bloedcirculatie, warme 
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ischemie, vanaf hartstilstand tot het spoelen van de organen met een koude 
perfusievloeistof. Door deze warme ischemie treedt er acute nierschade op, 
waardoor er na transplantatie een verhoogde kans bestaat op primaire non-functie 
of vertraagde transplantaatfunctie in vergelijking met getransplanteerde nieren van 
hersendode donoren (Hoofdstuk 2) (2). Deze vroege complicaties hebben geleid 
tot een terughoudendheid bij het accepteren van deze nieren voor transplantatie 
(Hoofdstuk 2) (3).
RESULTATEN NA NIERTRANSPLANTATIE VAN DONOREN NA 
EEN HARTSTILSTAND
Het is algemeen bekend dat niertransplantatie leidt tot een langere 
levensverwachting en betere kwaliteit van leven, in vergelijking met dialysebehandeling 
(4, 5). Daarom heeft een niertransplantatie de eerste voorkeur in de behandeling 
van patiënten met eindstadium nierfalen (3). Donatie van nieren na overlijden aan 
een hartstilstand kan de hoeveelheid beschikbare nieren met 2,5 – 4 maal vergroten 
(6). Slechts een klein aantal patiënten dat overlijdt op de intensive care na het staken 
van een zinloze medische behandeling komt in aanmerking als orgaandonor (7). Het 
aantal patiënten dat overlijdt na een niet succesvolle reanimatie is veel groter, en omvat 
daardoor een groter potentieel om het aantal orgaandonoren uit te breiden. 
 Snoeijs et al. (2010) hebben het overlevingsvoordeel van patiënten die een 
nier van een donor na hartstilstand kregen vergeleken met de patiënten die bleven 
dialyseren en wachtten op een conventionele nier na hersendood. In die studie werd een 
groot cohort van patiënten onderzocht; 2575 patiënten geregistreerd op de Nederlandse 
wachtlijst voor niertransplantatie (8). De kans op falen van de transplantatienier 
binnen 3 maanden na transplantatie was tweemaal zo groot voor donornieren na een 
hartstilstand in vergelijking met donornieren na hersendood. Het risico op overlijden na 
niertransplantatie van standaard donoren na hartstilstand is echter 56% lager vergeleken 
met het voortzetten van dialysebehandeling en wachten op een conventionele 
donornier na hersendood. Dit lagere risico vertaald zich in een 2,4 maanden langere 
levensverwachting na niertransplantatie van donoren na hartstilstand gedurende de 
eerste 4 jaar na transplantatie. De lange termijn resultaten van niertransplantaties van 
ongecontroleerde donoren na hartstilstand zijn echter onbekend.
 Om deze reden hebben we de lange termijn uitkomsten van niertransplantaties 
van ongecontroleerde donoren na hartstilstand uit regio Maastricht die zijn 
getransplanteerd in de Eurotransplant regio tussen 1981 en 2009 vergeleken met 
niertransplantaties van gecontroleerde donoren na hartstilstand (Hoofdstuk 2). In deze 
studie laten we zien dat de initiële functie en lange termijn resultaten tussen beide 
groepen vergelijkbaar zijn. Echter, een nauwkeurige selectie van zowel de donornieren 
als de ontvangers blijft belangrijk om het risico op falen van de getransplanteerde nier 
te verkleinen (7). 
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 Bovenstaande bevindingen laten zien dat ongecontroleerde nierdonoren 
na hartstilstand een waardevolle uitbreiding zijn van het aantal donoren, met 
goede lange-termijn resultaten. Drastische maatregelen zijn echter nodig om het 
percentage primaire non-functie te reduceren. Het is niet exact duidelijk welke 
factoren invloed hebben op de uitkomst van ongecontroleerde donornieren 
na hartstilstand. De meeste studies die transplantatie-uitkomsten beschrijven 
hebben alleen gecontroleerde donornieren na hartstilstand, of gecontroleerde 
en ongecontroleerde donornieren na hartstilstand samen, bestudeerd. Bij een 
toegenomen populariteit van ongecontroleerde donornieren na hartstilstand is het 
echter essentieel welke nieren kunnen worden geaccepteerd voor transplantatie 
en welke nieren afgewezen dienen te worden. Om de mogelijkheden en limieten 
van ongecontroleerde donornieren na hartstilstand te beschrijven hebben we de 
resultaten van transplantaties van deze nieren bestudeerd en gekeken naar welke 
factoren geassocieerd zijn met primaire non-functie of verminderde functie na 
transplantatie (Hoofdstuk 3). In deze relatief grote studie met 135 ongecontroleerde 
donornieren na hartstilstand hebben we gefocust op de associatie van verschillende 
donor-, nier- en ontvanger karakteristieken met primaire non-functie. Alleen 
donorleeftijd bleek een onafhankelijke risicofactor voor primaire non-functie in een 
univariate analyse (OR 1.035, 95%CI 1.004–1.068, p=0.028) en bleef sterk geassocieerd 
met primaire non-functie in een multivariate analyse (OR 1.064, 95%CI 1.013 – 1.118, 
p=0.014). Verdere analyse van donorleeftijd, met gebruik van de ROC-grafiek en 
de bijbehorende tabel, toonde dat de grootste associatie met primaire non-functie 
optreedt vanaf een leeftijd van 54 jaar (OR 2.857, 95% CI 1.242 – 6.571; p=0.013). 
Nieren van ongecontroleerde donoren na hartstilstand ouder dan 54 jaar hebben een 
hoger percentage primaire non-functie in vergelijking met jongere donoren (35% vs. 
16%, p=0.012, respectievelijk). De voorspellende waarde van donorleeftijd is echter 
matig, met een AURC van 0.640, 95%CI 0.553–0.721. Uit Hoofdstuk 3 kan niet worden 
geconcludeerd dat er meerdere factoren een rol spelen voor een slechte nierfunctie 
na transplantatie. Ondanks het relatief hoge percentage primaire non-functie en 
de relatief grote populatie ongecontroleerde nierdonoren, is het moeilijk om alle 
mogelijke risicofactoren voor primaire non-functie te identificeren. Samengevat laat 
Hoofdstuk 3 zien dat donorleeftijd van ongecontroleerde donoren na hartstilstand 
geassocieerd is met nierfunctie na transplantatie en daarom blijft donorleeftijd een 
belangrijk criterium om een nier te accepteren of af te wijzen voor transplantatie.
VALKUILEN BIJ NIERTRANSPLANTATIES VAN DONOREN NA 
HARTSTILSTAND
Ondanks het feit dat niertransplantaties van donoren na hartstilstand 
een overlevingsvoordeel brengt voor dialysepatiënten op de wachtlijst voor een 
niertransplantatie, blijft het relatief hoge percentage primaire non-functie een prikkel 
om het huidige transplantatiebeleid omtrent nieren van donoren na hartstilstand te 
verbeteren. 
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 Nieren van donoren na hartstilstand hebben een grotere kans op het 
ontwikkelen van primaire non-functie en vertraagde nierfunctie in vergelijking 
met nieren van hersendode donoren (8-10). Vertraagde nierfunctie is een serieuze 
complicatie na transplantatie. Het leidt vaak tot een langere opnameduur, oplopende 
medische kosten en een vergroot risico op nierfalen. Tevens blijven deze patiënten 
langer afhankelijk van dialyse. Een vertraagde nierfunctie na transplantatie is echter 
niet de meest belangrijke parameter om op te selecteren, omdat het in de praktijk 
weinig consequenties met zich meebrengt (2, 11-13). De lange termijn resultaten van 
nieren van donoren na hartstilstand met een vertraagde functie na transplantatie 
verschillen niet significant van getransplanteerde nieren die direct functioneren. 
Primaire non-functie daarentegen is een ernstige complicatie, hetgeen is geassocieerd 
met het onnodige risico van de operatie en de immunosuppressieve behandeling. 
Tevens kunnen ontvangers immunologisch gesensibiliseerd raken tegen antigenen 
van de donor, waardoor de kans op een succesvolle her-transplantatie afneemt (14). 
Strategieën om het risico op primaire non-functie te beperken zijn daarom van groot 
belang.
VERBETERINGEN IN NIERTRANSPLANTATIES VAN DONOREN 
NA HARTSTILSTAND
Zoals hierboven reeds vermeld, is primaire non-functie een grote complicatie 
na een niertransplantatie en daarom zijn er verbeteringen noodzakelijk om de 
incidentie van primaire non-functie te verlagen. Om optimaal gebruik te maken van 
donoren na hartstilstand zonder het percentage primaire non-functie te verhogen, 
hebben we meerdere studies verricht om potentiële risicofactoren voor primaire non-
functie te identificeren en om methoden te zoeken om de kans hierop te verminderen.
 In het Maastricht University Medical Center (MUMC+) werd gestart met het 
niertransplantatie programma in 1980. In die periode werden alleen donornieren van 
perfecte kwaliteit van jonge donoren na hersendood getransplanteerd. De wachtlijst 
voor niertransplantaties bleef echter groeien, terwijl het aantal nierdonoren stabiel 
bleef. Om die reden werd er gezocht naar additionele soorten orgaandonoren. Men 
kwam uit bij de donoren na hartstilstand. In de eerste jaren van het transplantatie 
programma werden nieren van donoren na hartstilstand zelden gebruikt. De vraag 
naar donororganen bleef echter groeien waardoor het gebruik van donoren na 
hartdood werd gestimuleerd. In ons centrum werd begonnen met het accepteren 
van oudere donoren na hartdood en donoren met langere warme ischemie tijden. 
In het begin van de jaren negentig bestond ongeveer 25% van de overleden 
donoren uit donoren na hartdood. Het uitbreiden van het totaal aantal donoren 
met donoren van mindere kwaliteit werd echter gecompliceerd door een stijging in 
het percentage primaire non-functie. Daarom hebben we de kwaliteit van zorg in 
ons centrum geëvalueerd en hebben we bestudeerd welke verbeteringen gemaakt 
konden worden om het hoge percentage primaire non-functie te reduceren zonder 
het aantal donoren na hartdood te verminderen (Hoofdstuk 4).
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 Potentiële risicofactoren voor primaire non-functie die werden geanalyseerd 
waren donorleeftijd, donorcategorie, warme ischemie tijd en duur van de koude 
ischemie. Eerdere studies van onze groep lieten zien dat nieren van donoren na 
hartstilstand van 60 jaar en ouder een hogere incidentie van primaire non-functie 
hadden en een slechtere overleving van de getransplanteerde nier ten opzichte 
van jongere donoren (15). De categorie ongecontroleerde donoren na hartstilstand 
vertoonde geen groter risico op primaire non-functie (Hoofdstuk 2), langere duur 
van in situ preservatie was geassocieerd met een hoger percentage primaire non-
functie en directe cannulatie van de aorta was superieur ten opzichte van in situ 
preservatie voor gecontroleerde donoren na hartstilstand (16, 17).
 Met bovengenoemde gegevens werden er verbeteringen in ons centrum 
ingevoerd om het percentage primaire non-functie te verminderen. De veranderingen 
bestonden uit 1) routine biopten van nieren van donoren ouder dan 60 jaar. Van deze 
donoren werd de beslissing om één nier te transplanteren, beide nieren samen in één 
ontvanger of beide nieren niet te accepteren voor transplantatie gebaseerd op de 
uitkomst van de biopten die voor de transplantatie werden afgenomen. 2) donoren 
met een in situ preservatie tijd langer dan 30 minuten werden in principe niet 
geaccepteerd voor transplantatie. 3) voor gecontroleerde donoren na hartstilstand 
werd directe cannulatie van de aorta de voorkeursmethode in plaats van in situ 
preservatie. 4) extra aandacht werd besteed aan kortere koude ischemie tijden door 
de beschikbaarheid van de operatiezaal te versnellen. 
 Door deze veranderingen is in ons centrum het percentage van primaire 
non-functie van nieren van donoren na hartstilstand verlaagd tot 5%, zonder het 
aantal donoren na hartstilstand te verkleinen. Dit percentage is vergelijkbaar met de 
resultaten van andere transplantatiecentra (9, 10, 18).
 Samengevat, een liberale acceptatie van marginale donoren na hartstilstand 
kan bijdragen aan een wijdverspreide strategie om nieren van donoren na hartstilstand 
te transplanteren, met een reductie van het aantal patiënten op de wachtlijst die de 
met een hogere mortaliteit geassocieerde dialyse ondergaan. Echter, een dergelijke 
strategie behoeft zorgvuldige controle van de transplantatie uitkomsten om te 
garanderen dat de resultaten binnen de geaccepteerde limieten van goede klinische 
zorg blijven. 
DIAGNOSTISCHE HULPMIDDELEN OM DE KWALITEIT VAN 
NIEREN VAN DONOREN NA HARTSTILSTAND TE BEOORDELEN 
Beoordeling van kwaliteit van een donornier vóór het transplanteren kan 
clinici helpen bij het besluiten om een nier te accepteren of af te wijzen voor 
transplantatie. Adequate selectie van geschikte nieren voor transplantatie is 
cruciaal om het risico op primaire non-functie en vertraagde transplantaatfunctie te 
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reduceren, hetgeen geassocieerd is met een verhoogd risico op falen, acute rejectie, 
verlengde ziekenhuisopname en hogere kosten (19-22). Daarnaast zouden, zonder 
betrouwbare methoden om de kwaliteit en viabiliteit van donornieren te kunnen 
bepalen, potentieel geschikte nieren afgewezen kunnen worden. Daarom zijn 
diagnostische methoden om de viabiliteit van donornieren vóór transplantatie te 
kunnen bepalen van groot belang. 
Beoordeling van viabiliteit van door machine geperfuseerde nieren
In de afgelopen jaren is nierpreservatie door hypothermische machine perfusie 
opnieuw in de belangstelling gekomen. Naast het veronderstelde voordeel van 
verbeterd weefsel preservatie, zorgt machineperfusie ook voor de mogelijkheid om 
de kwaliteit van een donornier te beoordelen met behulp van perfusie parameters en 
biomarkers in het perfusaat (23, 24). Perfusaat biomarkers glutathione S-transferase 
(GST) en lactaat dehydrogenase (LDH) zijn veelbelovende of geaccepteerde methoden 
om nieren te accepteren of af te wijzen voor transplantatie (25-27). Echter, de meeste 
studies die de waarde van perfusaat biomarkers als voorspellers van de viabiliteit 
beoordelen, hebben dit beoordeeld in een geselecteerde groep nieren en beschrijven 
de verbeteringen van de resultaten van niertransplantatie na hartstilstand na de 
introductie van perfusaat biomarkers om viabiliteit te beoordelen, of hebben een 
beperkt aantal nieren geïncludeerd die een a priori goede prognose hebben en 
daardoor een te lage power hebben (Hoofdstuk 5). 
 In Hoofdstuk 5 hebben we de voorspellende waarde van potentiële 
biomarkers GST, LDH, heart-type fatty acid binding protein (H-FABP), redox-actief ijzer, 
interleukine (IL)-18 en neutrophil gelatinase-associated lipocalin (NGAL) beoordeeld 
in een grote (N = 335) niet geselecteerde groep van nieren van donoren na hartdood 
met een relatief slechte prognose en een hoge incidentie van transplantaatfalen. 
In dit cohort waren alleen LDH en IL-18 geassocieerd met primaire non-functie in 
de multivariate analyse (OR 1.001, 95% CI 1.000 – 1.002, p=0.005 and 1.001, 95% CI 
1.000 – 1.002, p=0.003, respectievelijk). Echter, de diagnostische nauwkeurigheid voor 
primaire non-functie was matig voor alle onderzochte biomarkers. Daarom moet de 
diagnostische nauwkeurigheid van de perfusaat biomarkers GST, LDH, H-FABP, redox-
actief ijzer, IL-18 en NGAL niet leiden tot het afwijzen van nieren van donoren na 
hartstilstand. 
 Naast de beoordeling van perfusaat biomarkers, biedt machine perfusie ook 
de mogelijkheid om perfusie parameters te bepalen, waaronder perfusiedruk, de 
perfusiesnelheid en de vaatweerstand in de nier. Deze parameters kunnen mogelijk 
de viabiliteit na transplantatie voorspellen (28-31). De waarde van machine perfusie 
karakteristieken om primaire non-functie te voorspellen is echter relatief onbekend. 
Zodoende hebben we onderzocht of de vaatweerstand is geassocieerd met primaire 
non-functie in een groot cohort van marginale machine geperfundeerde nieren van 
donoren na hartstilstand, waarin perfusie karakteristieken niet gebruikt worden om 
de organen af te wijzen (Hoofdstuk 6). De resultaten laten zien dat vaatweerstand 
in het begin van machine perfusie significant en onafhankelijk is geassocieerd met 
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primaire non-functie (OR 2.040, 95% CI 1.362 – 3.056, p=0.001). De voorspellende 
waarde is echter beperkt. Daarom zouden marginale nieren niet afgewezen moeten 
worden enkel gebaseerd op vaatweerstand. 
 De periode van warme ischemie kan leiden tot capillaire schade door 
trombose, vasoconstrictie en oedeem, en kan vervolgens resulteren in een 
verminderd circulerend volume in de nier. Het beoordelen van het circulerend 
volume vóór transplantatie zou mogelijk geassocieerd kunnen worden met de ernst 
van ischemische schade en zou dus een waardevolle voorspeller van transplantatie 
uitkomst kunnen zijn. De ‘ultrasound dilution technique’ werd oorspronkelijk 
gebruikt om het circulerend volume in hemodialyse apparatuur te bepalen. Hierbij 
is deze techniek accuraat en zijn de resultaten reproduceerbaar (32-35). Het is een 
relatief makkelijke methode om intravasculair volume te meten en is nog niet 
toegepast in transplantatie chirurgie. Daarom hebben wij de reproduceerbaarheid 
en validiteit van deze techniek bepaald en hebben we de effecten van warme 
ischemie op het circulerend volume beoordeeld in machine geperfundeerde 
varkensnieren (Hoofdstuk 7). We laten zien dat de ‘ultrasound dilution technique’ 
een reproducerende manier is om renovasculair circulerend volume te bepalen in 
machine geperfuseerde varkensnieren en dat deze techniek geschikt is om verschillen 
in warme ischemie tijd te detecteren. Echter, meer onderzoek is nodig om de waarde 
van deze techniek als voorspeller van transplantatie uitkomst in humane nieren te 
beoordelen. 
 De bovenstaande ‘viabiliteitstesten’ voor machine geperfundeerde nieren van 
donoren na hartstilstand en andere recent onderzochte potentiële viabiliteitstesten 
hebben helaas onvoldoende diagnostische nauwkeurigheid om klinisch bruikbaar te 
zijn in de beslissing om een nier te transplanteren of af te wijzen (Hoofdstuk 8). 
Beoordeling van nierschade vóór orgaandonatie
Kwaliteitstesten voor machine geperfundeerde nieren zijn uitgebreid 
bestudeerd. Machine perfusie karakteristieken en perfusaat biomarkers correleren 
met de uitkomst van transplantatie, maar de huidige onderzoeken zijn geen 
betrouwbare voorspellers van transplantatie uitkomst. Het bestuderen van de 
kwaliteit van nieren vóór orgaandonatie is echter minder bestudeerd. 
 Het eiwit neutrophil gelatinase-associated lipocalin (NGAL), ook wel bekend 
als lipocalin-2, is onlangs ontdekt als een nieuwe biomarker voor acute nierschade 
(36). De concentratie van NGAL stijgt enorm na acute nierschade en gaat vooraf 
aan de stijging van klassieke biomarkers voor nierletsel, zoals serum creatinine (37). 
Daarom hebben wij NGAL concentraties gemeten in zowel donoren na hartstilstand 
(ongecontroleerde Maastricht categorie I en II donoren en gecontroleerde Maastricht 
categorie III donoren) als in donoren na hersendood en onderzochten de waarde van 
NGAL als voorspeller voor transplantatie uitkomst (Hoofdstuk 9). In dat hoofdstuk 
laten we zien dat de NGAL concentratie vóór orgaandonatie niet geassocieerd is met 
transplantaatfunctie na transplantatie. Voor nieren na harststilstand echter, werd een 
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significant verschil gevonden voor NGAL concentratie tussen nieren met vertraagde 
transplantaat functie en onmiddellijke functie. Hoewel het een waardevolle biomarker 
is voor nierletsel in patiënten op de intensive care, is de waarde als voorspeller van 
transplantatie uitkomst beperkt. 
BEHANDELING VAN ACUUT ISCHEMISCHE NIERSCHADE IN 
DIERMODELLEN
Niertransplantatie na hartstilstand is op dit moment beperkt tot nieren die 
relatief korte periodes van warme ischemie hebben geleden. Het reduceren van 
nierletsel na ischemie en reperfusie kan potentieel leiden tot het reduceren van de 
incidentie van vroege transplantaat dysfunctie en kan resulteren in het bijdragen van 
de uitbreiding van de donorpool met nieren die langdurig ischemische schade hebben 
opgelopen. Daarom hebben wij nieuwe potentiële therapieën onderzocht voor 
acute ischemische schade in experimentele muis modellen met het uiteindelijke doel 
om vroege transplantaat functie te verbeteren in niertransplantatie na hartstilstand.
 Ischemie-reperfusie leidt tot een complexe reeks van gebeurtenissen, 
waaronder het ontstaan van ontstekingsmediatoren, leukocyten infiltratie en, 
afhankelijk van de ernst van de schade, uiteindelijk tot celdood door ofwel necrose 
of apoptose (38, 39). Inefficiënte opruiming van apoptotische cellen leidt tot necrose, 
wat is gekarakteriseerd door de onderbreking van het celmembraan en het vrijkomen 
van de celinhoud (40). De mechanismen die leiden tot ontsteking na necrotische 
celdood zijn maar gedeeltelijk bekend. Recente data laat zien dat het C-type lectine 
‘Mincle’ betrokken is bij dit proces. Mincle herkent het eiwit SAP130 wat vrijkomt 
uit necrotische cellen, en activeert de ontsteking via cytokine afgifte, hetgeen leidt 
tot het aantrekken van neutrofielen (40, 41). De volledige ontstekingscyclus is nog 
niet bekend, maar we weten dat necrotische niercellen, apoptose en ontsteking 
gedurende en na ischemie-reperfusie significant bijdragen aan de pathogenese 
van acute ischemische nierschade (42). Het blokkeren van de Mincle-receptor kan 
resulteren in een minder heftige ontstekingsrespons, wat kan leiden tot minder 
nierschade na celdood. Daarom hebben wij het effect van ‘anti-Micle’ op ischemie-
reperfusie schade aan de nier onderzocht in een muizenmodel (Hoofdstuk 10). 
De effecten van Mincle op ischemie-reperfusie schade en de ontstekingsrespons 
zijn bestudeerd in een ischemie-reperfusie muizenmodel, gebruik makend van 25 
minuten ischemie en 24 uur reperfusie. De Mincle-receptor werd geblokkeerd met 
een Mincle-specifiek antilichaam (anti-Mincle) en vergeleken met dieren die rat IgG 
als controle kregen. Nierfunctie (creatinine 232 ± 34 vs. 211 ± 22 µmol/L, p=0.200 en 
ureum 61.2 ± 5.6 vs. 58.2 ± 5.9, p=0.355, respectievelijk), histologische schade en de 
hoeveelheid geïnfiltreerde neutrofielen waren vergelijkbaar tussen beide groepen. 
Concluderend, het blokkeren van de Mincle-receptor met specifiek anti-Mincle 
antilichaam verhindert de ontstekingsrespons in een muizenmodel niet na ischemie-
reperfusie en draagt niet bij aan verminderde nierschade en verbeterde nierfunctie. 
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 Het vrijkomen van vrije zuurstofradicalen gedurende koude ischemie 
en bij reperfusie leidt tot oxidatieve stress en wordt algemeen beschouwd als een 
belangrijke bijdrage aan ischemische nierschade en het veroorzaakt vaatvernauwing 
en veroorzaakt beschadiging aan cellulaire vetten, eiwitten en DNA, hetgeen 
uiteindelijk kan leiden tot celdood van het tubulusepitheel wanneer de natuurlijke 
verdediging tegen vrije zuurstofradicalen uitgeput raakt (43-45). In Hoofdstuk 11 
bestudeerden we het mechanisme achter het ontstaan van vaatvernauwing bij 
oxidatieve stress en het voorkomen hiervan. We beschreven dat oxidatieve modificatie 
van arachidonzuur in celmembranen lijdt tot de formatie van stabiele F2-isoprostanen 
die vrijkomen in het plasma en daar actief zijn door signalering via thromboxaan A2 
receptoren (46, 47). Eerdere studies laten een afname van de doorbloeding van de 
nier en glomerulaire filtratiesnelheid zien door vaatvernauwing in de aanvoerende 
glomerulaire arteriolen, na het toedienen van F2-isoprostanes aan ratten en varkens 
(48, 49). In de muizen zonder Thromboxaan A2 receptoren, waardoor signalering van 
F2-isoprostanes niet mogelijk is, zagen we geen bescherming tegen acute ischemische 
nierschade, hoewel F2-isoprostanes aanwezig waren in urine na ischemie-reperfusie. 
Hieruit concluderen we dat F2-isoprostanes geen grote invloed hebben op het 
ontstaan van acute ischemische nierschade.
TOEKOMSTPERSPECTIEVEN IN NIERDONATIE EN 
TRANSPLANTATIE NA HARTSTILSTAND
Gerichte interventies kunnen orgaanschade als gevolg van hersendood 
of ischemie-reperfusie verminderen na transplantatie. Het beïnvloeden van 
ontstekingsreacties en aangeboren immuniteit kan hierin een belangrijke rol spelen 
in de toekomst. Nieuwe behandelstrategieën kunnen de kwaliteit van de organen 
verbeteren en op die manier het aantal organen dat veilig kan worden geaccepteerd 
voor transplantatie verhogen. Interventies kunnen toegepast worden in de donor, 
maar ook tussen orgaandonatie en transplantatie gedurende koude machine 
preservatie of gedurende warme, ook wel normotherme, machine preservatie. In het 
geval van laatstgenoemde is het metabolisme hoger waardoor theoretisch gezien een 
betere modificatie van het orgaan mogelijk is. 
Zoals beschreven in Hoofdstuk 8 zou normotherme machine perfusie 
(NMP) nieuwe en andere mogelijkheden kunnen bieden om de kwaliteit van een 
donororgaan te beoordelen voor transplantatie. Ook kan NMP ischemische schade 
herstellen in plaats van verdere schade toe te brengen (50). Het belangrijkste voordeel 
van NMP is de mogelijkheid van het meten van functionele parameters zoals diurese 
en creatinine klaring.
SAMENVATTING
195 
CONCLUSIE
In dit proefschrift beschrijven we het gebruik van organen van donoren 
na hartstilstand, met name de ongecontroleerde Maastricht categorie II donoren, 
de lange termijn resultaten en mogelijkheden om transplantatie uitkomsten te 
verbeteren. Ondanks de hogere incidentie van primaire non-functie bij nieren 
van ongecontroleerde donoren na hartstilstand, zijn de lange-termijn resultaten 
vergelijkbaar met nieren van gecontroleerde donoren na hartstilstand. Het risico op 
primaire non-functie kan worden gereduceerd door het identificeren van marginale 
orgaandonoren met leeftijd, histologische beoordeling van pre-implantatie biopten 
van oude donornieren, donorcategorie en warme- en koude ischemietijd. Hierdoor 
kan de donorpool uitgebreid worden met ongecontroleerde donoren om de nog 
steeds groeiende wachtlijst voor niertransplantatie te reduceren.  
Ischemie-reperfusie leidt tot een complexe serie van gebeurtenissen. Daarom 
vereist behandeling van acute ischemische schade aan nieren een combinatie van 
interventies die gericht zijn op verschillende pathofysiologische onderdelen. In dit 
proefschrift zijn mogelijke behandelingen van losse elementen van de pathofysiologie 
van ischemie-reperfusie bestudeerd zonder positieve effecten. Een combinatie van 
interventies daarentegen zou wel succesvol kunnen zijn in toekomstige studies. 
Met de in dit proefschrift gepresenteerde resultaten kan het gebruik 
van nieren van donoren na hartstilstand, vooral ongecontroleerde donoren na 
hartstilstand, verder uitgebreid worden. Echter, grote inspanningen blijven cruciaal 
om de kwaliteit van deze nieren te verbeteren en hierbij deze groep donoren te 
gebruiken naar zijn volledige potentieel.
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3DUS Three dimensional ultrasound
AKI  Acute kidney injury
Ala-AP  Alanine aminopeptidase
AST  Aspartate transaminase
ATP  Adenosine triphosphate
AUC  Area under the curve
AURC  Area under the ROC-curve
BUN  Blood urea nitrogen
CEUS  Contrast-enhanced ultrasound
CIT  Cold ischemia time
CPR  Cardiopulmonary resuscitation
CS  Cold storage
CV  Coefficient of variation
DAMPs  Damage-associated molecular pattern molecules
DBD  Donation/donor after brain death
DBTL  Double-balloon triple-lumen
DCD  Donation/donor after cardiac death
DEC  Animal experiments committee
DGF  Delayed graft function
ECD  Expanded criteria donors
ECMO  Extracorpereal membrane oxygenation
eGFR  estimated glomerular filtration rate
GSH  Glutathione S-transferase
H-FABP  Heart-type fatty acid binding protein
HLA  Human leukocyte antigen
HMP  Hypothermic machine perfusion
HR  Hazards ratio
HTK  Histidine-tryptophan-ketoglutarate
ICU  Intensive care unit
IF  Immediate function
IL  Interleukin
IQR  Interquartile range
I/R  Ischemia reperfusion
IRB  Institutional review board
ISP  In situ preservation
LDH  Lactate dehydrogenase
LPOP  Lipid peroxidation products
MDA  Malondialdehyde
MDRD  Modification of diet in renal disease
Mincle  Macrophage-inducible C-type Lectin
MPO  Myeloperoxidase
MRS  Magnetic resonance spectrometry
MTT  Mean transit time
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MUMC  Maastricht University Medical Center
NAG  N-acetyl-b-D-glucosaminidase
NGAL  Neutrophil gelatinase-associated lipocalin
NMP  Normothermic machine perfusion
NPV  Negative predictive value
OPTN  Organ Procurement and Transplantation Network
OR  Odds ratio
PNF  Primary non-function
PPV  Positive predictive value
PRA  Panel reactive antibody
ROC  Receiver operating characteristics
RR  Renovascular resistance
SCD  Standard criteria donors
SD  Standard deviation
SPSS  Statistical Package for the Social Sciences
TAS  Total antioxidant status
TLR  Toll-like receptor
UW  University of Winsconsin
UW-MPS  University of Winsconsin – machine preservation solution
WIT  Warm ischemia time
WLST  Withdrawal of life-supporting treatment
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